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SCIENTIFIC OPINION
Scientific opinion on Flavouring Group Evaluation 25, Revision 3
(FGE.25Rev3): Aliphatic hydrocarbons from chemical group 311
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids (CEF)2, 3
European Food Safety Authority (EFSA), Parma, Italy
ABSTRACT
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety
Authority was requested to evaluate 14 flavouring substances in the Flavouring Group Evaluation 25,
Revision 3, using the Procedure in Commission Regulation (EC) No 1565/2000. None of the substances was
considered to have a genotoxic potential. This revision is made due to the inclusion of new toxicity data on the
supporting substances β-caryophyllene [FL-no: 01.007] and myrcene [FL-no: 01.008] considered in 
FGE.78Rev2 to cover the assessment of 4(10)-thujene [FL-no: 01.059], 2,6-dimethylocta-2,4,6-triene [FL-no:
01.035], cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070]. The substances were
evaluated through a stepwise approach (the Procedure) that integrates information on structure-activity
relationships, intake from current uses, toxicological threshold of concern, and available data on metabolism and
toxicity. The Panel concluded that all 14 substances [FL-no: 01.001, 01.027, 01.028, 01.033, 01.034, 01.035,
01.038, 01.039, 01.046, 01.054, 01.057, 01.059, 01.064, 01.070] do not give rise to safety concerns at their
levels of dietary intake, estimated on the basis of the MSDI approach. Besides the safety assessment of these
flavouring substances, the specifications for the materials of commerce have also been considered. Adequate
specifications including complete purity and identity criteria for the materials of commerce have been provided
for all 14 candidate substances.
© European Food Safety Authority, 2015
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SUMMARY
Following a request from the European Commission, the EFSA Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (the Panel) was asked to deliver a scientific opinion on the
implications for human health of chemically defined flavouring substances used in or on foodstuffs in
the Member States. In particular, the Panel was requested to evaluate 14 flavouring substances in the
Flavouring Group Evaluation 25, Revision 3 (FGE.25Rev3), using the Procedure as referred to in the
Commission Regulation (EC) No 1565/2000. These 14 flavouring substances belong to chemical
group 31, Annex I of the Commission Regulation (EC) No 1565/2000.
The present revision of FGE.25, Revision 3 includes the assessment of a 90-day study on ß-
caryophyllene [FL-no: 01.007] supporting the candidate substance 4(10)-thujene [FL-no: 01.059] and
a 90-day study on myrcene [FL-no: 01.008] supporting the candidate substances 2,6-dimethylocta-
2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] and 1-octene [FL-no:
01.070].
Since the publication of FGE.25Rev2, Industry has informed EFSA that 23 substances [former FL-no:
01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 01.036, 01.037, 01.042, 01.043, 01.044, 01.047,
01.050, 01.051, 01.052, 01.053, 01.055, 01.056, 01.058, 01.060, 01.066, 01.067 and 01.078] are no
longer supported for use as flavouring substances in Europe by Industry. The FGE.25Rev3 therefore
deals with 14 flavouring substances in total.
The 14 candidate substances are aliphatic hydrocarbons from chemical group 31, which have been
divided into four subgroups: I) acyclic alkanes, II) acyclic alkenes, III) cyclohexene hydrocarbons, IV)
is now empty as all the substances are no longer supported by Industry, V) bicyclic, non-aromatic
hydrocarbon ,VI) is now empty as all the substances are no longer supported by Industry.
Seven of the 14 flavouring substances possess chiral centres and three can exist as geometrical
isomers.
All of the 14 candidate substances are classified into structural class I, according to the decision tree
approach presented by Cramer et al. (1978).
Twelve of the 14 candidate substances have been reported to occur naturally in a wide range of food
items.
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI)
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the
Panel examined the information provided by the European Flavour Industry on the use levels in
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly
underestimate the intake by regular consumers of products flavoured at the use level reported by the
Industry, especially in those cases where the annual production values were reported to be small. In
consequence, the Panel had reservations about the data on use and use levels provided and the intake
estimates obtained by the MSDI approach.
In the absence of more precise information that would enable the Panel to make a more realistic
estimate of the intakes of the flavouring substances, the Panel decided also to perform an estimate of
the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” (mTAMDI)
approach based on the normal use levels reported by Industry. In those cases where the mTAMDI
approach indicated that the intake of a flavouring substance might exceed its corresponding threshold
of concern, the Panel decided not to carry out a formal safety assessment using the Procedure. In these
cases the Panel requires more precise data on use and use levels.
According to the default MSDI approach, 12 of the 14 flavouring substances in this group have intakes
in Europe from 0.0085 to 14 µg/capita per day, which are below the threshold of concern value for
structural class I (1800 µg/person per day) substances. For limonene [FL-no: 01.001] and l-limonene
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[FL-no: 01.046] the intakes are 4000 and 2100 µg/capita per day, which are above the threshold of
concern value for structural class I (1800 µg/person per day).
On the basis of the reported annual production volumes in Europe (MSDI approach), the total
combined intakes of the candidate and supporting substances can be calculated for the substances in
subgroup I, II, III and V (those subgroups still containing substances) evaluated through the
Procedure.
Subgroup I (acyclic alkanes): the combined intake of the five candidate substances, all from structural
class I and evaluated via the A-side of the Procedure (Appendix A), is 3.0 µg/capita per day, which
does not exceed the threshold of 1800 µg/person per day.
Subgroup II (acyclic alkenes): the combined intake of the three candidate substances, all from
structural class I and evaluated via the B-side of the Procedure (Appendix A), is 23 µg/capita per day,
which does not exceed the threshold of 1800 µg/person per day.
Subgroup III (cyclohexene hydrocarbons): the combined intake of the three candidate substances, all
from structural class I and evaluated via the A-side of the Procedure (Appendix A), is 6100 µg/capita
per day, which does exceed the threshold of 1800 µg/person per day. The total combined intake of the
three candidate and four supporting substances (also from structural class I) is approximately 42 000
µg/capita per day. This intake exceeds the threshold of 1800 µg/person per day for a structural class I
substance. However, together, limonene [FL-no: 01.001], l-limonene [FL-no: 01.046] and d-limonene
(supporting substance [FL-no: 01.045]) account for approximately 40 000 µg/capita per day. The total
combined intake of 42 000 µg/capita per day for the candidate and the supporting substances
corresponds to 700 µg/kg bw per day for a person with a body weight of 60 kg. Thus, based on the
NOAEL for d-limonene of 215 mg/kg bw per day, a margin of safety of 307 can be calculated, and
accordingly these substances are not expected to be of safety concern at the estimated level of intake.
Subgroup V (bicyclic, non-aromatic hydrocarbons): as no sufficient data are available to conclude that
the candidate substance [FL-no: 01.059] will be metabolised to innocuous products, it is evaluated via
the B-side of the Procedure (Appendix A). The total combined intake of the one candidate and eight
supporting substances (also from structural class I) is approximately 3800 µg/capita per day. This
intake exceeds the threshold of 1800 µg/person per day for a structural class I substance. However,
three supporting substances, pin-2(10)-ene [FL-no: 01.003], pin-2(3)-ene [FL-no: 01.004] and β-
caryophyllene [FL-no: 01.007] together account for approximately 3400 µg/capita per day. The total
combined intake of 3800 µg/capita per day for the candidate and the supporting substances
corresponds to 63 µg/kg bw per day for a person with a body weight of 60 kg. Thus, based on the
NOAEL for β-caryophyllene of 222 mg/kg bw per day, a margin of safety of 3500 can be calculated, 
and accordingly this substance is not expected to be of safety concern at the estimated level of intake.
The available information on metabolism of the 14 candidate substances evaluated through the
Procedure or the supporting substances for this FGE was limited. For the following 10 candidate
substances it can be concluded that they will be metabolised into innocuous metabolites: [FL-no:
01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and [FL-no: 0.001, 01.027, 01.028,
01.039 and 01.046] from subgroup III. For two candidate substances there are data, which show that
they may be metabolised to toxic metabolites [FL-no: 01.064 and 01.070]. For the remaining two
candidate substances [FL-no: 01.035 and 01.059], the information is too limited and it cannot be
assumed that they are metabolised to innocuous metabolites.
It was noted that where toxicity data were available they were consistent with the conclusions in the
present flavouring group evaluation using the Procedure.
It is concluded that the 10 candidate substances which are expected to be metabolised to innocuous
substances, [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and [FL-no: 01.001,
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01.027, 01.028, 01.039 and 01.046] from subgroup III, would not give rise to safety concerns at their
estimated intakes arising from their use as flavouring substances based on the MSDI approach.
For 4(10)-thujene [FL-no: 01.059], from subgroup V, which is not expected to be metabolised to
innocuous substances, a margin of safety could be calculated based upon a NOAEL (222 mg/kg/bw)
for the supporting substance ß-caryophyllene [FL-no: 01.007]. Compared to the MSDI of 4(10)-
thujene of 14 µg/capita per day corresponding to 0.2 µg/kg bw per day, the NOAEL provides a margin
of safety of 9.5 x 105.
For the three remaining substances, 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-
1,3,6-octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070] a margin of safety could be calculated
based upon a NOAEL (44 mg/kg bw) for the supporting substance myrcene [FL-no: 01.008].
Compared to the MSDI of 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-1,3,6-
octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070] of 9.1, 14 and 0.0085 µg/capita per day
equal to 0.15, 0.23 and 0.00014 µg/kg bw per day, the NOAEL provides a margin of safety of 2.9 x
105, 1.9 x 105 and 3.1 x 108.
The mTAMDI values for 11 candidate substances are above the threshold for structural class I of 1800
µg/person per day. For these substances more reliable exposure data are requested in order for them to
be considered using the Procedure. For limonene [FL-no: 01.001] the mTAMDI is 1800 µg/person per
day and for each of l-limonene and 1-octene [FL-no: 01.046 and 01.070] the mTAMDI is
1600 µg/person per day.
In order to determine whether this conclusion could be applied to the materials of commerce, it is
necessary to consider the available specifications. The specifications including complete purity criteria
and identity for the materials of commerce have been provided for all 14 flavouring substances.
Thus, for all 14 candidate substances [FL-no: 01.001, 01.027, 01.028, 01.033, 01.034, 01.035, 01.038,
01.039, 01.046, 01.054, 01.057, 01.059, 01.064 and 01.070] the Panel concluded that they would
present no safety concern at their estimated levels of intake based on the MSDI approach.
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION
The use of flavourings in food is regulated under Regulation (EC) No 1334/2008 of the European
Parliament and Council of 16 December 20084 on flavourings and certain food ingredients with
flavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for flavouring substances.
The Union list of flavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20125. The list contains flavouring substances for which the scientific
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006.
FGE.78Rev1
On 19 May 2011, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids (CEF) adopted an opinion on Flavouring Group Evaluation 78, Revision 1 (FGE.78Rev1):
Consideration of aliphatic and alicyclic and aromatic hydrocarbons evaluated by JECFA (63rd
meeting) structurally related to aliphatic and aromatic hydrocarbons evaluated by EFSA in
FGE.25Rev27.
The substances [FL-no: 01.008, 01.018, 01.040 and 01.061] were among the 14 substances for which
the Panel had “reservations (no European production volumes available, preventing them from being
evaluated using the Procedure, and/or missing information on stereoisomerism/composition of
mixture)” and also among those for which “additional toxicity data was requested”.
FGE.25Rev2
On 19 May 2011, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids (CEF) adopted an opinion on Flavouring Group Evaluation 25, Revision 2 (FGE.25Rev2):
Aliphatic and aromatic hydrocarbons from chemical group 318.
The substances with [FL-no: 01.035, 01.064, 01.070 and 01.035] were among the 27 candidate
substances for which “additional toxicity data” were required by EFSA. For [FL-no: 01.035] also
“additional information on composition” was requested.
FGE.18Rev2
On 30 September 2010, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids (CEF) adopted an opinion on Flavouring Group Evaluation 18, Revision 2
(FGE.18Rev2): Aliphatic, alicyclic and aromatic saturated and unsaturated tertiary alcohols, aromatic
tertiary alcohols and their esters from chemical groups 6 and 8.
For the flavouring substance [FL-no: 02.146], the Panel considered that “additional data” are needed
including “information on specifications/stereoisomerism/composition of mixture”.
4 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p.34-50.
5 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC)
No 1565/2000 and Commission Decision 1999/217/EC.OJ L 267, 2.10.2012, p. 1-161.
6 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16.
7 EFSA Journal 2011;9(6):2178
8 EFSA Journal 2011;9(6):2177
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On 21 November 2012, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids (CEF) adopted a statement on the re-evaluation of 3,7-dimethylocta-1,5,7-trien-3-ol
[FL-no: 02.146] based on additional data on a supporting substance9.
The Panel concluded that “linalool [FL-no: 02.013] is not sufficiently structurally related to 3,7-
dimethylocta-1,5,7-trien-3-ol [FL-no: 02.146] for a re-evaluation of [FL-no: 02.146]. Accordingly, “a
90-day study on 3,7- dimethylocta-1,5,7-trien-3-ol [FL-no: 02.146] or on a sufficiently structurally
related substance has to be provided in order to establish on appropriate NOAEL”.
New data and relationship with other substances
On 5 and 11 July 2013, the applicant submitted additional data on the following acyclic terpene
hydrocarbons [FL-no: 01.008, 01.018, 01.040, 01.061, 01.035, 01.064, 01.070 and 02.146, represented
by myrcene [FL-no: 01.008].
As regards the related substances also evaluated in these opinions, namely [FL-no: 01.003, 01.004,
01.007, 01.009, 01.017, 01.024, 01.026, 01.029 and 01.059], data was submitted and are currently
being evaluated (EFSA-Q-2013-00185 to – 00193).
As regards substance with [FL-no: 01.014], data should be submitted by 31 December 201310.
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION
The European Commission requests the European Food Safety Authority (EFSA) to finalise its safety
assessment on this group of flavouring substances in accordance with Commission Regulation (EC)
No 1565/2000.
SUPPORTING DOCUMENTS
Submission by the European Flavour Association
INTERPRETATION OF THE TERMS OF REFERENCE
The above background and terms of reference include also a previous mandate received from the
European Commission on 6 February 201311. The present scientific opinion FGE.25Rev3 covers the
safety assessment of the following flavouring substances: 4(10)-thujene with [FL-no: 01.059], 2,6-
Dimethylocta-2,4,6-triene with [FL-no: 01.035], cis-3,7-Dimethyl-1,3,6-octatriene with [FL-no:
01.064] and 1-Octene with [FL-no: 01.070].
9 EFSA Journal 2012;10(12):2995
10 This substance is in the process of being deleted from the Union List (DG SANTE, 2015)
11 SANCO.E3/SH/km D (2013) Ares(2013)15188
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ASSESSMENT
1. History of the Evaluation of the Substances in the Present FGE
The first version of the Flavouring Group Evaluation 25 (FGE.25) dealt with 32 aliphatic and aromatic
hydrocarbons which have been divided into eight subgroups: I) acyclic alkanes, II) acyclic alkenes,
III) cyclohexene hydrocarbons, IVa) benzene hydrocarbons, IVb) napthalene hydrocarbons, IVc)
diphenylmethane, V) bi-and tricyclic, non-aromatic hydrocarbons and VI) macrocyclic, non-aromatic
hydrocarbons. For one candidate substance, 2-methylbuta-1,3-diene [former FL-no: 01.049]
(synonym: isoprene) evaluated in FGE.25 there was evidence of a genotoxic potential in vivo and of
carcinogenic effects in experimental animals. Therefore, this substance could not be evaluated through
the Procedure and could not be considered safe when used as a chemically defined flavouring
substance. Subsequently, the substance has been deleted from the Register (Mennicke et al., 1983).
The first Revision of FGE.25 (FGE.25Rev1) included the assessment of three additional candidate
substances [FL-no: 01.059, 01.070 and 01.078]. For two of these substances additional genotoxicity
data on structurally related substances have been provided. A survey in open literature did not result in
further data.
The second Revision of FGE.25 (FGE.25Rev2) included the assessment of three additional candidate
substances [FL-no: 01.001, 01.021 and 01.046]. No toxicity or metabolism data were provided for
these three substances. A survey in open literature did not result in further data for these three
substances. In the FGE.25 and FGE.25Rev1, the Panel considered that additional toxicity data were
needed for 26 of the substances evaluated through the Procedure as no adequate toxicity study from
which a NOAEL could be established was available, neither on the candidate substances nor on
supporting substances. Additional toxicity and genotoxicity data had become available for the
supporting substance myrcene [FL-no: 01.008] as had additional genotoxicity data for one of the 26
substances [FL-no: 01.047] and on cedrene washed (unspecified cedrene). Since the publication of
FGE.25Rev1 new tonnage data for [FL-no: 01.035, 01.047 and 01.064] had become available (Flavour
Industry, 2010), and included in this revision. Industry has also submitted additional information on
stereoisomeric composition [FL-no: 01.027, 01.032, 01.034, 01.035, 01.050, 01.055, 01.056 and
01.060], composition of mixture [FL-no: 01.078] and missing ID-test [FL-no: 01.078].
Since the publication of FGE.25Rev2, 23 substances [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031,
01.032, 01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055,
01.056, 01.058, 01.060, 01.066, 01.067 and 01.078] are no longer supported for use as flavouring
substances in Europe by Industry and will therefore not be considered any further (DG SANCO, 2012;
DG SANCO, 2013). Information from the previous version of FGE.25 on these substances is collected
in Appendix D. However, information on these substances will be kept in the main text if relevant for
the remaining candidate substances. The 23 substances are listed here below.
FL-no EU Register name
01.021 delta-Cadinene
01.022 α-Cedrene 
01.023 1(5),11-Guaiadiene
01.030 β-Cubebene 
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene
01.032 2,3-Dihydrofarnesene
01.036 Diphenylmethane
01.037 Dodec-1-ene
01.042 Germacra-1(10),4(14),5-triene
01.043 3,7,10-Humulatriene
01.044 Isolongifolene
01.047 Longifolene
01.050 3-Methylhexane
01.051 2-Methylnaphthalene
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FL-no EU Register name
01.052 α-Muurolene 
01.053 Naphthalene
01.055 β-Phellandrene 
01.056 α-Santalene 
01.058 1,2,3,4-Tetrahydro-1,1,6-
trimethylnaphthalene
01.060 1,1,7-
Trimethyltricyclo[2.2.1.0.(2.6)]heptane
01.066 2-Cedrene
01.067 8(14)-Cedrene
01.078 2,4-Nonadiene
As a consequence the following supporting substance has been deleted from this revision; moreover 1-
methylnaphthalene is also in the process of being deleted from the Union List (DG SANTE, 2015)
FL-no
JECFA no
EU Register name Structural formula
01.014
1335
1-Methylnaphthalene
The table below gives information on publication dates and links to the published versions.
FGE Opinion Adopted
by EFSA
Link No. of
Candidate
Substances
FGE.25 1 April 2008 http://www.efsa.europa.eu/en/efsajournal/doc/918.pdf 32
FGE.25Rev1 23 September 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1334.htm 34
FGE.25Rev2 18 May 2011 http://www.efsa.europa.eu/en/efsajournal/pub/2177.htm 37
FGE.25Rev3 18 March 2015 14
The present Revision of FGE.25, FGE.25Rev3, deals with additional toxicity data from a 90-day study
provided for β-caryophyllene [FL-no: 01.007] considered in FGE.78Rev2 (EFSA, in press). This 
information is used for the assessment of 4(10)-thujene [FL-no: 01.059]. Furthermore, new short term
study and genotoxicity data have been provided for [FL-no: 01.007] (EFFA, 2012). Additional toxicity
data from a 90-day study provided for the supporting substance myrcene [FL-no: 01.008] are also
evaluated. This information is used for the assessment of 2,6-dimethylocta-2,4,6-triene [FL-no:
01.035], cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070].
Furthermore, new information on European production figures has been provided for [FL-no: 01.035,
01.064 and 01.070] (IOFI, 2013) and use levels have been provided for [FL-no: 01.001, 01.046 and
01.070] (EFFA, 2015).
2. Presentation of the Substances in Flavouring Group Evaluation 25, Revision 3
2.1. Description
The present Flavouring Group Evaluation 25, Revision 3 (FGE.25Rev3) using the Procedure as
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000) (The Procedure – shown in
schematic form in Appendix A of this FGE), deals with 14 aliphatic hydrocarbons (candidate
substances) from chemical group 31, Annex I of Commission Regulation (EC) No 1565/2000 (EC,
2000). The candidate substances in the group have been divided into the following subgroups:
I) Acyclic alkanes,
II) Acyclic alkenes,
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III) Cyclohexene hydrocarbons,
IV) The group was divided into IVa) benzene hydrocarbons, IVb) naphthalene hydrocarbons,
IVc) diphenylmethane; the substances previously allocated to these groups are no longer
supported for use as flavouring substances in Europe,
V) Bicyclic, non-aromatic hydrocarbons and
VI) Macrocyclic, non-aromatic hydrocarbons. The substances previously allocated to the group are
no longer supported for use as flavouring substances in Europe by Industry.
One flavouring substance, 2-methylbuta-1,3-diene [former FL-no: 01.049] (synonym: isoprene)
evaluated in FGE.25 has been deleted from the Register of flavouring substances as it showed
genotoxic potential in vivo and carcinogenic effects in experimental animals. Therefore this substance
will not be further discussed as a candidate substance in the current Revision 3 of FGE.25
(FGE.25Rev3).
The 14 candidate substances under consideration, with their chemical Register names, FLAVIS -
(FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract
Manufacturers Association- (FEMA-) numbers, structure and specifications, are listed in Table 1.
A summary of the safety evaluation of the candidate substances under consideration in the present
evaluation are listed in Table 7.
The 14 candidate substances are closely related structurally to 18 flavouring substances (supporting
substances) evaluated at the 63rd JECFA meeting (JECFA, 2005b) in the groups of “Aliphatic and
alicyclic hydrocarbons”. The supporting substances are listed in Table 8.
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SUMMARY OF SPECIFICATION DATA
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25, Revision 3
FL-no EU Register
name
Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index (d)
Spec.gravity (e)
Specification
comments
01.001 Limonene 2633
491
138-86-3
Liquid
C10H16
136.23
Insoluble
Soluble
178
MS
95 %
1.4760-1.4820
0.843-0.851 With respect to
specific gravity it is
noted that limonene
and l-limonene are
submitted by
different applicants.
01.027 Bisabola-
1,8,12-triene
17627-44-0
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
99 (5 hPa)
MS
95 %
1.483-1.489
0.912-0.918 Racemate, mixture
of (E)- and (Z)-
isomers (EFFA,
2010). 50 - 70 %
(E)-isomer (EFFA,
2013). CASrn in
Register refers to the
racemate.
01.028 beta-Bisabolene
495-61-4
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
130 (13 hPa)
MS
95 %
1.489-1.495
0.879-0.885 CASrn in Register
refers to the (4S)-
isomer.
01.033 2,2-
Dimethylhexane
590-73-8
Liquid
C8H18
114.23
Practically
insoluble or
insoluble
Freely soluble
107
MS
95 %
1.390-1.396
0.693-0.699
01.034 2,4-
Dimethylhexane
589-43-5
Liquid
C8H18
114.23
Practically
insoluble or
insoluble
Freely soluble
109
MS
95 %
1.390-1.396
0.697-0.703 Racemate (EFFA,
2010).
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25, Revision 3
FL-no EU Register
name
Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index (d)
Spec.gravity (e)
Specification
comments
01.035 2,6-
Dimethylocta-
2,4,6-triene 673-84-7
Liquid
C10H16
136.24
Practically
insoluble or
insoluble
Freely soluble
75 (13 hPa)
MS
95 %
1.539-1.545
0.809-0.815 Mixture of (E)- and
(Z)-isomers (EFFA,
2010). 4E,6E (25 -
50 %); 4E,6Z (25 -
30 %); 4Z,6E (25 -
30 %); 4Z,6Z (10 -
20 %) (EFFA,
2013). CASrn in
Register does not
specify
stereoisomeric
composition.
01.038 Dodecane
112-40-3
Liquid
C12H26
170.34
Practically
insoluble or
insoluble
Freely soluble
216
MS
95 %
1.417-1.423
0.746-0.752
01.039 delta-Elemene
10996
20307-84-0
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
107 (13 hPa)
MS
95 %
1.480-1.486
0.856-0.862 CASrn in Register
refers to the (3R,
4R)-isomer.
01.046 l-Limonene 2633
491
5989-54-8
Liquid
C10H16
136.23
Insoluble
Soluble
177
MS
95 %
1.469 - 1.473
0.837 - 0.841 With respect to
specific gravity it is
noted that limonene
and l-limonene are
submitted by
different applicants.
CASrn in Register
refers to the (4S)-
isomer.
01.054 Pentadecane
629-62-9
Liquid
C15H32
212.42
Practically
insoluble or
insoluble
Freely soluble
270
10
MS
95 %
1.428-1.434
0.765-0.771
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 25, Revision 3
FL-no EU Register
name
Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index (d)
Spec.gravity (e)
Specification
comments
01.057 Tetradecane
629-59-4
Liquid
C14H30
198.39
Practically
insoluble or
insoluble
Freely soluble
252
5
MS
95 %
1.422-1.428
0.759-0.765
01.059 4(10)-Thujene
11018
3387-41-5
Liquid
C10H16
136.24
Practically
insoluble or
insoluble
Freely soluble
165
MS
96 %
1.463-1.469
0.840-0.846 Assay value of 96%:
mixture of 70 %
4(10)-thujene, 6 %
alpha-pinene, 19 %
beta-pinene, 1 %
myrcene, <4 % not
identified (EFFA).
01.064 cis-3,7-
Dimethyl-1,3,6-
octatriene 3338-55-4
Liquid
C10H16
136.24
Practically
insoluble or
insoluble
Freely soluble
177
MS
95 %
1.483-1.489
0.796-0.802 Synonym: cis-beta-
ocimene.
01.070 1-Octene 4293
111-66-0
Liquid
C8H16
112.22
Insoluble
Soluble
121
IR NMR MS
97 %
1.410-1.416
0.718-0.722
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95 % ethanol, if not otherwise stated.
(c): At 1013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
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2.2. Stereoisomers
It is recognised that geometrical and optical isomers of substances may have different properties. Their
flavour may be different, they may have different chemical properties resulting in possible variability
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be
provided on the configuration of the flavouring substance, i.e. whether it is one of the
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of
purity will be considered in order to determine whether the safety evaluation carried out for candidate
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring
substances with different configurations should have individual chemical names and codes (CAS
number, FLAVIS number etc.).
Seven of the 14 candidate substances possess chiral centres. For five of these chiral substances the
chemical names and CAS numbers specify the stereoisomers. For two of the substances [FL-no:
01.027 and 01.034] information on the stereoisomeric composition has been provided (EFFA, 2010)
(see Table 1).
Due to the presence and the position of double bonds three of the 14 candidate substances can exist as
geometrical isomers. For two of these flavouring substances [FL-no: 01.027 and 01.035] Industry has
provided the information on the ratios of these isomers (see Table 1). For [FL-no: 01.064] CAS
number and name specify the configuration of the double bond.
2.3. Natural Occurrence in Food
Twelve of the 14 candidate substances have been reported to occur in various types of alcoholic
beverages, chicken, egg (boiled), fish (raw), guinea hen, lamb fat, cheese, milk, butter, various herbs,
various fruits and vegetables, tea, mace and liquorice.
Table 2: Candidate Substances Reported to Occur in Food (TNO, 2000; TNO, 2010)
FL-no: Name: Quantitative data reported
01.001 Limonene Up to 1.6 mg/kg in carrot, up to 0.3 in black currants, up to 1.4mg/kg in tea and very high content in citrus oil
01.028 β-Bisabolene 
33.3 mg/kg in parsley, up to 1.18 mg/kg in carrot, 0.003
mg/kg in artichoke, 0.0003 mg/kg in guava fruit, trace
amounts in mace and in nutmeg
01.033 2,2-Dimethylhexane Up to 0.9 mg/kg in tea
01.034 2,4-Dimethylhexane Up to 2 mg/kg in tea
01.035 2,6-Dimethylocta-2,4,6-triene 0.45 mg/kg in mango, 0.03 mg/kg in orange juice, up to 0.08mg/kg in blackcurrants, trace amounts in sage
01.038 Dodecane
Up to 3.5 mg/kg in butter, up to 0.1 mg/kg in passiflora, 0.1
mg/kg in beans, 0.1 mg/kg in cocoa, 0.1 mg/kg in tea, up to
0.1 mg/kg in lamb, 0.08 mg/kg in dill, up to 0.05 mg/kg in
strawberry, 0.02 mg/kg in chicken, up to 0.01 mg/kg in loquat,
up to 0.01 mg/kg in papaya, 0.01 mg/kg in pea, up to 0.004
mg/kg in egg, 0.009 mg/kg in Guinea hen, 0.0006 mg/kg in
raw fish, trace amounts in liquorice
01.039 delta-Elemene Trace amounts in mandarin juice
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Table 2: Candidate Substances Reported to Occur in Food (TNO, 2000; TNO, 2010)
FL-no: Name: Quantitative data reported
01.054 Pentadecane
Up to 2.3 mg/kg in butter, up to 0.4 mg/kg in mango, up to
0.346 mg/kg in cheese, 0.1 mg/kg in chicken, 0.1 mg/kg in
tea, up to 0.05 mg/kg in strawberry, up to 0.03 mg/kg in raw
fish, 0.029 mg/kg in Guinea hen, up to 0.02 mg/kg in egg
(boiled), 0.014 mg/kg in milk powder, up to 0.01 mg/kg in
papaya, 0.02 mg/kg in tamarind, 0.00001 mg/kg in aubergine,
trace amounts in liquorice
01.057 Tetradecane
Up to 1.9 mg/kg in butter, 0.3 mg/kg in liquorice, up to 0.3
mg/kg in mango, up to 0.3 mg/kg in dill, 0.021 mg/kg in
guinea hen, up to 0.15 mg/kg in cheese, 0.1 mg/kg in cocoa,
0.1 mg/kg in tea, 0.088 mg/kg in passiflora, up to 0.05 mg/kg
in strawberry, up to 0.01 mg/kg in papaya, up to 0.003 mg/kg
in egg, 0.001 mg/kg in milk 0.0005 mg/kg in chicken, 0.0008
mg/kg in raw fish, trace amounts in thymus, aubergine,
coconut and lamb
01.059 4(10)-Thujene
Up to 1000 mg/kg in caraway seed (oil), up to 1.9 mg/kg in
blackcurrant, up to 5.2 mg/kg in carrot, up to 49000 mg/kg in
cardamom (oil), up to 4000 mg/kg in coriander seed (oil), up
to 4800 mg/kg in cumin seed (oil), 239000 mg/kg in pepper
(oil) (different species), 334000 mg/kg in ginger (oil), up to
87600 mg/kg in laurel (oil), up to 510000 mg/kg in nutmeg
(oil)
01.064 cis-3,7-Dimethyl-1,3,6-octatriene
Up to 13.6 mg/kg in guava fruit, up to 7.5 mg/kg in mango,
5.3 mg/kg in celery, 2.7 mg/kg in parsley, 2 mg/kg in dill, up
to 0.6 mg/kg in tea, up to 0.5 mg/kg in papaya, up to 0.2
mg/kg in blackcurrant, 0.18 mg/kg in grapefruit, 0.05 mg/kg
in cocoa, up to 0.01 mg/kg in passiflora, trace amounts in
nectarine
01.070 1-Octene Up to 0.009 mg/kg in butter (1.7 mg/kg in heated butter), up to0.001 mg/kg in boiled egg, 0.002 mg/kg in guinea hen
According to TNO two of the substances have not been reported to occur naturally in any food items
(Table 3):
Table 3: Candidate Substances Not Reported to Occur in Food (TNO, 2000; TNO, 2011)
FL-no: Name:
01.027 Bisabola-1,8,12-triene
01.046 l-limonene
3. Specifications
Purity criteria for the 14 substances have been provided by the Flavour Industry (EFFA, 2005a; EFFA,
2006a; EFFA, 2006b; Flavour Industry, 2006; Flavour Industry, 2009) (see Table 1).
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC,
2000), this information is adequate for all 14 candidate substances (see Section 2.2 and Table 1).
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4. Intake Data
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU
population are consumers (SCF, 1999).
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties in
the underreporting correction factor and to uncertainties in the percentage of consumers, the reliability
of intake estimates on the basis of the MSDI approach is difficult to assess.
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In
such cases, the human exposure thresholds below which exposures are not considered to present a
safety concern might be exceeded.
Considering that the MSDI model may underestimate the intake of flavouring substances by certain
groups of consumers, the SCF recommended also taking into account the results of other intake
assessments (SCF, 1999).
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable
beverages and foods in general, with exceptional levels for particular foods. This method is regarded
as a conservative estimate of the actual intake by most consumers because it is based on the
assumption that the consumer regularly eats and drinks several food products containing the same
flavouring substance at the upper use level.
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use
levels of the flavouring substances. This modified approach is less conservative (e.g., it may
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels
reported) (EC, 2000). However, it is considered as a suitable tool to screen and prioritise the
flavouring substances according to the need for refined intake data (EFSA, 2004a).
4.1. Estimated Daily per Capita Intake (MSDI Approach)
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach,
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999). These
data are derived from surveys on annual production volumes in Europe. These surveys were conducted
in 1995 by the International Organization of the Flavour Industry (IOFI), in which flavour
manufacturers reported the total amount of each flavouring substance incorporated into food sold in
the EU during the previous year (IOFI, 1995). The intake approach does not consider the possible
natural occurrence in food.
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is
consumed by 10 % of the population12 (Eurostat, 1998). This is derived for candidate substances from
estimates of annual volume of production provided by Industry and incorporates a correction factor of
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999).
In the present FGE.25Rev3 the total annual production volume of the 14 candidate substances from
use as flavouring substances in Europe was reported to be approximately 51 000 kg13 (EFFA, 2005a;
12 EU figure 375 million. This figure relates to EU population at the time for which production data are available, and is
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available
for the enlarged EU.
13 The substances which are no longer supported have such low production volumes that their removal from this FGE hardly
affects the total annual production volume.
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EFFA, 2005b; EFFA, 2006a; EFFA, 2006b; EFFA, 2008; Flavour Industry, 2006). For the
18 supporting substances the total annual volume of production in Europe is approximately 330 000
kg. d-Limonene [FL-no: 01.045] accounts for 280 000 kg and 47 000 kg is accounted for by seven
other supporting substances: [FL-no: 01.003, 01.004, 01.005, 01.006, 01.007, 01.008 and 01.020]
(JECFA, 2005b).
On the basis of the annual volumes of production reported for the 14 candidate substances, the MSDI
values for each of these flavourings have been estimated (Table 7).
Nearly 100 % of the total annual volume of production for the candidate substances is accounted for
by two substances [FL-no: 01.001 and 01.046]. The estimated daily per capita intake from use as
flavouring substance is 4000 and 2100 µg, respectively. The daily per capita intakes for each of the
remaining substances are less than 28 µg (Table 7).
4.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI)
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values
is based on the approach used by SCF up to 1995 (SCF, 1995).
The assumption is that a person may consume a certain amount of flavourable foods and beverages per day.
For all candidate substances information on food categories and normal and maximum use levels14,15
were submitted by the Flavour Industry (EFFA, 2005a; EFFA, 2006a; EFFA, 2007, EFFA, 2015). For
the present calculation of mTAMDI, the reported normal use levels were used. In the case where
different use levels were reported for different food categories the highest reported normal use level
was used.
Table 4: Use of Candidate Substances
Food
category
Description Flavourings used
01.0 Dairy products, excluding products of category 2 14
02.0 Fats and oils, and fat emulsions (type water-in-oil) 14
03.0 Edible ices, including sherbet and sorbet 14
04.1 Processed fruits 14
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers,
pulses and legumes), and nuts & seeds
None
05.0 Confectionery 14
06.0 Cereals and cereal products, incl. flours & starches from roots &
tubers, pulses & legumes, excluding bakery
14
07.0 Bakery wares 14
08.0 Meat and meat products, including poultry and game 14
09.0 Fish and fish products, including molluscs, crustaceans and
echinoderms
14
10.0 Eggs and egg products FL-no: 01.001, 01.046, 01.070
11.0 Sweeteners, including honey FL-no: 01.001, 01.046, 01.070
12.0 Salts, spices, soups, sauces, salads, protein products etc. 14
13.0 Foodstuffs intended for particular nutritional uses 14
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 14
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic
counterparts
14
15.0 Ready-to-eat savouries 14
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that
could not be placed in categories 1 – 15
14
14 “Normal use” is defined as the average of reported usages and “maximum use” is defined as the 95th percentile of reported
usages (EFFA, 2002).
15 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived
from 12 model flavouring substances (EFFA, 2004).
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According to the Flavour Industry the normal use levels for the 14 candidate substances, for which use
levels have been provided, are in the range of 1 - 20 mg/kg food, and the maximum use levels are in
the range of 1 - 100 mg/kg (EFFA, 2002; EFFA, 2005a; EFFA, 2006a; EFFA, 2007, EFFA, 2015)
Table B.1.2, Appendix B.
The mTAMDI values are for 11candidate substances from structural class I (see Table 6) above the
threshold for structural class I of 1800 µg/person per day. For limonene [FL-no: 01.001] the mTAMDI
is 1800 µg/person per day and for each of l-limonene and 1-octene [FL-no: 01.046 and 01.070] the
mTAMDI is 1600 µg/person per day.
For detailed information on use levels and intake estimations based on the mTAMDI approach, see
Section 7 and Appendix B.
5. Absorption, Distribution, Metabolism and Elimination
Generally, the available data indicate that the aliphatic and alicyclic hydrocarbons may participate in
similar metabolic pathways. Being lipophilic and of relatively low molecular weight, these
hydrocarbons may be assumed to be absorbed in the gastrointestinal tract. Subsequently, they can be
oxidised to polar oxygenated metabolites, e.g. by CYP-450 enzymes. The phase I metabolites can then
be conjugated and excreted mainly in the urine. The candidate and supporting substances are expected
to be metabolised either by side chain oxidation or epoxidation of the exocyclic or endocyclic double
bonds. Alkyl oxidation initially yields hydroxylated metabolites that may be excreted in conjugated
form or undergo further oxidation, yielding more polar metabolites, which can also be excreted. If a
double bond is present, intermediate epoxide metabolites may be formed, which are transformed either
by hydrolysis to yield diols or by conjugation with glutathione to yield mercapturic acid derivatives.
The saturated alkanes in this group may be anticipated to be metabolised via omega and omega-1, -2, -
3 or -4 oxidation. Whereas omega oxidation would ultimately lead to the formation of carboxylic
acids, the other oxidations would give rise to secondary alcohols and ketones. The carboxylic acids
may be expected to participate in the endogenous fatty acid metabolism.
However, for most of the four subgroups (see Appendix C) the information available was scarce and
the similarity between candidate and supporting substances was limited. In addition, proper mass
balance data were not available. The few mass balance data available indicated only slow elimination.
For several subgroups no data were available at all. In Table 5 the final conclusion for each of the
candidate substances have been presented together with a brief explanatory statement. For subgroup
III there are only data for one supporting substance, d-limonene [FL-no: 01.045], which is oxidised in
both side chains to yield alcohols and carboxylic acids, which may be conjugated and eliminated in the
urine.
A more detailed description of the metabolism is given in Appendix C.
Flavouring Group Evaluation 25 Revision 3
EFSA Journal 2015;13(4):4069 19
Table 5: Can Innocuous Metabolites be Expected to be Formed Based on Available Data?
FL-no: Substance name Innocuous metabolites?
Subgroup I: ACYCLIC ALKANES
01.033 2,2-Dimethylhexane Yes
01.034 2,4-Dimethylhexane Yes
01.038 Dodecane Yes
01.054 Pentadecane Yes
01.057 Tetradecane Yes
Subgroup II: ACYCLIC ALKENES
01.035 2,6-Dimethylocta-2,4,6-triene No
01.064 cis-3,7-Dimethyl-1,3,6-octatriene No (presence of terminal double bond which may
give rise to reactive metabolites without counteracting
metabolic options)
01.070 1-Octene No (presence of terminal double bond which may
give rise to reactive metabolites without counteracting
metabolic options)
Subgroup III: CYCLOHEXENE HYDROCARBONS
01.027 Bisabola-1,8,12-triene Yes
01.028 β-Bisabolene Yes
01.039 delta-Elemene Yes
01.001 Limonene Yes
01.046 l-Limonene Yes
Subgroup IV: AROMATIC HYDROCARBONS
The substances previously allocated to this subgroup are no longer supported for use as flavouring substances in Europe
by Industry
Subgroup V: BICYCLIC, NON-AROMATIC HYDROCARBON
01.059 4(10)-Thujene No
Subgroup VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS
The substances previously allocated to this subgroup are no longer supported for use as flavouring substances in Europe
by Industry
6. Application of the Procedure for the Safety Evaluation of Flavouring Substances
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach.
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure.
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake
estimations based on the MSDI approach and the mTAMDI approach, see Section 7.
For the safety evaluation of the 14 candidate substances from chemical group 31, the Procedure as
outlined in Appendix A was applied, based on the MSDI approach. The stepwise evaluations of these
14 substances are summarised in Table 7.
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Step 1
All 14 candidate substances evaluated using the Procedure are classified into structural class I [FL-no:
01.001, 01.027, 01.028, 01.033, 01.034, 01.035, 01.038, 01.039, 01.046, 01.054, 01.057, 01.059,
01.064 and 01.070], according to the decision tree approach presented by Cramer et al. (Cramer et al.,
1978).
Step 2
On the basis of the metabolism information available, candidate substances of subgroup I [FL-no:
01.033, 01.034, 01.038, 01.054 and 01.057] and candidate substances of subgroup III [FL-no: 01.001,
01.027, 01.028, 01.039 and 01.046] may be predicted to be metabolised to innocuous products at the
estimated levels of intake based on the MSDI approach. Accordingly the evaluation of these 10
substances, all belonging to structural Cramer class I, will proceed along the A-side of the Procedure
scheme.
Two candidate substances from subgroup II [FL-no: 01.064 and 01.070] contain terminal double
bonds in the absence of other functional groups that may provide alternative routes of detoxication.
Therefore, for these two substances it cannot be concluded that they will be metabolised to innocuous
products, and accordingly they proceed along the B-side of the Procedure scheme.
For the remaining two candidate substances [FL-no: 01.035 and 01.059] there are not sufficient data
available on biotransformation to conclude that they will be metabolised to innocuous products, and
therefore their evaluation will proceed along the B-side of the Procedure scheme.
Step A3
The five candidate substances from subgroup I [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057]
and three candidate substances from subgroup III [FL-no: 01.027, 01.028 and 01.039], proceeding via
the A-side, have been assigned to structural class I and have estimated European daily per capita
intakes ranging from 0.012 to 2.7 µg (Table 6). These intakes are below the threshold of concern of
1800 µg/person per day for structural class I. Accordingly, it is concluded that these eight candidate
substances do not pose a safety concern as flavouring substances when used at estimated levels of
intake, based on the MSDI approach. Two candidate substances from subgroup III [FL-no: 01.001 and
01.046] have an estimated European daily per capita intakes of 4000 and 2100 µg, respectively, which
are above the threshold of concern of 1800 µg/person per day for structural class I. These two
candidate substances will therefore proceed to step A4 of the Procedure scheme.
Step A4
The candidate substances [FL-no: 01.001 and 01.046] or their metabolites are not endogenous.
Step A5
The two candidate substances [FL-no: 01.001 and 01.046] are supported by the substance [FL-no:
01.045] for which an adequate carcinogenicity study is available. From this study a no observed
adverse effect level (NOAEL) of 215 mg/kg bw per day can be derived. The estimated daily per capita
intake is 4000 µg for [FL-no: 01.001] and 2100 µg for [FL-no: 01.046], corresponding to 0.07 mg/kg
bw per day and 0.035 mg/kg bw per day at a body weight of 60 kg, respectively. Thus, a margin of
safety of 3070 can be calculated for [FL-no: 01.001] and a margin of safety of 6140 can be calculated
for [FL-no: 01.046]. These two substances are accordingly not expected to be of safety concern at the
estimated levels of intake.
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Step B3
The four candidate substances [FL-no: 01.035, 0.059, 01.064 and 01.070] proceeding via the B-side
and which have been assigned to Cramer structural class I have estimated European daily per capita
intakes between 0.0085 and 14 µg (Table 6). These intakes are below the threshold of concern of 1800
µg/person per day for structural class I. Accordingly, these four substances proceed to step B4 of the
Procedure.
Step B4
For one of these substances, 4(10)-thujene [FL-no: 01.059] a margin of safety could be calculated
based upon a NOAEL (222 mg/kg bw per day) for the supporting substance ß-caryophyllene [FL-no:
01.007]. Compared to the MSDI of 4(10)-thujene of 14 µg/capita per day equal to 0.2 µg/kg bw per
day, the NOAEL provides a margin of safety of 9.5 x 105.
For the three remaining substances, 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-
1,3,6-octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070] margins of safety could be calculated
based upon a NOAEL (44 mg/kg bw per day) for the supporting substance myrcene [FL-no: 01.008].
Compared to the MSDI of 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-1,3,6-
octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070] of 9.1, 14 and 0.0085 µg/capita per day
equal to 0.15, 0.23 and 0.00014 µg/kg bw per day, the NOAEL provides margins of safety of 2.9 x
105, 1.9 x 105 and 3.1 x 108.
7. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI
Approach
For 11 of the 14 candidate substances, the mTAMDIs are above the threshold for structural class I of
1800 µg/person per day. For limonene [FL-no: 01.001] the mTAMDI is 1800 µg/person per day and
for each of l-limonene and 1-octene [FL-no: 01.046 and 01.070] the mTAMDI is 1600 µg/person per
day.For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach,
see Table 6.
For 11 of the 14 candidate substances, further information is required. This would include more
reliable intake data and then, if required, additional toxicological data.
Table 6: Estimated intakes based on the MSDI approach and the mTAMDI approach
FL-no EU Register name MSDI
(µg/capita/day)
mTAMDI
(µg/person/day)
Structura
l class
Threshold of
concern
(µg/person/day)
01.027 Bisabola-1,8,12-triene 0.024 3900 Class I 1800
01.028 beta-Bisabolene 2.7 3900 Class I 1800
01.033 2,2-Dimethylhexane 1.2 3900 Class I 1800
01.034 2,4-Dimethylhexane 1.2 3900 Class I 1800
01.038 Dodecane 0.012 3900 Class I 1800
01.039 delta-Elemene 0.012 3900 Class I 1800
01.054 Pentadecane 0.61 3900 Class I 1800
01.057 Tetradecane 0.012 3900 Class I 1800
01.035 2,6-Dimethylocta-2,4,6-triene 9.1 3900 Class I 1800
01.059 4(10)-Thujene 14 3100 Class I 1800
01.064 cis-3,7-Dimethyl-1,3,6-octatriene 14 3900 Class I 1800
01.070 1-Octene 0.0085 1600 Class I 1800
01.001 Limonene 4000 1800 Class I 1800
01.046 l-Limonene 2100 1600 Class I 1800
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8. Considerations of Combined Intakes from Use as Flavouring Substances
Because of structural similarities of candidate and supporting substances, it can be anticipated that
many of the flavourings are metabolised through the same metabolic pathways and that the
metabolites may affect the same target organs. Further, in case of combined exposure to structurally
related flavourings, the pathways could be overloaded. Therefore, combined intake should be
considered. As flavourings not included in this FGE may also be metabolised through the same
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed.
The total estimated combined daily per capita intake of structurally related flavourings is estimated by
summing the MSDI for individual substances.
The combined intakes have been calculated on the basis of the annual production volumes from use as
flavouring substances in Europe (EFFA, 2005a; EFFA, 2005b; EFFA, 2006a; EFFA, 2006b; Flavour
Industry, 2006; JECFA, 2005b).
Subgroup I (acyclic alkanes): The combined intake of the five candidate substances, all from structural
class I and evaluated via the A-side of the Procedure (Appendix A), is 3.0 µg/capita per day, which
does not exceed the threshold of 1800 µg/person per day. There are no supporting substances in
subgroup I.
Subgroup II (acyclic alkenes): The combined intake of the three candidate substances, all from
structural class I and evaluated via the B-side of the Procedure (Appendix A), is 23 µg/capita per day,
which does not exceed the threshold of 1800 µg/person per day. Subgroup III (cyclohexene
hydrocarbons): The combined intake of the five candidate substances, all from structural class I and
evaluated via the A-side of the Procedure (Appendix A), is 6100 µg/capita per day, which exceeds the
threshold of 1800 µg/person per day. The total combined intake of the five candidate and six
supporting substances (also from structural class I) is approximately 42000 µg/capita per day. This
intake exceeds the threshold of 1800 µg/person per day for a structural class I substance. However,
together, limonene [FL-no: 01.001], l-limonene [FL-no: 01.046] and d-limonene (supporting substance
[FL-no: 01.045]) account for approximately 40000 µg/capita per day. The total combined intake of
42000 µg/capita per day for the candidate and the supporting substances corresponds to 700 µg/kg bw
per day for a person with a body weight of 60 kg. Thus, based on the NOAEL for d-limonene of
215 mg/kg bw per day, derived from a chronic 2-year toxicity study, a margin of safety of 307 can be
calculated, and accordingly these substances are not expected to be of safety concern at the estimated
level of intake.
Subgroup V (bicyclic, non-aromatic hydrocarbons): The total combined intake of the one candidate
and eight supporting substances, all from structural class I and evaluated via the B-side of the
Procedure (Appendix A) is approximately 3800 µg/capita per day. This intake exceeds the threshold
of 1800 µg/person per day for a structural class I substance. However, together, three supporting
substances, pin-2(10)-ene [FL-no: 01.003], pin-2(3)-ene [FL-no: 01.004] and β-caryophyllene [FL-no: 
01.007] account for approximately 3400 µg/capita per day. The total combined intake of
3800 µg/capita per day for the candidate and the supporting substances corresponds to 63 µg/kg bw
per day for a person with a body weight of 60 kg. Thus, based on the NOAEL for β-caryophyllene of 
222 mg/kg bw per day, a margin of safety of 3500 can be calculated, and accordingly these substances
are not expected to be of safety concern at the estimated level of intake.
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9. Toxicity
9.1. Acute Toxicity
Data are available for two candidate substances, 15 supporting substances and one structurally related
substance (1-methyl cyclohexa-1,3-diene [former FL-no: 01.077]). Oral LD50 values in rat and mouse
ranged from 1590 to 13 000 mg/kg body weight (bw).
The acute toxicity data are summarised in Table 9.
9.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies
Data are available for two supporting substances from subgroup II (myrcene [FL no: 01.008] and
undeca-1,3,5-triene [FL no: 01.061], for one supporting substance from subgroup III (d-limonene
[FL no: 01.045]), for three supporting substances for subgroup V (pinene [FL no: 01.003], β-
caryophyllene [FL-no: 01.007] and camphene [FL no: 01.009]) (see also Table 10). In the text below
the relevant studies are discussed.
Subgroup II
Myrcene [01.008]
Mice, 90 day study (NTP, 2010)
Male and female B6C3F1 mice (10/sex/group) were administered 0, 250, 500, 1000, 2000 or 4000
mg/kg bw of myrcene by gavage 5 days a week for 14 weeks. Body weights and clinical observations
were recorded weekly. Blood was collected from mice surviving to the end of the study for
haematological analyses and micronuclei evaluation. Sperm morphology and vaginal cytology
evaluations were conducted at the end of the study on animals in the control and three lowest dose
groups. At necropsy, organ weights were measured and complete histopathological examination was
performed on animals from the dose groups 0, 1000, 2000 and 4000 mg/kg bw, and all animals that
died early.
All animals in the 4000 mg/kg bw group died within the first three days while 9 of 10 males and 8 of
10 females in the 2000 mg/kg bw group died prior to week 5. In animals that died prior to study
termination, clinical signs included lethargy, abnormal breathing and/or thin appearance. The final
mean body weights and body weight gain of the 1000 mg/kg bw males and 500 mg/kg bw females
were significantly less than those of vehicle controls. Because of the low survival in the two top doses,
further results are not reported for those doses.
A significant, approximately 15-20 % decrease in hematocrit, haemoglobin and erythrocyte count
values was observed in the 1000 mg/kg bw dose group in both females and males at week 14. A dose-
dependent significant increase in the relative liver weight (approximately 7 %, 6 % and 17 %) were
observed for all doses in male mice, and a significant increase in absolute liver weight were observed
for the low dose males only. In female mice a dose-dependent significant increase in relative kidney
weight was observed at all doses (approximately 14 %, 12 % and 22 %), with a significant increase in
absolute kidney weight in the 1000 mg/kg bw dose group only. Also for female mice dose-dependent
increases in absolute and relative liver weight (approximately 8 %, 17 % and 26 %) were observed,
but the increase reached statistical significance only at 500 and 1000 mg/kg bw. There were no
significant changes seen in the weights of the reproductive organs, in the sperm parameters, or in
oestrous cyclicity at any dose level. No significant histopathological changes in other organs
examined, including kidney, were observed in mice receiving up to 1000 mg/kg bw myrcene for
14 weeks.
As a significant dose-dependent increase in the relative kidney weight was observed for female mice
at all treatment doses, no NOAEL for this study could be allocated.
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Rats, 90-day study (NTP, 2010)
Male and female F344N Fisher rats (10/sex/group) were administered 0, 250, 500, 1000, 2000 or 4000
mg/kg bw of myrcene by gavage 5 days a week for 14 weeks. Body weights and clinical observations
were recorded weekly. Blood was collected from rats surviving to the end of the study for clinical
chemistry and haematological analyses. Sperm morphology and vaginal cytology evaluations were
conducted at the end of the study on animals in the control and three lowest dose groups. At necropsy,
organ weights were measured and complete histopathological examination was performed on animals
from the dose groups 0, 2000 and 4000 mg/kg bw, and all animals that died early. Tissues were
examined in the lower dose groups to a no-effect level, including renal pathology in all dose groups.
Additionally sections of kidney from both sexes were stained using the Mallory-Heidenhain technique
for investigation of hyaline droplet formation (indicative of development of α2µ-globulin). 
All animals in the group receiving 4000 mg/kg bw myrcene died within the first week of the study,
except for one male that died at day 11. One male receiving 500 mg/kg bw, one male and one female
receiving 1000 mg/kg bw and two males and four females receiving 2000 mg/kg bw died before the
end of the study. Final mean body weight and mean body weight gains of males and females
administered 500 mg/kg bw or more were significantly less than those of vehicle control. At
termination at week 14, dose-related decreases in plasma creatinine concentration in both males and
females were observed, statistically significant at 500 mg/kg bw and above in males and at 250 mg/kg
bw and above in females. These decreases were suggested by the authors to be associated with the
decreased body weight gains observed in treated rats. No other consistent changes in clinical
chemistry parameters were found.
Absolute kidney and liver weights were significantly increased in both male and female rats receiving
myrcene. Also a dose-dependent increase in the relative liver and kidney weights were observed for
males (25-150 % in kidney, 13-46 % in liver) and females (27-100 % in kidney, 13-67 % in liver).
Microscopically, the incidence of renal tubular necrosis was significantly increased in all dosed groups
of males and females, with increasing severity from minimal to moderate related to dose. Both control
and treated rats showed development of chronic progressive nephropathy (CPN), although the
incidence was higher in treated rats. Treatment-related increases in the incidences and severity of
hyaline droplet accumulation were found in the 250, 500 and 1000 mg/kg bw males, accompanied by
granular casts in the outer medulla of the kidney. Hyaline droplet formation was not observed in the
2000 mg/kg bw males, although the animals showed a high incidence of renal tubular necrosis,
nephrosis and CPN. No evidence of hyaline droplet accumulation was found in female rats, however
treated females showed both nephrosis and CPN. A significant increase in nephrosis was observed in
the 1000 and 2000 mg/kg bw dose groups of both males and females, with a dose-related increase in
severity from minimal to moderate. Nephrosis is an uncommon lesion defined as renal tubule
epithelial degeneration and regeneration.
A dose-related effect of myrcene in the nose was observed in both sexes as degeneration of the
olfactory epithelium and necrosis of the respiratory epithelium (significant only at 2000 mg/kg bw)
accompanied by chronic inflammatory change (significant at 1000 and 2000 mg/kg bw).
The incidence of splenic atrophy were significantly increased in both sexes receiving 2000 mg/kg bw,
accompanied by thymic necrosis in one male and three females. In the mesenteric lymph node, the
incidence of atrophy were increased in males receiving 2000 mg/kg bw and females receiving 1000 or
2000 mg/kg bw. The lymphoid changes in these organs were considered by the authors to be
secondary to morbidity rather than a direct toxic effect of myrcene.
It has been argued that increased hyaline droplet accumulation in male rats is characteristic of α2µ-
globulin nephropathy (Hard et al., 1993), which is a male rat specific effect with little relevance for
humans. The evidence provided for the mechanistic background of the hyaline droplet formation was
considered too limited to completely disregard the nephrotoxic effects in male rats as irrelevant for
humans. Involvement of α2µ-globulin accumulation (e.g. by immunohistochemical techniques) was 
not demonstrated. In addition, also renal toxicity was observed in the female animals. Therefore, based
on the presence of renal tubular necrosis in all test groups, a NOAEL could not be assigned.
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Mice, 2-year carcinogenicity study (NTP, 2010)
Groups of B6C3F1 mice (50/sex/group) were administered 0, 250, 500 or 1000 mg myrcene/kg bw per
day in corn oil by gavage once per day, five days a week for 104 (females) weeks or 105 weeks
(males). The animals were observed twice per day and weighed once per week for 12 weeks and once
per month thereafter. Complete necropsies and microscopic examination were performed on all
animals. Histological examinations were performed on all animals and tissues from all major organs
were examined.
Mean body weights of males receiving 1000 mg/kg bw and females receiving 500 or 1000 mg/kg bw
were less than those of the vehicle control. Survival of the high-dose group was significantly reduced
for both males and females. Due to the high mortality in the 1000 mg/kg bw dose group, the results
from this group are not described further.
In the liver there was an increase in hepatocellular carcinoma in both males and females, with a
significant increase in incidence in males at the 500 mg/kg bw dose level (incidence 1 in controls, 4 in
the 250 mg/kg bw group and 9 in the 500 mg/kg bw group) and females at 250 mg/kg bw, but not at
500 mg/kg bw. Males and to a lesser extent females showed an increase in hepatocellular adenoma in
the liver at both 250 and 500 mg/kg bw. Liver hypertrophy was observed to increase with dose both in
incidence and severity, reaching statistical significance only at 500 mg/kg bw in both males and
females. Eosinophilic foci and cytoplasmic vacuolization were noted in both male and female
treatment groups.
Treatment-related changes in other organs included increases in hyperplasia, inflammation, necrosis
and ulcer of the forestomach, which were most likely attributable to gavage administration of an
irritant substance. Bone marrow atrophy and mandibular and mesenteric lymph node atrophy was
observed in both males and females at the 500 mg/kg bw dose. In addition, male mice showed atrophy
of the spleen at the 500 mg/kg bw dose.
Taking into account the high sensitivity of this mice strain to tumour development in the liver, these
effects were not regarded relevant to humans. A NOAEL of 250 mg/kg bw for myrcene was allocated,
based on the increase in bone marrow atrophy and lymph node atrophy observed in both males and
females at 500 mg/kg bw dose.
Rats, two-year carcinogenicity study (NTP, 2010)
A chronic two-year bioassay on myrcene using the standard NTP protocol with F344/N rats was
conducted. Doses were determined from the results of the prior 13-week subchronic study. Groups of
F344/N rats (50/sex/group) were administered 0, 250, 500 or 1000 mg myrcene/kg bw per day in corn
oil by gavage once per day, five days a week for 104 weeks. The animals were observed twice per day
and weighed once per week for 12 weeks and once per month thereafter. Complete necropsies and
microscopic examination were performed on all animals. Histological examinations were performed
on all animals and tissues from all major organs were examined.
Survival rates of females were comparable across all control and treatment groups. Survival of males
in the low- and mid-dose groups was similar to that in the controls. However, no males in the high-
dose group survived past 83 weeks of the study, due to renal toxicity. Body weight gain was
significantly reduced in high-dose males and females, while the mean body weight of the 500 mg/kg
females were less than those of the vehicle controls during much of the study but were similar by the
end of the study. Due to the high mortality of males in the 1000 mg/kg bw group, the data from this
dose group are not presented further.
The incidences of renal tubular adenoma and of renal tubule adenoma or carcinoma (combined)
showed a significant and dose-dependent increase in the 250 and 500 mg/kg bw males. Two renal
tubule adenomas occurred in the 1000 mg/kg bw females, the incidence being higher than the
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historical control mean for the laboratory. In males high increase in both the incidence and severity of
renal tubular nephrosis were observed, already at the lowest dose, with 84 and 92 % incidence at 250
and 500 mg/kg bw, respectively. A significant but not dose related increase in papilla mineralisation,
epithelial hyperplasia and inflammation was seen in the dose groups 250 and 500 mg/kg bw. In female
rats a dose-dependent increase in nephropathy (CPN) were observed for the doses 250, 500 and 1000
mg/kg bw and a dose-dependent increase in the incidence and severity of renal tubule nephrosis at the
doses 500 and 1000 mg/kg bw. In addition a non-dose related significant increase in renal tubular
hyperplasia was reported at the doses (250, 500, 1000 mg/kg bw). Nephrosis, observed both in male
and female rats, was reported by the authors to be an uncommon lesion defined as renal tubule
epithelial degeneration and regeneration. This indicates that myrcene might cause nephrotoxicity by a
mechanism other than, or in addition to, α2µ-globulin nephropathy. The observation of renal 
neoplasms in female rats also suggests a mechanism of carcinogenesis that may be related to nephrosis
and is distinct from the α2µ-globulin mechanism. 
Other histopathological changes seen in the study included chronic active inflammation in the nose
and forestomach, suggesting that the substance is an irritant. In females, the incidence of thyroid gland
C-cell adenomas was significantly increased in the 250 mg/kg bw group, but the incidence did not
increase with increasing dose. In the lung, the incidence of alveolar/bronchiolar adenoma in the
250 mg/kg bw group exceeded the control means, but was not observed at higher doses.
Due to the observation of renal tubular adenomas and carcinomas in all dose groups in male rats,
accompanied by an increased incidence and severity of nephrosis in both sexes, a NOAEL for
myrcene from this study could not be allocated.
Overall conclusion for the NTP study on myrcene
No overall NOAEL from the NTP study on myrcene could be allocated due to the observation renal
toxicity in male and female rats at all dose groups. The Panel has considered deriving a BMDL from
the NTP study of myrcene. However, a BMDL from this study could not be derived because of a lack
of dose-response since nearly 100 % incidence of nephropathy was observed in rats already at the
lowest dose of myrcene.
Since the publication of FGE.25Rev2 (EFSA CEF Panel, 2011) new data on myrcene have become
available (Bauter, 2013b). The results are described in more detail in FGE.78Rev 2 (EFSA CEF Panel,
in press).
In an OECD 408 compliant 90-day study the subchronic toxicity of myrcene (93.3 % pure) was
evaluated in male and female rats, based on daily exposure to the test substance in the diet (Bauter,
2013b). Four groups of adult Sprague-Dawley rats (10/sex/group) were maintained on diets prepared
to contain 0, 700, 2100 or 4200 mg/kg feed of myrcene. However, the myrcene content of the diet
decreased considerably over 7 days, so that every week a new batch of the diet was prepared.
Therefore, the Panel decided to take the concentration of myrcene in the diet on the last day of the
week for quantification of the exposure, rather than the (logarithmic) mean over the whole week.
Accordingly, an adjusted calculated mean daily intake of 8.0, 40 and 44 mg/kg bw per day,
respectively for males, and 9.6, 48 and 53 mg/kg bw per day, respectively, for females for 90 days was
calculated.
There were no mortalities, clinical, or ophthalmological changes attributable to myrcene
administration. There were no statistically significant, dietary concentration-dependent changes in
body weight, body weight gain, food consumption, or food efficiency in males and females attributed
to the administration of myrcene during the study.
There were no clinical pathological findings, changes in macroscopic or microscopic histopathology,
or organ weight changes in the groups administered myrcene. Some incidental changes in clinical
chemistry and hematology parameters were within approximate historical control values, did not
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correlate with macroscopic or histopathological findings, were without biologic impact, and were
considered not toxicologically relevant. A few histopathological changes were considered incidental,
spontaneous in nature as observed for the age and strain of rat used in this study, and had no
established relationship to administration of the test substance.
Under the conditions of the study and based on the toxicological endpoints evaluated, the no-adverse-
effect level (NOAEL) for administration of myrcene in the diet was determined to be the highest dose-
group, calculated to provide an estimated daily intake of 44 mg/kg bw per day for males and 53 mg/kg
bw per day for females, respectively.
The Panel took note of the fact that two 90-day studies are available on myrcene: the NTP study and
the study by Bauter (2013b). While the NTP study showed kidney toxicity in all animals at 250 mg/kg
body wt per day, the study by Bauter (2013b) observed no toxicity at all in the kidneys at 44 and
53 mg/kg bw per day in males and females resp. The Panel decided to accept the NOAEL of the study
by Bauter (2013b) (44 mg/kg bw per day) because the NTP study is a gavage study, which leads to
peak exposure levels compared to the Bauter study in which the compound was added in the food.
Thus, the Bauter study reflects the dietary administration (consumption with food matrix, over a more
extended period of time) in consumers much better than gavage (NTP) study. Additionally, in the
Bauter study no kidney toxicity was observed at all and the NOAEL derived from the Bauter study is
six-fold lower than the effect level in the NTP study.
Subgroup III
d-Limonene [FL-no: 01.045]
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) evaluated the supporting
substance d-limonene as an additive in its forty-first meeting in 1993, and withdrew the previous ADI
for d-limonene and allocated an ADI “not specified” (JECFA, 1993). This assessment was mainly
based on an NTP study with d-limonene from 1990 (NTP, 1990). In the carcinogenicity study, F344
rats (n = 50/dose/sex) were treated with 0, 75 and 150 mg/kg d-limonene (males) and 0, 300 and
600 mg/kg (females) by gavage in corn oil for five days a week. B6C3F1 mice (n = 50/dose/sex) were
treated with 0, 250 and 500 mg/kg d-limonene (males) and 0, 500 and 1000 mg/kg (females) in corn
oil by gavage for five days a week. In the high dose female rats, the survival was reduced. No effect
on survival or any other toxic effect was observed in the females of the low dose group. The major
toxicological effect in the male rats was found in the kidneys where a dose dependent increase in both
renal mineralization and epithelial hyperplasia, and a dose-dependent increase in renal tubular cell
adenomas and adenocarcinomas was observed. These effects were accompanied with dose related
increase in α2µ-globulin in the kidney of male rats. No increase in α2µ-globulin, kidney nephropathy 
or renal adenomas or carcinomas was found in female rats. Therefore, the toxicological effects seen in
the male rat kidneys are due to α2µ-globulin accumulation related nephropathy specifically seen in 
male rats, which is not relevant for humans (Hard et al., 1993). A reduction in the mean body weights
at the high dose group was observed for male and female rats (4 – 7 %) and high dose female mice (5-
15 %). For the male rats this reduction in mean body weight may have been linked to the toxicity in
the kidneys. Based on the decreased body weights in female mice, a NOAEL of 500 mg/kg bw per day
(5 days/week) could be derived, but considering the decrease in survival in the female rats exposed at
600 mg/kg bw per day (5 days/week) an overall NOAEL of 300 mg/kg bw per day (5 days/week)
should be derived from these NTP studies. This would correspond to 215 mg/kg bw per day for daily
exposure.
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Subgroup V
Supporting substance
ß-Caryophyllene [FL-no: 01.007]
In a 14 day range finding dietary study (Bauter, 2011), groups (3/sex/dietary intake level) of male and
female Hsd:SD® rats were fed a diet designed to provide 0 (dietary control), 6000, 18 000 and 48 000
mg/kg feed of β-caryophyllene daily. These estimated dietary levels correspond to the measured 
intakes of 0, 516, 1547 and 3569 mg/kg bw per day for males and 0, 528, 1582 and 4438 mg/kg bw
per day for females, respectively. Clinical observations were recorded daily and body weights and
food consumption observations were made on days 0, 7 and 14. There were no mortalities.
Hyperactivity observed in 1/3 (33 %) of males and females in group 4 (48 000 mg/kg feed) in the
latter part of the study may be possibly attributed to test substance administration. Dose-dependent
decreases in male food consumption and food efficiency with significant corresponding decreases in
group 4 male body weight and body weight gain were considered a result of test substance
administration, but were not correlated with any other clinical signs. Females did not exhibit
significant differences from female control. Findings at terminal sacrifice included all (100 %) males
and females of group 4 with distention (cecum) and slight redness of the stomach, small intestines, and
cecum. Based upon the limited toxicological endpoints evaluated, the study authors selected doses for
the 90-day study.
90-Day Study on β-Caryophyllene [FL-no: 01.007] 
In an OECD 408 compliant 90-day study, 4 groups of rats (10/sex/dietary intake level) of male and
female CRL Sprague-Dawley CD®IGS rats were fed a diet designed to provide 0 (dietary control),
3500, 7000 and 21 000 mg/kg feed and 3500, 14 000 and 56 000 mg/kg feed of β-caryophyllene for 
males and females, respectively, daily (Bauter, 2013a). These dietary levels corresponded to measured
daily intakes of 0, 222, 456 and 1367 mg/kg bw for males and 0, 263, 1033 and 4278 mg/kg bw for
females, respectively (Bauter, 2013a). The purity of the β-caryophyllene preparation was between 
99 % (start of study) and 96 % (end of study). Clinical observations of toxicity were performed on day
0 and weekly until sacrifice. Animals were weighed on day 0 at the start of the study and weekly
thereafter. Food consumption and efficiency were measured and calculated weekly. Blood chemistry
and haematology were performed on blood drawn via sublingual bleed during week 12 after overnight
fast. Urine was collected during the 15 hours prior to the blood draw. Prior to initiation of the study
and on day 91 the eyes of all rats were examined by focal illumination and indirect ophthalmoscopy.
At termination of the study all survivors were sacrificed and subject to full necropsy.
There were no mortalities, clinical signs of toxicity or ophthalmological changes associated with the
presence of β-caryophyllene in the diet. There were statistically significant and concentration-related 
reductions in body weight gain, food consumption and food efficiency in males and females at the 21
000 mg/kg feed and 56 000 mg/kg feed concentration groups, respectively (body weight of high dose
groups: males 77.3 %, females 82.6 % as compared to controls).
Although for some parameters statistically significant differences were found when compared to
concurrent controls, haematology, clinical chemistry, coagulation and urine analysis parameters for the
middle and high concentrations for both males in general were within the range of historical controls.
Most of these changes were small, and observed in the highest dose group. Thus, in the female test
groups, a statistically significant increase for platelet count was reported at the highest dietary level;
such an increase was not observed in the male test groups. A dose dependent increase in white blood
cells in males reached statistical significance at the middle and high dose; several other blood cells
showed significant changes at the highest dose as well in males; the effects in females were less
pronounced. There were no histopathology findings correlating to these variations.
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In females a dose-dependent decrease in serum glucose concentrations and an increase in triglyceride
levels reached statistically significance only at the highest dose level. In conjunction with changes
reported in the liver these changes were attributed to metabolic changes as a result of high
concentrations of β-caryophyllene in the diet. Pathological findings include increases in absolute and 
relative liver weights; these were found statistically significant in the mid- and high-dose groups of
both sexes. Histopathological liver changes at the mid and high intake levels for both sexes were
characterized by centrilobular to midzonal distributed hepatocellular hypertrophy. Based on
hepatocyte hypertrophy in both sexes, the increases in absolute and/or relative liver weights at the
mid- and highest dietary levels, and the absence of any other significant abnormality upon
histopathological examination, the study authors conclude that the hepatocyte hypertrophy is the result
of hepatic enzyme induction; this has, however, not been confirmed by measurements of relevant
enzymes.
Necropsy revealed enlarged kidneys in one male at the highest test concentration and significant
increases in relative kidney weight of male high-dose as well as of female mid- and high-dose groups.
Microscopic examination revealed mononuclear infiltration in only one of ten females of the highest
dose group. No other microscopically visible alterations were reported in the kidneys of female rats.
The increase in kidney weights in female remains unexplained. Microscopical examination of the
kidney of males revealed an increased incidence of nephropathy characterised by regeneration of
proximal cortical tubules with thickened membranes, mononuclear cell infiltration and tubular casts at
all dose levels. The severity of the nephropathy exhibited a dose-dependent shift from low to high
grades. Kidney cells of affected males also were reported to have necrotic nuclei and an increase in
eosinophilic cytoplasm. Likewise, in the kidneys of all treated males eosinophilic cytoplasmic droplets
were present, with a dose-dependent shift to higher grades In a supplementary study the kidney slides
of exclusively male rats were stained also with Mallory Heidenhain stain (Zook and Garlick, 2013),
which results in enhanced staining of the cytoplasmic droplets (De Rijk et al., 2003; Frazier et al.,
2012); this confirmed the observations of the eosine staining. An increased hyaline droplet
accumulation in male rats exclusively is characteristic of α2u-globulin nephropathy (Hard et al., 1993),
which is considered a male rat specific effect with little relevance for humans. Although no specific
immunohistochemical staining of α2u –globulin has been done to confirm the presence of this protein,
the Panel considers the evidence sufficient to conclude that this kidney toxicity in male rats
exclusively is not relevant for humans.
Microscopic examination of the mesenteric lymph nodes revealed the presence of erythrocytes in the
sinuses at the mid- and high-intake levels for both sexes. Additionally, reduced spleen weights for
males at the highest dietary level were considered related to general reductions in lymphoid system
weights.
The Panel concluded that under the conditions of the present 90-day dietary toxicity study and based
on the toxicological findings in haematology in males, the liver, the mesenteric lymph node pathology
in both sexes and non-explained effects in female kidneys only the lowest dose provides a no-adverse-
effect level (NOAEL) for β-caryophyllene, which is the lowest in male rats: 222 mg/kg bw per day. 
Repeated dose toxicity data are summarised in Table 10.
9.3. Developmental / Reproductive Toxicity Studies
No developmental or reproductive studies are available for the candidate substances but for three
supporting substances.
The developmental/reproductive toxicity data are summarised in Table 11.
9.4. Genotoxicity Studies
Data from in vitro tests are available for two candidate substances (subgroup I: [FL-no: 01.038 and
FL-no: 01.057]) and 10 supporting flavouring substances (one from subgroup II, four from subgroup
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III, and five from subgroup V (for pin-2(3)-ene [FL-no: 01.004] also data for separate stereoisomers
were available (+ and -)- α-pinene ), and one structurally related substance, (2-methylbuta-1,3-diene) 
not used as flavouring substance from subgroup II. Data for three supporting substances [FL-no:
01.008 (subgroup II), FL-no: 01.019 (subgroup III), FL-no: 01.004 (subgroup V), and data for the
structurally related substance from subgroup II are considered valid.
Data from in vivo tests are available for two supporting substances (one from subgroup II and one
from subgroup III) and for one substance structurally related to subgroup II (2-methylbuta-1,3-diene).
Candidate substances
Subgroup I
The two candidate substances [FL-no: 01.038 and 01.057] tested in vitro for bacterial gene mutations
gave negative results in bacterial reverse gene mutation tests and for mammalian cell gene mutations.
Subgroup II
For the three candidate substances in subgroup II [FL-no: 01.035, 01.064 and 01.070] there are no
genotoxicity data available, but it was noted that in contrast to the structurally related substance 2-
methyl-1,3-butadiene, these substances do not contain conjugated terminal double bonds, except [FL-
no: 01.064].
The available in vivo studies on the structurally related substance 2-methylbuta-1,3-diene (isoprene)
reported a negative result in a valid chromosomal aberration assay in the bone marrow of mice after 12
days of inhalatory exposure to isoprene. However, isoprene induced sister chromatid exchanges (SCE)
in the bone marrow and micronuclei in peripheral blood cells of mice after 12 days of inhalatory
exposure in two valid studies carried out within NTP. Induction of micronuclei in peripheral blood
cells of mice has also been reported after inhalatory exposure for 13 weeks. In contrast, inhalatory
exposure of isoprene to male and female rats for four weeks did not result in an increase in the
frequency of micronuclei in the lung fibroblasts. The validity of the latter two studies cannot be
evaluated due to limited details available. Isoprene has been reported to bind covalently to
haemoglobin in vivo (IARC, 1999).
The genotoxic and carcinogenic potential of isoprene has been evaluated by IARC (1999a). It was
concluded that there is sufficient evidence of carcinogenicity in experimental mammalians and that
isoprene is ‘possibly carcinogenic to humans’ (Group 2B) (IARC, 1999). Isoprene has been classified
in the EU as a ‘Muta. Cat. 3; R68’ and ‘Carc. Cat. 2; R45’ (EFSA, 2004b).
The available data on in vivo genotoxicity of isoprene indicate a genotoxic potential of the substance.
In the light of the evidence of carcinogenic activity of isoprene in rats and mice (NTP, 1999) and the
genotoxic effects of isoprene in mice and the fact that the structurally related substance 1,3-butadiene
is classified as a genotoxic carcinogen, the Panel concluded that there is reason for concern with
respect to genotoxicity and carcinogenicity of isoprene. This substance has been deleted from the
Register.
For the supporting substances myrcene, several in vitro genotoxicity tests and three in vivo
genotoxicity studies were available. All the in vitro genotoxicity tests on myrcene were negative. Two
micronucleus tests on peripheral blood cells and one chromosomal aberration assay with myrcene
gave negative results.
Conclusion on Genotoxicity for subgroup II
The supporting substance myrcene [FL-no: 01.008] (that is considered by the Panel a more adequate
supporting substance for the substances in subgroup II) has like isoprene, two conjugated terminal
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double bonds but has a longer chain length, with 10 carbon atoms, like [FL-no: 01.064]. The
genotoxicity data available on myrcene do not give rise to concern with respect to genotoxicity.
Therefore, the Panel has not concern for genotoxicity for the three substances in subgroup II.
Subgroup III
For the five candidate substances in subgroup III no genotoxicity studies were available. For the four
supporting substances, d-limonene [FL-no: 01.045], gamma-terpinene [FL-no: 01.020], α-terpinene 
[FL-no: 01.019] and α-phellandrene [FL-no: 01.006], several in vitro studies on genotoxicity were
available and they were all negative. Also two in vivo Comet assay with d-limonene and a study with
d-limonene in BigBlueTM rats were found negative. Therefore, the Panel has no concern for
genotoxicity for the substances in subgroup III.
Subgroup V
For the candidate substance in subgroup V there are no genotoxicity data available. For the supporting
substances, only negative results were reported in the available studies except for delta-3-carene (see
Table 12). Delta-3-carene was studied individually as a component in wood fumes and wood fume
condensates. A bacterial reverse gene mutation study (insufficiently reported) showed that delta-3-
carene induced gene mutations in TA100 and TA102 strains in the absence of metabolic activation at
high concentrations only, while it was negative in the presence of metabolic activation (Kurttio et al.,
1990).
Information on the supporting substance β-caryophyllene [FL-no: 01.007] has been provided by EFFA 
(EFFA, 2012). The new data submitted cover a bacterial reverse mutation assay and an in vivo mouse
erythrocyte micronucleus test.
In vitro
No evidence of genotoxic potential was observed when S. typhimurium strains TA98 and TA100 and
E. coli WP2uvrA were incubated with five test concentrations between 2300 and 9000 μg/plate in the 
presence or absence of rat liver (S9) bioactivation system using the plate incorporation method (Di
Sotto et al., 2008). The positive and negative controls provided the appropriate response in the tester
strains. However, the study design and reporting exhibits major deviations from OECD guideline 471
and is considered of insufficient quality.
In vivo
In an in vivo micronucleus induction assay, groups of mice (National Institute of Hygiene, Mexico)
(5/sex/dose) were administered a single dose of 0, 20, 200 and 2000 mg/kg bw of β-caryophyllene by 
corn oil gavage. Blood was drawn and smears for analysis were prepared at 24, 48, 72 and 96 hours
post dose. No significant increase in the induction of micronucleated polychromatic erythrocytes
(MNPE) was observed for the treatments groups while all positive controls provided the appropriate
response (Molina-Jasso et al., 2009). In a follow up study, groups of the same strain of mice
(5/sex/dose) were administered daily doses of 0, 20, 200 and 2000 mg/kg bw for three consecutive
days by corn oil gavage with blood sampled and smears for analysis prepared at 24, 48, 72 and 96
hours post administration. There was no significant increase in MNPE however there was a slight
increase in MNPE at the highest dose tested from 48 - 96 hours post dose. The authors did not
consider this an indication of genotoxic potential due to the high dose administered over three
consecutive days (Molina-Jasso et al., 2009). The Panel noted that the limit dose (2000 mg/kg) was
applied in both treatment regimens without signs of toxicity (altered PCE/NCE ratio). The study is
compliant with OCED guideline 474, except the reporting of individual data and historical controls;
therefore, this study is considered of limited validity.
Altogether, the Panel has no concern for genotoxicity for the substances in subgroup V.
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Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity
could not be assessed adequately for these substances. However, the Panel concluded that the available
data do not preclude evaluating the 14 candidate substances using the Procedure.
Data on genotoxicity are summarised in Table 12 and 13.
New Mutagenicity/Genotoxicity Studies on β-Caryophyllene [FL-no: 01.007] 
Information on the representative substance β-caryophyllene [FL-no: 01.007] has been provided by 
EFFA (EFFA, 2012). The new data submitted cover a bacterial reverse mutation assay and an in vivo
mouse erythrocyte micronucleus test.
In vitro
No evidence of genotoxic potential was observed when S. typhimurium strains TA98 and TA100 and
E. coli WP2uvrA were incubated with 5 test concentrations between 2300 and 9000 μg/plate in the 
presence or absence of rat liver (S9) bioactivation system using the plate incorporation method (Di
Sotto et al., 2008). The positive and negative controls provided the appropriate response in the tester
strains. However, the study design and reporting exhibits major deviations from OECD guideline 471
(see Table12).
In vivo
In an in vivo micronucleus induction assay, groups of mice (5/sex/dose; mouse strain from National
Institute of Hygiene (NIH), Mexico) were administered by gavage as a single dose of 0, 20, 200 and
2000 mg/kg bw of β-caryophyllene solved in corn oil. Blood was drawn and smears for analysis were 
prepared at 24, 48, 72 and 96 hours post dose. No significant increase in the induction of
micronucleated polychromatic erythrocytes (MNPE) was observed for the treatment groups while all
positive controls provided the appropriate response (Molina-Jasso et al., 2009). In a follow up study
groups of NIH mice (5/sex/dose) were administered daily doses of 0, 20, 200 and 2000 mg/kg bw for
three consecutive days by gavage with blood sampled and smears for analysis prepared at 24, 48, 72
and 96 hours post administration. The Panel noted that the limit dose (2000 mg/kg) was applied in
both treatment regimens without signs of toxicity (altered reticulocyte/NCE ratio). A slight, non-
significant increase in the MNPE frequency was observed in the highest dose group at 48, 72 and 96
hours, respectively. However, at none of these time points the effects were clearly dose-related since
the low and medium doses resulted in lower MNPE frequencies than that observed in control animals.
Overall, the Panel concluded that β-caryophyllene did not cause a significant increase in MNPE. 
However, the study exhibits deviations from OECD guideline 474 and therefore, is considered to be of
limited validity (see Table 13).
Although the newly submitted data are of limited validity they do not preclude the substances to be
evaluated using the Procedure.
For a summary of in vitro / in vivo genotoxicity data on β-caryophyllene, see Table 14. 
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CONCLUSIONS
The present revision of FGE.25, Revision 3 includes the assessment of a 90-day study on ß-
caryophyllene [FL-no: 01.007] supporting the candidate substance 4(10)-thujene [FL-no: 01.059] and
a 90-day study on myrcene [FL-no: 01.008] supporting the candidate substances 2,6-dimethylocta-
2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] and 1-octene [FL-no:
01.070].
Since the publication of FGE.25Rev2, the Industry has informed EFSA that 23 substances [former FL-
no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 01.036, 01.037, 01.042, 01.043, 01.044, 01.047,
01.050, 01.051, 01.052, 01.053, 01.055, 01.056, 01.058, 01.060, 01.066, 01.067 and 01.078] are no
longer supported for use as flavouring substances in Europe by Industry. The FGE.25Rev3 therefore
deals with 14 flavouring substances in total.
The 14 candidate substances are aliphatic hydrocarbons from chemical group 31, which belong to the
subgroups I) acyclic alkanes, II) acyclic alkenes, III) cyclohexene hydrocarbons and V) bicyclic, non-
aromatic hydrocarbons.
Seven of the 14 flavouring substances possess chiral centres and three can exist as geometrical
isomers.
All of the 14 candidate substances are classified into structural class I, according to the decision tree
approach presented by Cramer et al. (1978).
Twelve of the 14 candidate substances have been reported to occur naturally in a wide range of food
items.
According to the default MSDI approach, 12 of the 14 flavouring substances in this group have intakes
in Europe from 0.0085 to 14 µg/capita per day, which are below the threshold of concern value for
structural class I (1800 µg/person per day) substances. For limonene [FL-no: 01.001] and l-limonene
[FL-no: 01.046] the intakes are 4000 and 2100 µg/capita per day, which are above the threshold of
concern value for structural class I (1800 µg/person per day).
On the basis of the reported annual production volumes in Europe (MSDI approach), the total
combined intakes of the candidate and supporting substances can be calculated for the substances in
subgroup I , II, III and V.
Subgroup I (acyclic alkanes): the combined intake of the five candidate substances, all from structural
class I and evaluated via the A-side of the Procedure (Appendix A), is 3.0 µg/capita per day, which
does not exceed the threshold of 1800 µg/person per day. There are no supporting substances in
subgroup I.
Subgroup II (acyclic alkenes): the combined intake of the three candidate substances, all from
structural class I and evaluated via the B-side of the Procedure (Appendix A), is 23 µg/capita per day,
which does not exceed the threshold of 1800 µg/person per day.
Subgroup III (cyclohexene hydrocarbons): the combined intake of the five candidate substances, all
from structural class I and evaluated via the A-side of the Procedure (Appendix A), is 6100 µg/capita
per day, which does exceed the threshold of 1800 µg/person per day. The total combined intake of the
five candidate and six supporting substances (also from structural class I) is approximately 42 000
µg/capita per day. This intake exceeds the threshold of 1800 µg/person per day for a structural class I
substance. However, together, limonene [FL-no: 01.001], l-limonene [FL-no: 01.046] and d-limonene
(supporting substance [FL-no: 01.045]) account for approximately 40 000 µg/capita per day. The total
combined intake of 42 000 µg/capita per day for the candidate and the supporting substances
corresponds to 700 µg/kg bw per day for a person with a body weight of 60 kg. Thus, based on the
NOAEL for d-limonene of 215 mg/kg bw per day, derived from a chronic 2-year toxicity study, a
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margin of safety of 307 can be calculated, and accordingly these substances are not expected to be of
safety concern at the estimated level of intake.
Subgroup V (bicyclic, non-aromatic hydrocarbon): the total combined intake of the one candidate and
eight supporting substances, all from structural class I and evaluated via the B-side of the Procedure
(Appendix A) is approximately 3800 µg/capita per day. This intake exceeds the threshold of 1800
µg/person per day for a structural class I substance. However, together, three supporting substances,
pin-2(10)-ene [FL-no: 01.003], pin-2(3)-ene [FL-no: 01.004] and β-caryophyllene [FL-no: 01.007] 
account for approximately 3400 µg/capita per day. The total combined intake of 3800 µg/capita per
day for the candidate and the supporting substances corresponds to 63 µg/kg bw per day for a person
with a body weight of 60 kg. Thus, based on the NOAEL for β-caryophyllene of 222 mg/kg bw per 
day, a margin of safety of 3500 can be calculated, and accordingly these substances are not expected
to be of safety concern at the estimated level of intake.
The available information on metabolism of the 14 candidate substances evaluated through the
Procedure or the supporting substances for this FGE was very limited. Overall, for the following 10
candidate substances it can be concluded that they will be metabolised into innocuous metabolites:
[FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and [FL-no: 01.001, 01.027,
01.028, 01.039 and 01.046] from subgroup III. For four candidate substances [FL-no: 01.064, 01.070,
01.035 and 01.059], it cannot be assumed that they are metabolised to innocuous metabolites.
It was noted that where toxicity data were available they were consistent with the conclusions in the
present flavouring group evaluation using the Procedure.
It is concluded that the 10 candidate substances which are expected to be metabolised to innocuous
substances, [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] from subgroup I and [FL-no: 01.001,
01.027, 01.028, 01.039 and 01.046] from subgroup III, would not give rise to safety concerns at their
estimated intakes arising from their use as flavouring substances based on the MSDI approach.
For 4(10)-thujene [FL-no: 01.059], one of the substances from subgroup V which are not expected to
be metabolised to innocuous substances, a margin of safety could be calculated based upon a NOAEL
(222 mg/kg/bw) for the supporting substance ß-caryophyllene [FL-no: 01.007]. Compared to the
MSDI of 4(10)-thujene of 14 µg/capita per day equal to 0.2 µg/kg bw per day, the NOAEL provides a
margin of safety of 9.5 x 105.
For the three remaining substances, 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-
1,3,6-octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070] margins of safety could be calculated
based upon a NOAEL (44 mg/kg bw) for the supporting substance myrcene [FL-no: 01.008].
Compared to the MSDI of 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-1,3,6-
octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070] of 9.1, 14 and 0.0085 µg/capita per day
equal to 0.15, 0.23 and 0.00014 µg/kg bw per day, the NOAEL provides margins of safety of 2.9 x
105, 1.9 x 105 and 3.1 x 108.
The mTAMDI values for 11 candidate substances are above the threshold for structural class I of 1800
µg/person per day. For these substances more reliable exposure data are requested in order for them to
be considered using the Procedure. For limonene [FL-no: 01.001] the mTAMDI is 1800 µg/person per
day and for each of l-limonene and 1-octene [FL-no: 01.046 and 01.070] the mTAMDI is 1600
µg/person per day.
Intake estimates according to the mTAMDI for the 11 candidate substances for which use levels
exceed the thresholds of concern for the structural class, and more reliable exposure data are
requested. On the basis of such additional data, the flavouring substances should be considered using
the Procedure. Subsequently, additional data might become necessary.
Flavouring Group Evaluation 25 Revision 3
EFSA Journal 2015;13(4):4069 35
In order to determine whether this conclusion could be applied to the materials of commerce, it is
necessary to consider the available specifications.
Specifications including complete purity criteria and identity for the materials of commerce have been
provided for all 14 flavouring substances.
Thus, for all 14 candidate substances [FL-no: 01.001, 01.027, 01.028, 01.033, 01.034, 01.035, 01.038,
01.039, 01.046, 01.054, 01.057, 01.059 and 01.070] the Panel concluded that they would present no
safety concern at their estimated levels of intake based on the MSDI approach.
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SUMMARY OF SAFETY EVALUATION
Table 7: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach)
FL-no EU Register
name
Structural formula MSDI (a)
(µg/capita per
day)
Class (b)
Evaluation
procedure path
(c)
Outcome on the
named
compound
(d or e)
Outcome on
the material of
commerce
(f, g, or h)
Evaluation
remarks
01.027 Bisabola-1,8,12-
triene
0.024 Class I
A3: Intake below
threshold
d g
01.028 beta-Bisabolene 2.7 Class I
A3: Intake below
threshold
d f
01.033 2,2-
Dimethylhexane
1.2 Class I
A3: Intake below
threshold
d f
01.034 2,4-
Dimethylhexane
1.2 Class I
A3: Intake below
threshold
d f
01.038 Dodecane 0.012 Class I
A3: Intake below
threshold
d f
01.039 delta-Elemene 0.012 Class I
A3: Intake below
threshold
d f
01.054 Pentadecane 0.61 Class I
A3: Intake below
threshold
d f
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Table 7: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach)
FL-no EU Register
name
Structural formula MSDI (a)
(µg/capita per
day)
Class (b)
Evaluation
procedure path
(c)
Outcome on the
named
compound
(d or e)
Outcome on
the material of
commerce
(f, g, or h)
Evaluation
remarks
01.057 Tetradecane 0.012 Class I
A3: Intake below
threshold
d f
01.035 2,6-Dimethylocta-
2,4,6-triene
9.1 Class I
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
01.059 4(10)-Thujene 14 Class I
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d
01.064 cis-3,7-Dimethyl-
1,3,6-octatriene
14 Class I
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
01.070 1-Octene 0.0085 Class I
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
01.001 Limonene 4000 Class I
A3: Intake above
threshold, A4: Not
endogenous, A5:
Adequate NOAEL
exists
d f
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Table 7: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach)
FL-no EU Register
name
Structural formula MSDI (a)
(µg/capita per
day)
Class (b)
Evaluation
procedure path
(c)
Outcome on the
named
compound
(d or e)
Outcome on
the material of
commerce
(f, g, or h)
Evaluation
remarks
01.046 l-Limonene 2100 Class I
A3: Intake above
threshold, A4: Not
endogenous, A5:
Adequate NOAEL
exists
d f
(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita per day.
(b): Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d): No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach).
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or
information on stereoisomerism.
(h): No conclusion can be drawn due to lack of information on the purity of the material of commerce.
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SUPPORTING SUBSTANCES SUMMARY
Table 8: Supporting Substances Summary
FL-no EU Register
name
Structural formula FEMA no
CoE no
CAS no
JECFA no
Specification
available
MSDI (EU)
(a)
(µg/capita per
day)
SCF status (b)
JECFA status (c)
CoE status (d)
Comments
01.003 Pin-2(10)-ene 2903
2114
127-91-3
1330
JECFA specification
(JECFA, 2005a).
1300
No safety concern (JECFA,
2005b)
Category B (CoE, 1992)
JECFA name: beta-Pinene.
EFSA conclusion: additional data
required (EFSA, 2009b).
01.004 Pin-2(3)-ene 2902
2113
80-56-8
1329
JECFA specification
(JECFA, 2005a)
1800
No safety concern (JECFA,
2005b)
Category B (CoE, 1992)
JECFA name: Alpha-Pinene.
EFSA conclusion: additional data
required (EFSA, 2009b).
01.005 Terpinolene 3046
2115
586-62-9
1331
JECFA specification
(JECFA, 2005a).
660
No safety concern (JECFA,
2005b)
Category B (CoE, 1992)
01.006 alpha-
Phellandrene
2856
2117
99-83-2
1328
JECFA specification
(JECFA, 2005a).
79
No safety concern (JECFA,
2005b)
Category B (CoE, 1992)
01.007 beta-
Caryophyllene
2252
2118
87-44-5
1324
JECFA specification
(JECFA, 2005a).
330
No safety concern (JECFA,
2005b)
Category B (CoE, 1992)
EFSA conclusion: additional data
required (EFSA, 2009b).
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Table 8: Supporting Substances Summary
FL-no EU Register
name
Structural formula FEMA no
CoE no
CAS no
JECFA no
Specification
available
MSDI (EU)
(a)
(µg/capita per
day)
SCF status (b)
JECFA status (c)
CoE status (d)
Comments
01.008 Myrcene 2762
2197
123-35-3
1327
JECFA specification
(JECFA, 2005a)
290
No safety concern (JECFA,
2005b)
Category B (CoE, 1992)
EFSA conclusion: B4-No,
additional data required (EFSA,
2009b).
01.009 Camphene 2229
2227
79-92-5
1323
JECFA specification
(JECFA, 2005a)
13
No safety concern (JECFA,
2005b)
Category B (CoE, 1992)
EFSA conclusion: additional data
required (EFSA, 2009b).
01.016 1,4(8),12-
Bisabolatriene
3331
10979
495-62-5
1336
JECFA specification
(JECFA, 2005a).
13
No safety concern (JECFA,
2005b)
JECFA name: Bisabolene.
01.017 Valencene 3443
11030
4630-07-3
1337
JECFA specification
(JECFA, 2005a)
53
No safety concern (JECFA,
2005b)
EFSA conclusion: additional data
required (EFSA, 2009b).
01.018 beta-Ocimene
(E)- isomer shown
3539
11015
13877-91-3
1338
JECFA specification
(JECFA, 2005a).
55
No safety concern (JECFA,
2005b)
JECFA name: 3,7-Dimethyl-
1,3,6-octatriene.
01.019 alpha-Terpinene 3558
11023
99-86-5
1339
JECFA specification
(JECFA, 2005a)
28
No safety concern (JECFA,
2005b)
JECFA name: p-Mentha-1,3-
diene.
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Table 8: Supporting Substances Summary
FL-no EU Register
name
Structural formula FEMA no
CoE no
CAS no
JECFA no
Specification
available
MSDI (EU)
(a)
(µg/capita per
day)
SCF status (b)
JECFA status (c)
CoE status (d)
Comments
01.020 gamma-Terpinene 3559
11025
99-85-4
1340
JECFA specification
(JECFA, 2005a)
1200
No safety concern (JECFA,
2005b)
JECFA name: p-Mentha-1,4-
diene.
01.024 beta-Bourbonene H
H H
11931
5208-59-3
1345
JECFA specification
(JECFA, 2005a).
0.012
No safety concern (JECFA,
2005b)
EFSA conclusion: additional data
required (EFSA, 2009b). MSDI
based on USA production figure.
01.026 1(5),7(11)-
Guaiadiene
S
S 88-84-6
1347
JECFA specification
(JECFA, 2005a).
0.012
No safety concern (JECFA,
2005b)
JECFA name: Guaiene. EFSA
conclusion: additional data
required (EFSA, 2009b).
01.029 delta-3-Carene 3821
10983
13466-78-9
1342
JECFA specification
(JECFA, 2005a)
290
No safety concern (JECFA,
2005b)
EFSA conclusion: additional data
required (EFSA, 2009b).
01.040 alpha-Farnesene 3839
10998
502-61-4
1343
JECFA specification
(JECFA, 2005a).
0.61
No safety concern (JECFA,
2005b)
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Table 8: Supporting Substances Summary
FL-no EU Register
name
Structural formula FEMA no
CoE no
CAS no
JECFA no
Specification
available
MSDI (EU)
(a)
(µg/capita per
day)
SCF status (b)
JECFA status (c)
CoE status (d)
Comments
01.045 d-Limonene 2633
491
5989-27-5
1326
JECFA specification
(JECFA, 2005a).
34000
No safety concern (JECFA,
2005b)
ADI not specified (JECFA,
2006).
01.061 Undeca-1,3,5-
triene
3795
16356-11-9
1341
JECFA specification
(JECFA, 2005a).
0.24
No safety concern (JECFA,
2005b)
JECFA name: 1,3,5-
Undecatriene. EFSA conclusion:
additional data required (EFSA,
2009b).
(a): EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita per day.
(b): Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to
evidence of toxicity.
(c): No safety concern at estimated levels of intake.
(d): Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs.
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TOXICITY DATA
Table 9: Acute Toxicity
Chemical Name [FL-no] * Species Sex Route LD50
(mg/kg bw)
Reference Comments
Tetradecane [01.057] Rat NR Oral > 5000 (Enichem Augusta Ind., 1987) Study not available
Rat NR Oral > 5000 (PETRESA, 19??b) Study not available
(Undeca-1,3,5-triene [01.061]) Rat M, F Oral > 8000 (Pellmont, 1973) Data not possible to interprete
Mouse M, F Oral 2000 - 4000 (Pellmont, 1973) Data not possible to interprete
(Myrcene [01.008]) Rat M Oral > 5000 (Moreno, 1972a) Identity of compound not stated as other
than code number
(β-Ocimene [01.018])  Rat NR Oral 5000 (Moreno, 1976a) One dose tested
(d-Limonene [01.045]) Rat M Oral > 5000 (Moreno, 1972d) Identity of compound not stated as other
than code number
Rat M, F Oral M: 4400
F: 5100
(Tsuji et al., 1975a) Study is on dogs, rats not mentioned in
English text. Study in Japanese
Mouse M, F Oral M: 5600
F: 6600
(Tsuji et al., 1975a) Study is on dogs, mice not mentioned in
English text. Study in Japanese
(Terpinolene [01.005]) Rat NR Oral 4.39 ml/kg (3784) (Levenstein, 1975) Observation period not given.
(α-Terpinene [01.019])  Rat NR Oral 1680 (Moreno, 1973b)
(gamma-Terpinene [01.020]) Rat M, F Oral 3650 (Moreno, 1973a)
(α-Phellandrene [01.006]) Rat M, F Oral > 5700 (Moreno, 1972b) Submitted study is on dermal toxicity.
Rat M, F Oral 1.87 ml/kg
(1590)
(Brownlee, 1940) Substance mixed with acacia. 6 animals per
dose group
β-Bisabolene [01.028] Rat NR Oral > 5000 (Moreno, 1974a) One dose tested
Mouse M, F Oral > 13,360 (Hoffman-LaRoche, Inc., 1967) No of dose levels not given.
(delta-3-Carene [01.029]) Rat M Oral 4800 (Moreno, 1972c) Identity of compound not stated
(Pin-2(3)-ene [01.004]) Rat M, F Oral 3700 (Moreno, 1972e) Identity of compound not stated
(Pin-2(10)-ene [01.003]) Rat NR Oral > 5000 (Moreno, 1975) One dose tested.
(Camphene [01.009]) Rat NR Oral > 5000 (Moreno, 1974b) One dose tested
(Valencene [01.017]) Rat M Oral > 5000 (Moreno, 1980) One dose tested
(β–Caryophyllene [01.007]) Rat M, F Oral > 5000 (Hart and Wong, 1971) One dose tested
(1(5),7(11)-Guaiadiene [01.026]) Rat NR Oral > 5000 (Moreno, 1976b) One dose tested
(1-methyl cyclohexa-1,3-diene [01.077]) Rat M, F Oral > 2000 (Felice, 2005) Acute toxic class method. 2000 mg/kg is
only dose tested, no death was observed.
* Supporting substances are listed in brackets.
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Table 10: Subacute / Subchronic / Chronic / Carcinogenicity Studies
Chemical Name [FL-no] Species;
Sex
No./Group
Route Dose levels Duration NOAEL
(mg/kg bw per
day)
Reference Comments
(Undeca-1,3,5-triene
[01.061])
Rat; M, F
10
Diet Calculated to provide 10 mg
Galbelica/kg bw per day
corresponding to 2 mg
undecatriene, 8 mg pinene and
the rest dodecene.
14 days Corresponding to
2 mg
undecatriene1
(Shapiro, 1988) Not valid. See footnote1.
(d-Limonene [01.045]) Rat; M
5
Gavage 0, 75, 150 or 300 mg/kg bw per
day 5 days a week
6 or 27 days
(5 or 25
doses)
75 (Kanerva et al., 1987) Study is on kidney toxicity
specifically.
Rat; M
5 – 10
Gavage 0, 2, 5, 10, 30 or 75 mg/kg bw
per day, 5 days/week
90 days 5 (Webb et al., 1989) Study is on kidney toxicity
specifically.
Dog; M, F
6
Gavage 0, 0.4, 1.2 or 3.6 ml/kg bw per
day corresponding to 0, 340,
1000 or 3000 mg/kg bw per
day
180 days M: 340
F: 340
(Tsuji et al., 1975a) Study is in Japanese, only
summary and tables in English.
Quality of study not possible to
assess.
Dog; M, F
10
Gavage
(divided
doses)
0, 0.12 or 1.2 ml/kg bw per day
corresponding to 0, 100 or
1000 mg/kg bw per day.
180 days 100 (Webb et al., 1990)
Mouse; M,
F
10
Gavage 0, 413, 825, 1650, 3300 or
6600 mg/kg bw per day for 12
days over 16-day period
16 days 1650 (NTP, 1990)
Mouse; M,
F
20
Gavage 0, 125, 250, 500, 1000 or 2000
mg/kg bw per day 5 days per
week
90 days M: 500
F: 500
(NTP, 1990) Clinical signs of rough hair coat
and decrased activity were
observed at the two highest
doses.
Mouse; M,
F
M:50 F:50
Gavage M: 0, 250 or 500 mg/kg bw per
day
F: 0, 500, 1000 mg/kg bw per
day
5 days per week
2 years M: 250
F: 500
(NTP, 1990)
Rat; M, F
10
Gavage 0, 413, 825, 1650, 3300 or
6600 mg/kg bw per day for 12
days over 16-day period
16 days 1650 (NTP, 1990)
Rat; M, F
20
Gavage 0, 150, 300, 600, 1200 or 2400
mg/kg bw per day 5 days per
week
90 days M: None
F: 1200
(NTP, 1990) Dose-dependent nephropathy in
all treated males.
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Table 10: Subacute / Subchronic / Chronic / Carcinogenicity Studies
Chemical Name [FL-no] Species;
Sex
No./Group
Route Dose levels Duration NOAEL
(mg/kg bw per
day)
Reference Comments
Rat; M, F
M:50 F:50
Gavage M: 0, 75 or 150 mg/kg bw per
day
F: 0, 300 or 600 mg/kg bw per
day
5 days per week
2 years M: None
F: 300
(NTP, 1990)
(Pin-2(10)-ene [01.003]) Rat; M, F
10
Diet Calculated to provide 10 mg
Galbelica/kg bw per day
corresponding to 8 mg pin-
2(10)-ene
14 days Corresponding to
8 mg pin-2(10)-
ene1
(Shapiro, 1988) Not valid. See footnote1.
(Camphene [01.009]) Rat; M, F
10
Gavage 0, 62.5, 250, 1000 mg/ kg bw
per day
28 days M: None
F: 250
(Hoechst, 1991) Study report very limited in
details. Study according to
OECD Guideline 407.
(Myrcene [01.008]) Mouse;
M,F
M:10 F:10
Gavage 0, 250, 500, 1000, 2000 or
4000 mg/kg bw for 5 days a
week
90 days 250 (NTP, 2010) This study was performed at a
either a single dose or multiple
dose levels that produced no
effects. Therefore, this dose
level is not a true NOEL, but
the highest dose tested that
produced no adverse effects.
The actual NOEL would be
higher.
Mouse; M,
F
M:50 F:50
Gavage 0, 250, 500 or 1000 mg/kg bw
for 5 days a week
2 years 250 (NTP, 2010)
Rat; M, F
M:10 F:10
Gavage 0.250, 500, 1000, 2000 or 4000
mg/kg bw per day
90 days (NTP, 2010) Study showed nephrotoxicity at
the lowest dose level (250
mg/kg body wt)
Rat; M, F
M:50 F:50
Gavage 0 ,250, 500 or 1000 mg/kg bw
for 5 days a week
2 years (NTP, 2010) Study showed nephrotoxicity at
the lowest dose level and kidnet
tumors at hihger dose levels
Rat; M, F
M:10 F:10
Diet
0, 8,0 , 40 , and 44 mg/kg bw
per day (males)
0, 9,6 , 48 , and 53 mg/kg bw
per day (females)
90 days 44 (males)
53 (females)
(Bauter, 2013b) No toxicity at highest dose level
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Table 10: Subacute / Subchronic / Chronic / Carcinogenicity Studies
Chemical Name [FL-no] Species;
Sex
No./Group
Route Dose levels Duration NOAEL
(mg/kg bw per
day)
Reference Comments
(β-Caryophyllene 
[01.007])
Rat; M, F
M:10 F:10
Diet 0, 220, 460 and 1.370 mg/kg
bw per day (males)
0, 260, 1.030 and 4.280 mg/kg
bw per day (females),
90 days 222 (males)
263(females)
(Bauter, 2013a) Study according to OECD
Guideline 408.
Rat; M, F
M:3 F:3
Diet 0, 520, 1.550 and 3.570mg/kg
bw per day (males)
0, 530, 1.580 and 4.440 mg/kg
bw per day (females)
14 days - (Bauter, 2011)
1 Study performed using a dose of 10 mg/kg body weight per day of Galbelica, which is a solution composed of 80 % β-pinene and 20 % 1,3,5-undecatriene and dodecene.  
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Table 11: Developmental and Reproductive Toxicity Studies
Chemical Name
[FL-no]
Study type
Durations
Species/Sex
No / group
Route Dose levels NOAEL (mg/kg bw per day),
Including information of
possible maternal toxicity
Reference Comments
(Myrcene
[01.008])
Developmental
Toxicity:
Gestation Days 6 - 15
Rat; F
16 - 29
Gavage 250, 500 or 1200
mg/kg bw per
day
Maternal: 5001
Foetal: 500
(Delgado et al.,
1993a)
Study considered valid.
Peri- and Postnatal
Developmental
Toxicity:
Gestation Day 15 to
Postnatal
Day 21
Rat; F
12 - 18
Gavage 0, 250, 500,
1000, 1500
mg/kg bw per
day
Maternal: 5002
Peri- and
Post-natal: 250
(Delgado et al.,
1993b)
Study considered valid.
Reproductive and
developmental
toxicity: Prior to
mating until postnatal
day 21
Rat; M, F
60
Gavage 0, 100, 300, 500
mg/kg bw per
day
Maternal/paternal: 500 mg/kg
bw per day
Foetal: 300 mg/kg bw per day
(Paumgartten et
al., 1998)
Study considered valid.
(d-Limonene
[01.045])
Developmental
Toxicity:
Gestation Days 9 - 15
Rat; F
20
Oral 0, 591 or 2869
mg/kg bw per
day
Maternal: 591
Foetal: 591
(Tsuji et al.,
1975b)
Study in Japanese, only summary and tables
in English. Quality of study not possible to
assess.
Developmental
Toxicity:
Gestation Days 7 - 12
Mouse; F
15
Oral 0, 591 or 2363
mg/kg bw per
day
Maternal: 591
Foetal: 591
(Kodama et al.,
1977a)
Study in Japanese, only summary and tables
in English. Quality of study not possible to
assess.
Developmental
toxicity: gestation
days 6 - 18
Rabbit; F
10, 18 in
highest dose
group
Oral 0, 250, 500 or
1000 mg/kg bw
per day
Maternal: 250
Foetal: 1000
(Kodama et al.,
1977b)
Study in Japanese, only summary and tables
in English. Quality of study not possible to
assess.
(Pin-2(3)-ene
[01.004])
Developmental
toxicity:
Gestation days 9 - 14
Rat; F
12 - 17
Oral Not relevant Not relevant (Hasegawa and
Toda, 1978)
Study is not considered valid.
Study is on a mixture of menthol, menthone,
pinene, borneol cineol, camphene
rheochrysin in olive oil. Pin-2(3)-ene
content is 17 %. Study in Japanese.
Developmental
toxicity:
Gestation Days 6 - 15
Rat; F
20
Gavage Maternal: 2503
Foetal: 1000
(Leuschner, 1992;
LPT Research,
1992)
Study not submitted.
1 Test substance was myrcene.
2 Study performed using a dose of 10 mg/kg body weight per day of Galbelica, which is a solution composed of 80 % β-pinene and 20 % 1,3,5-undecatriene. 
3 Test substance was 78 % pure.
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Table 12: Genotoxicity (in vitro)
Chemical Name
[FL-no] *
Test System Test Object Concentration Result Reference Comments
Cedrene washed6
[CAS no 11028-42-5]
Ames test S. typhimurium
TA97, TA98; TA100;
TA1535; TA102
8-50004 Negative1 (Gocke, 1999) Validity cannot be evaluated as substance is not
specified.
Cedarwood oil terpenes and tertonoids.
Ames test S. typhimurium
TA97, TA98; TA100;
TA1535; TA102
1.6-10005 Negative1 (Gocke, 1999) Validity cannot be evaluated as substance is not
specified.
Cedarwood oil terpenes and tertonoids.
Dodecane [01.038] Ames test S. typhimurium
TA98; TA100
NR Negative1 (Tummey et al., 1992) Only part of abstract available. Validity of the study
cannot be evaluated due to insufficient report of
experimental details and results.
Mammalian cell
gene mutation
test (mouse
lymphoma
assay)
Mouse lymphocytes NR Negative1 (Tummey et al., 1992) Only part of abstract available. Validity of the study
cannot be evaluated due to insufficient report of
experimental details and results.
Mammalian cell
gene mutation
test
V79 Chinese hamster
ovary cells
0.12 mM (20
µg/ml)
Negative3 (Lankas et al., 1978) Published non-GLP study. Some important details of
study design and results are not reported. Thus, the
validity of the study cannot be evaluated. Study
designed to evaluate the ability of various alkanes to
enhance the mutagenicity induced by the chemical
carcinogen methylazoxymethanol acetate. Dodecane
showed no mutagenic activity per se, but increased the
mutagenesis induced by pretreatment with the
carcinogen.
Tetradecane [01.057] Ames test S. typhimurium
TA98; TA100;
TA1535; TA1537;
TA1538
50, 150, 500,
1500, 5000
µg/plate
Negative1 (PETRESA, 19??a) (Study carried out by Huntingdon Research Centre,
Report PEQ 5C/85914, sponsored by PETRESA; year
not indicated)
Unpublished GLP-study carried out in accordance with
OECD guideline 471 as stated in the IUCLID datasheet
submitted. IUCLID abstract available only. Validity of
the study cannot be evaluated.
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Table 12: Genotoxicity (in vitro)
Chemical Name
[FL-no] *
Test System Test Object Concentration Result Reference Comments
Mammalian cell
gene mutation
test
V79 Chinese hamster
ovary cells
0.12 mM (23
µg/ml)
Negative3 (Lankas et al., 1978) Published non-GLP study. Some important details of
study design and results are not reported. Thus, the
validity of the study cannot be evaluated. Study
designed to evaluate the ability of various alkanes to
enhance the mutagenicity induced by the chemical
carcinogen methylazoxymethanol acetate. Tetradecane
showed no mutagenic activity per se, but increased the
mutagenesis induced by pretreatment with the
carcinogen.
Ames test
(preincubation
method)
S. typhimurium
TA98; TA100;
UTH8414; UTH8413
0, 50, 100, 500,
1000, 2000
µg/plate
Negative1 (Connor et al., 1985) Published non-GLP study with insufficient report of
some details of method and results. Thus, the validity
of the study cannot be evaluated. Cytotoxicity not
reported.
(2-Methylbuta-1,3-
diene)
or isoprene
Ames test S. typhimurium
TA98; TA100;
TA1530; TA1535;
TA1538
25 %
atmosphere
concentration
Negative1 (De Meester et al.,
1981)
Published non-GLP study not in accordance with
OECD guideline 471. Part of a larger study evaluating
the effects of various experimental conditions (different
liver cell preparations and concentrations) on the
mutagenic activity of butadiene, hexachlorobutadiene
and isoprene. Some important details of study design
and results are not reported. Thus, the validity of the
study cannot be evaluated. Plates were exposed to a 25
% 2-methylbuta-1,3-diene atmosphere for 24 hours.
Ames test
(preincubation
method)
S. typhimurium
TA98; TA100;
TA1535; TA1537
0, 100, 333,
1000, 3333,
10000 µg/plate
Negative1 (Mortelmans et al.,
1986)
(NTP, 1999)
Published summary report including detailed results
from studies on 270 compounds tested in various
laboratories within the NTP to a large extent in
accordance with OECD guideline 471.
Ames test S. typhimurium
TA102; TA104
NR Negative (Kushi et al., 1985) Published abstract only, of which part of the text
including results is missing. No information on the use
of a metabolic activation system. Validity of the study
cannot be evaluated.
Ames test
(preincubation
method)
S. typhimurium
TA98; TA100;
TA1535
E. coli
WP2uvrA/pKM101
0, 500, 1000,
2000, 5000
µg/plate
Negative1 (Madhusree et al., 2002) Published non-GLP study with limited report of
experimental details and results. Thus, the validity of
the study cannot be evaluated.
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Table 12: Genotoxicity (in vitro)
Chemical Name
[FL-no] *
Test System Test Object Concentration Result Reference Comments
Sister chromatid
exchange test
Chinese hamster
ovary cells
0, 50, 160, 500,
1600 µg/ml (-
S9)
0, 160, 500,
1600, 5000
µg/ml (+S9).
Negative1 (NTP, 1999; Galloway
et al., 1987)
Published summary report including detailed results
from studies on 108 chemicals tested within the NTP to
a large extent in accordance with OECD guideline 479.
Chromosomal
aberration assay
Chinese hamster
ovary cells
0, 1600, 3000,
5000 µg/ml
Negative1 (NTP, 1999; Galloway
et al., 1987)
Published summary report including detailed results
from studies on 108 chemicals tested within the NTP to
a large extent in accordance with OECD guideline 473.
(Myrcene [01.008]) Chromosomal
aberration assay
Human lymphocytes 1000 µg/ml Negative1 (Kauderer et al., 1991) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Mammalian cell
gene mutation
assay
Chinese hamster
ovary V79 cells
1000 µg/ml Negative1 (Kauderer et al., 1991) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Sister chromatid
exchange test
Human lymphocytes 1000 µg/ml Negative1 (Kauderer et al., 1991) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Sister chromatid
exchange test
Chinese hamster
ovary cells and
hepatic tumour cell
line
500 µg/ml Negative1 (Röscheisen et al.,
1991)
Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test
(plate
incorporation
method)
S. typhimurium
TA97a ; TA98;
TA100; TA1535
Up to 1500
µg/plate
(16
concentrations)
Negative (Gomes-Carneiro et al.,
2005)
Valid studies which were carried out with a selection of
6 of the the concentrations mentioned. In the first run
concentrations up to cytotoxicity were studied; in a
second run only non-toxic concentrations were tested.
Ames S. typhimurium TA97;
TA98; TA100;
TA1535
10 – 10 000
µg/plate
Negative1 (NTP, 2010)
Reverse
mutation
E. coli
WP2uvrA/pKM101
50 – 10 000
µg/plate
Negative1 (NTP, 2010)
Ames S. typhimurium
TA97a; TA98;
TA100; TA1535
10 - 5000 Negative1 (Gomes-Carneiro et al.,
2005)
Ames S. typhimurium
TA97a; TA98;
TA100; TA1535
1 - 1500 Negative1 (Gomes-Carneiro et al.,
2005)
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Table 12: Genotoxicity (in vitro)
Chemical Name
[FL-no] *
Test System Test Object Concentration Result Reference Comments
(d-Limonene [01.045]) Ames test
(preincubation
method)
S. typhimurium
TA98; TA100;
TA1535; TA1537
0.03, 0.3, 3, 30
µM/plate
(4.1, 41, 410,
4100 µg/plate)
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium
TA98; TA100;
TA1535; TA1537;
TA1538
Up to 150,000
µg/plate
Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium
TA102
Up to 5000
µg/plate
Negative1 (Müller et al., 1993) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium TA98;
TA100; TA1535;
TA1537
Up to 3333
µg/plate
Negative1 (Haworth et al., 1983) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test
(preincubation
method)
S. typhimurium
TA98; TA100,
UTH8413 and
UTH8414
0, 10 to 500
µg/plate
(5
concentrations)
Negative1 (Connor et al., 1985) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Forward
mutation assay
L5178Y Mouse
lymphoma
Up to 100 µg/ml Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Forward
mutation assay
L5178Y Mouse
Lymphoma
Up to 100 µg/ml Negative1 (Myhr et al., 1990) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Chromosomal
aberration assay
Chinese hamster
ovary cells
500 µg/ml Negative1 (Anderson et al., 1990) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Sister chromatid
exchange test
Chinese hamster
ovary cells
162 µg/ml Negative1 (Anderson et al., 1990) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Sister chromatid
exchange test
Chinese hamster
ovary cells
1000 µM
(136.2 µg/ml)
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
(gamma-Terpinene
[01.020])
Ames test S. typhimurium TA98;
TA100; TA1535;
TA1537; TA1538
50,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Unscheduled
DNA synthesis
Rat hepatocytes 30 µg/ml Negative (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
(α-Terpinene [01.019]) Ames test 
(plate
incorporation
method)
S. typhimurium
TA97a ; TA98;
TA100; TA1535
Up to 1500
µg/plate
(13
concentrations)
Negative (Gomes-Carneiro et al.,
2005)
Valid studies which were carried out with a selection of
6 of the the concentrations mentioned. In the first run
concentrations up to cytotoxicity were studied; in a
second run only non-toxic concentrations were tested.
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Table 12: Genotoxicity (in vitro)
Chemical Name
[FL-no] *
Test System Test Object Concentration Result Reference Comments
(α-Phellandrene 
[01.006])
Sister chromatid
exchange test
Chinese hamster
ovary cells
1000 µM(136.2
µg/ml)
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
(delta-3-Carene
[01.029])
Ames test
(plate
incorporation
method)
S. typhimurium TA98;
TA100; TA102
up to 5 µl/plate
(up to 4300
µg/plate; 5
concentrations)
Positive3
Negative2
(Kurttio et al., 1990) Published non-GLP study with insufficiently reported
results. Limited validity. Positive without metabolic
activation in TA100 and TA102 and at doses of 2.5
µl/plate and higher.
(Pin-2(3)-ene [01.004]) Ames test S. typhimurium
TA98; TA100
100 µl/plate
(85,800 µg/
plate)
Negative2 (Rockwell and Raw,
1979)
Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium TA98;
TA100; TA1535;
TA1537
0.03, 0.3, 3, 30
µM/plate
(4.1, 41, 410,
4100 µg/ plate)
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium TA98;
TA100; TA1535;
TA1537; TA1538
25000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium TA98;
TA100; TA1535;
TA1537; TA1538
25 µl/plate
(21,450 µg/
plate)
Negative1 (Jagannath, 1984) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium TA98;
TA100; TA1535;
TA1537; TA1538
5 µl/plate
(4290 µg/plate)
Negative1 (DeGraff, 1983) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium TA98;
TA100; UTH8414;
UTH8413
0, 10 to 500
µg/plate
(5
concentrations)
Negative1 (Connor et al., 1985) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Unscheduled
DNA synthesis
Rat hepatocytes 10000 µg/ml Negative (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
(+)-α-pinene (pin-2(3)-
ene)
(isomer of [01.004])
Ames test
(plate
incorporation
method)
S. typhimurium
TA97a ; TA98;
TA100; TA1535
Up to 1000
µg/plate
(18
concentrations)
Negative (Gomes-Carneiro et al.,
2005)
Valid studies.
(-)-α-pinene (pin-2(3)-
ene)
(isomer of [01.004])
Ames test
(plate
incorporation
method)
S. typhimurium
TA97a ; TA98;
TA100; TA1535
Up to 4000
µg/plate
(19
concentrations)
Negative (Gomes-Carneiro et al.,
2005)
Valid studies.
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Table 12: Genotoxicity (in vitro)
Chemical Name
[FL-no] *
Test System Test Object Concentration Result Reference Comments
(Pin-2(10)-ene
[01.003])
Ames test S. typhimurium TA98;
TA100; TA1535;
TA1537; TA1538
5000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test
(preincubation
method)
S. typhimurium
TA98; TA100;
TA1535; TA1537
0.03, 0.3, 3, 30
µM/plate
(4.1, 41, 410,
4100 µg/plate)
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Sister chromatid
exchange
Chinese hamster
ovary cells
1000 µM (136.2
µg/ml)
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
(Camphene [01.009]) Ames test S. typhimurium
TA98; TA100
100 µl/plate
(84,500 µg/
plate)
Negative2 (Rockwell and Raw,
1979)
Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium TA98;
TA100; UTH8414;
UTH8413
0, 10 to 1000
µg/plate (5
concentrations)
Negative1 (Connor et al., 1985) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Sister chromatid
exchange test
Chinese hamster
ovary cells
1000 µM (136.2
µg/ml)
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
(β–Caryophyllene 
[01.007])
Ames test S. typhimurium TA98;
TA100; TA1535;
TA1537; TA1538
150,000
µg/plate
Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test S. typhimurium TA98;
TA100; TA1535;
TA1537; TA1538
150 µl/plate Negative1 (Lorillard, 1984) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Ames test
(plate
incorporation
method)
S. typhimurium TA98;
TA100; TA102;
TA1535; TA1537
10,000 µg/plate Negative1 (Longfellow, 1998) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
Sister chromatid
exchange test
Chinese hamster
ovary cells
1000 µM (204.4
µg/ml)
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting (JECFA,
2006).
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Table 12: Genotoxicity (in vitro)
Chemical Name
[FL-no] *
Test System Test Object Concentration Result Reference Comments
Ames test
(plate
incorporation
method)
S. typhimurium strains
TA98; TA100
E. coli WP2uvrA
2300 to 9000
μg/plate 
Negative1 (Di Sotto et al., 2008) Study not in compliance with OECD 471:
Assay does not include TA 1535 and TA 1537 (or
TA97, 97a, resp) - 5 concentrations tested (plate-
incorpration) but not given in detail (authors stated that
in range finder up to 9 mg/plate without cytotoxicity)
results not given in detail (no values, no raw data).
Methods and results poorly reported: no historical
contral data. The study is considered to be of
insufficient quality.
* Supporting substances are listed in brackets.
NR: Not Reported.
1 With and without S9 metabolic activation.
2 With metabolic activation.
3 Without metabolic activation.
4 Plate incorporation.
5 Pre-incubation.
6 An Ames test with cedrene washed (unspecified cedrene) was also submitted, but an adequate identification of the substance studied was not possible. Therefore the study is not further
discussed.
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Table 13: Genotoxicity (in vivo)
Chemical Name
[FL-no] *
Test System Test Object Route Dose Result Reference Comments
(2-Methylbuta-1,3-
diene)
In vivo
Chromosomal
aberration assay
Mouse
(B6C3F1) bone
marrow
(male mice)
Inhalation 0, 438, 1750, 7000 ppm for
6 hours per day for 12
exposures over a period of
16 days (Trial 1)
0, 70, 220, 700 ppm for 6
hours per day for 12
exposures over a period of
16 days (Trial 2)
Negative (Tice et al., 1987;
Tice, 1988;
Shelby, 1990)
Unpublished study report and published
summary report of a valid multiple endpoint
cytogenicity study sponsered by NTP,
roughly in accordance with OECD guideline
475 (special dosage regimen used).
In vivo Sister
chromatid
exchange test
Mouse
(B6C3F1) bone
marrow
(male mice)
Inhalation 0, 438, 1750, 7000 ppm for
6 hours per day for 12
exposures over a period of
16 days (Trial 1)
0, 70, 220, 700 ppm for 6
hours per day for 12
exposures over a period of
16 days (Trial 2)
Positive (Tice et al., 1987;
Tice, 1988;
Shelby, 1990)
Unpublished study report and published
summary report of valid cytogenicity study
sponsered by NTP. The study is considered
valid.
Significant (0.01<p<0.05) increase in the
frequency of SCE in the bone marrow cells
at all concentrations. In addition, a
significant delay in bone marrow cellular
proliferation kinetics (lengthening of the
generation time) was detected. The mitotic
index was not significantly altered.
In vivo
Micronucleus test
Mouse
(B6C3F1)
peripheral blood
cells
(male mice)
Inhalation 0, 438, 1750, 7000 ppm for
6 hours per day for 12
exposures over a period of
16 days
Positive (Tice et al., 1987;
Tice, 1988)
Unpublished study report and published
summary report of valid cytogenicity study
sponsored by NTP, roughly in accordance
with OECD guideline 474 (special dosage
regimen used). The study is considered
valid.
Significant (p<0.001) increase in the
frequency of micronucleated polychromatic
and normochromatic erythrocytes, and
percentage of PCE. A significant (p<0.001)
and dose-dependent decrease in the
percentage of circulating polychromatic
erythrocytes (suppression of erythropoiesis)
was noted.
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Table 13: Genotoxicity (in vivo)
Chemical Name
[FL-no] *
Test System Test Object Route Dose Result Reference Comments
In vivo
Micronucleus test
Mouse(B6C3F1)
peripheral blood
cells
(male and
female mice)
Inhalation 0, 70, 220, 700, 2200, 7000
ppm for 13-weeks
Positive (Jauhar et al.,
1988)
Study carried out within NTP. Only short
summary and tabulated results available
from NTP TR 486 (NTP, 1999). Percentage
of polychromatic erythrocytes among
erythrocytes in peripheral blood was
increased probable due to a possible
adaptation to cytotoxicity with chronic
exposure. Due to the limited details
available on this study, the validity cannot
be evaluated.
In vivo
Micronucleus test
Rat lung
fibroblasts
(male and
female rats)
Inhalation 0, 220, 700, 7000 ppm for
13-weeks
Negative (Khan and Heddle,
1991)
Study carried out within NTP. Only
tabulated results available from NTP TR
486 (NTP, 1999). Unusual study protocol.
Validity of the study cannot be evaluated.
(Myrcene [01.008]) In vivo
Chromosomal
aberration assay
Rat (Wistar)
bone marrow
Gavage 0, 100, 500, 1000 mg/kg bw
(single exposure)
Negative (Zamith et al.,
1993)
Abstracted by JECFA at their 63rd meeting
(JECFA, 2006).
In vivo
Micronucleus test
Mouse
(B6C3F1)
peripheral blood
cells
Gavage 0, 250, 500, 1000, 2000
mg/kg bw (single exposure)
Negative (NTP, 2003) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006).
Micronucleus
assay
Mouse
peripheral blood
cells
Gavage 250, 500, 1000 mg/kg bw/
day
Negative (NTP, 2010)
(d-Limonene
[01.045])
In vivo Comet
assay
Mouse (ddY) /
Rat (Wistar).
Oral 0, 2000 mg/kg Negative (Sekihashi et al.,
2002)
Abstracted by JECFA at their 63rd meeting
(JECFA, 2006).
In vivo
Mammalian spot
test
Mouse embryos
from
C57BL/6JHan x
T stocks
Intraperito
neal
injection
215 mg/kg bw Negative (Fahrig, 1984) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006).
In vivo Comet
assay
Rats (Sprague-
Dawley)
(males)
(Kidneys)
Gavage 0, 1000, 2000 mg/kg bw
(single exposure)
Negative (Nesslany et al.,
2007)
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Table 13: Genotoxicity (in vivo)
Chemical Name
[FL-no] *
Test System Test Object Route Dose Result Reference Comments
In vivo transgenic
mutagenisity
assay
Rats (Big blue)
(males) (liver,
kidney, bladder)
Diet 0, 525 mg/kg bw per day
(10 days)
Negative (Turner et al.,
2001)
The author do not specify whether the tested
compound is d- or l-limonene, and the purity
of the compound is not stated. However, the
stability of the limonene in the diet was
measured.
(β-caryophyllene 
[01.007])
micronucleus
induction assay
Mouse
(National
Institute of
Hygiene (NIH),
Mexico)
Gavage 0, 20, 200 and 2000 mg/kg
bw
Negative (Molina-Jasso et
al., 2009)
The study is compliance with OCED
guideline except: number of micronucleated
immature erythrocytes are not given
separately for each animal and historical
controls not given.
The study is reliable with restrictions and
therefore, considered to be of limited
validity.
* Supporting substances are listed in brackets.
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Table 14: Genotoxicity Data of β-Caryophyllene Submitted by EFFA (EFFA, 2012)  
FL-no
JECFA
-no
EU Register
name
JECFA name
Structural formula End-point Test system Concentratio
n
Results Reference Comments
In vitro
01.007
1324
β-Caryophyllene  Reverse
mutation
S.
typhimurium
TA98,
TA100,
E. coli
WP2uvrA
2300–9000
μg/plate
Negative1 (Di Sotto et al.,
2008)
Study not in compliance with OECD 471:
- assay does not include TA1535 and
TA1537 (or TA97, 97a, resp)
-5 concentrations tested (plate-
incorpration) but not given in detail
(authors stated that in range finder up to 9
mg/plate without cytotoxicity)
-results not given in detail (no values, no
raw data).
Methods and results poorly reported
-no historical contral data
insufficient quality.
In vivo
01.007
1324
β-Caryophyllene  Micronucleated
polychromatic
erythrocytes
Mice 0, 20, 200 and
2000 mg/kg
bw2
Negative (Molina-Jasso et al.,
2009)
In compliance with OECD 474
-except: number of micronucleated
immature erythrocytes not given
separately for each animal; historical
controls not given.
Reliable with restrictions=limited
validity.
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Appendix A. Procedure for the Safety Evaluation
The approach for a safety evaluation of chemically defined flavouring substances as referred to in
Commission Regulation (EC) No 1565/2000 (EC, 2000), named the "Procedure", is shown in schematic
form in Figure A.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed
on 2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA,
1996; JECFA, 1997; JECFA, 1999).
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a
safety concern.
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 µg/person per day,
respectively, are derived from a large database containing data on subchronic and chronic animal studies
(JECFA, 1996).
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps
address the following questions:
• can the flavourings be predicted to be metabolised to innocuous products16 (Step 2)?
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)?
• are the flavourings or their metabolites endogenous17 (Step A4)?
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)?
In addition to the data provided for the flavouring substances to be evaluated (candidate substances),
toxicological background information available for compounds structurally related to the candidate
substances is considered (supporting substances), in order to assure that these data are consistent with the
results obtained after application of the Procedure.
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore,
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions.
16 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated intakes of
the flavouring agent” (JECFA, 1997a).
17 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or conjugated;
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997a).
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Decision tree structural class
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
Do the conditions of use result in an intake greater than the
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the
threshold of concern for the structural class?
Data must be available on the
substance or closely related
substances to perform a safety
evaluation
Does a NOAEL exist for the substance which provides an adequate
margin of safety under conditions of intended use, or does a NOAEL
exist for structurally related substances which is high enough to
accommodate any perceived difference in toxicity between the
substance and the related substances?
Does a NOAEL exist for the substance which provides an adequate
margin of safety under conditions of intended use, or does a NOAEL
exist for structurally related substances which is high enough to
accommodate any perceived difference in toxicity between the
substance and the related substances?
Substance would not be
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required
Step 1.
Step 2.
Step A3.
Step A4.
Step A5.
Step B3.
Step B4.
Yes No
Yes
No
No
No
Yes
No
Yes
Yes
Yes
No
Figure A.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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Appendix B. Use Levels / mTAMDI
B.1 Normal and Maximum Use Levels
For each of the 18 Food categories (Table B.1.1) in which the candidate substances are used, Flavour
Industry reports a “normal use level” and a “maximum use level” (EC, 2000). According to the Industry the
“normal use” is defined as the average of reported usages and “maximum use” is defined as the 95th
percentile of reported usages (EFFA, 2002). The normal and maximum use levels in different food categories
have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004).
Table B.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000).
Food
category
Description
01.0 Dairy products, excluding products of category 02.0
02.0 Fats and oils, and fat emulsions (type water-in-oil)
03.0 Edible ices, including sherbet and sorbet
04.1 Processed fruit
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts &
seeds
05.0 Confectionery
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes,
excluding bakery
07.0 Bakery wares
08.0 Meat and meat products, including poultry and game
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms
10.0 Eggs and egg products
11.0 Sweeteners, including honey
12.0 Salts, spices, soups, sauces, salads, protein products, etc.
13.0 Foodstuffs intended for particular nutritional uses
14.1 Non-alcoholic ("soft") beverages, excl. dairy products
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts
15.0 Ready-to-eat savouries
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in
categories 01.0 - 15.0
The “normal and maximum use levels” are provided by Industry for the 12 of the 14 candidate substances in
the present flavouring group (Table B.1.2).
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Table B.1.2. Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.25Rev3 (EFFA, 2005a; EFFA, 2006a; EFFA, 2007).
FL-no Food Categories
Normal use levels (mg/kg)
Maximum use levels (mg/kg)
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0
01.001 5
25
2
5
5
10
1
1
0
0
10
25
5
10
5
25
1
10
1
5
1
5
1
5
2
20
3
10
2
10
5
10
2
5
1
5
01.027 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.028 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.033 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.034 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.035 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.038 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.039 7
35
5
25
10
50
7
35
-
-
10
50
4
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.046 3
15
2
5
5
10
1
1
0
0
5
15
2
10
5
20
1
5
1
5
1
5
1
5
2
15
3
10
2
10
4
10
2
5
2
5
01.054 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.057 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.059 3
15
2
10
3
15
2
10
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
3
15
5
8
15
75
5
25
01.064 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.070 3
15
2
10
3
15
2
10
0
0
4
20
2
10
5
25
1
5
1
5
1
5
1
5
2
10
3
15
2
10
4
20
5
25
2
10
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B.2 mTAMDI Calculations
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume
the amount of flavourable foods and beverages listed in Table B.2.1. These consumption estimates are then
multiplied by the reported use levels in the different food categories and summed up.
Table B.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed
per person per day (SCF, 1995).
Class of product category Intake estimate (g per day)
Beverages (non-alcoholic) 324.0
Foods 133.4
Exception a: Candy, confectionery 27.0
Exception b: Condiments, seasonings 20.0
Exception c: Alcoholic beverages 20.0
Exception d: Soups, savouries 20.0
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum)
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in
Commission Regulation (EC) No 1565/2000 (EC, 2000) and reported by the Flavour Industry in the
following way (see Table B.2.2):
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000)
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or 16
(EC, 2000)
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000)
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000)
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000)
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000)
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum.
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Table B.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000
(EC, 2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995).
Food categories according to Commission Regulation
1565/2000
Distribution of the seven SCF food
categories
Key Food category Food Beverages Exceptions
01.0 Dairy products, excluding products of category 02.0 Food
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food
03.0 Edible ices, including sherbet and sorbet Food
04.1 Processed fruit Food
04.2 Processed vegetables (incl. mushrooms & fungi, roots &
tubers, pulses and legumes), and nuts & seeds
Food
05.0 Confectionery Exception a
06.0 Cereals and cereal products, incl. flours & starches from
roots & tubers, pulses & legumes, excluding bakery
Food
07.0 Bakery wares Food
08.0 Meat and meat products, including poultry and game Food
09.0 Fish and fish products, including molluscs, crustaceans and
echinoderms
Food
10.0 Eggs and egg products Food
11.0 Sweeteners, including honey Exception a
12.0 Salts, spices, soups, sauces, salads, protein products, etc. Exception d
13.0 Foodstuffs intended for particular nutritional uses Food
14.1 Non-alcoholic ("soft") beverages, excl. dairy products Beverages
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic
counterparts
Exception c
15.0 Ready-to-eat savouries Exception b
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) -
foods that could not be placed in categories 01.0 - 15.0
Food
The mTAMDI values (see Table B.2.3) are presented for each of the 14 flavouring substances in the present
flavouring group (EFFA, 2005a; EFFA, 2006a; EFFA, 2007, EFFA, 2015). The mTAMDI values are only
given for the highest reported normal use levels.
Table B.2.3 Estimated intakes based on the mTAMDI approach.
FL-no EU Register name mTAMDI
(µg/person/day)
Structural class Threshold of
concern
(µg/person/day)
01.027 Bisabola-1,8,12-triene 3900 Class I 1800
01.028 beta-Bisabolene 3900 Class I 1800
01.033 2,2-Dimethylhexane 3900 Class I 1800
01.034 2,4-Dimethylhexane 3900 Class I 1800
01.038 Dodecane 3900 Class I 1800
01.039 delta-Elemene 3900 Class I 1800
01.054 Pentadecane 3900 Class I 1800
01.057 Tetradecane 3900 Class I 1800
01.035 2,6-Dimethylocta-2,4,6-triene 3900 Class I 1800
01.059 4(10)-Thujene 3100 Class I 1800
01.064 cis-3,7-Dimethyl-1,3,6-octatriene 3900 Class I 1800
01.070 1-Octene 1600 Class I 1800
01.001 Limonene 1800 Class I 1800
01.046 l-Limonene 1600 Class I 1800
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Appendix C. Metabolism
C.1. Introduction
This group of flavouring substances is very diverse with respect to the chemical structures. In order to
facilitate the evaluation of the metabolism aspects of the individual substances, the candidate substances in
the group have been divided into four subgroups: I) acyclic saturated hydrocarbons [FL-no: 01.033, 01.034,
01.038, 01.054 and 01.057], II) acyclic unsaturated hydrocarbons [FL-no: 01.001, 01.035, 01.046, 01.064
and 01.070], III) cyclohexene hydrocarbons [FL-no: 01.027, 01.028 and 01.039], V) bicyclic, non-aromatic
hydrocarbon [FL-no: 01.059, ]. From the evaluation of flavouring substances as carried out by the JECFA in
2004, a group of supporting substances has been identified. These supporting substances have also been
allocated to subgroups in the same way as has been indicated for the candidate substances. The allocation of
the candidate and supporting substances is shown in Table C.1.
Table C.1 Subgroups. The supporting substances are listed in brackets.
FL-no EU Register name Structural formula Structural class
I: ACYCLIC ALKANES
01.033 2,2-Dimethylhexane I
01.034 2,4-Dimethylhexane I
01.038 Dodecane I
01.054 Pentadecane I
01.057 Tetradecane I
II: ACYCLIC ALKENES
01.035 2,6-Dimethylocta-2,4,6-triene I
Deleted
from the
Register
2-Methylbuta-1,3-diene I
01.064 cis-3,7-Dimethyl-1,3,6-octatriene I
01.070 1-Octene I
(01.008) (Myrcene) I
(01.018) (β-Ocimene) I
(01.040) (α-Farnesene) I
(01.061) (Undeca-1,3,5-triene) I
III: CYCLOHEXENE HYDROCARBONS
01.001 Limonene I
Flavouring Group Evaluation 25 Revision 3
EFSA Journal 2015;13(4):4069 81
Table C.1 Subgroups. The supporting substances are listed in brackets.
FL-no EU Register name Structural formula Structural class
01.046 l-Limonene I
01.027 Bisabola-1,8,12-triene I
01.028 β-Bisabolene I
01.039 delta-Elemene I
(01.005) (Terpinolene) I
(01.006) (α-Phellandrene) I
(01.016) (1,4(8),12-Bisabolatriene) I
(01.019) (α-Terpinene) I
(01.020) (gamma-Terpinene) I
(01.045) (d-Limonene) I
IV: AROMATIC HYDROCARBONS
The substances previously allocated to the group are no longer supported for use as flavouring substances in Europe by Industry
V: BICYCLIC, NON-AROMATIC HYDROCARBONS
01.059 4(10)-Thujene I
(01.003) (Pin-2(10)-ene) I
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Table C.1 Subgroups. The supporting substances are listed in brackets.
FL-no EU Register name Structural formula Structural class
(01.004) (Pin-2(3)-ene) I
(01.007) (β-Caryophyllene) I
(01.009) (Camphene) I
(01.017) (Valencene) I
(01.024) (β-Bourbonene) H
H H
I
(01.026) (1(5),7(11)-Guaiadiene) I
(01.029) (delta-3-Carene) I
VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS
The substances previously allocated to the group are no longer supported for use as flavouring substances in Europe by Industry
For the majority of the substances no information of biotransformation had been submitted. Also data on
structural analogues were scarce. Therefore, an additional search was carried out. The additional information
retrieved has been included in the following text.
C.2. Absorption, Distribution and Elimination
Acyclic Alkanes (Candidate and Structurally Related Supporting Substances from Subgroup I)
No data on absorption, distribution and elimination were submitted for any of the candidate substances in
this subgroup. Some studies on saturated alkanes were retrieved from the additional data search, but apart
from two oral studies (Olson et al., 1986; Serve et al., 1995) and one subcutaneous study (Manini et al.,
1999), in all other studies retrieved, inhalation was the route of exposure. From these studies (Bahima et al.,
1984; Perbellini et al., 1986; Perbellini et al., 1982; Fedtke and Bolt, 1987; Holmberg et al., 1977),
absorption through the membranes of the inhalatory tract was observed. Absorption rates and distribution
ratios were dependent on blood/air and blood/tissue partition coefficients (Imbriani et al., 1985; Nilsen et al.,
1988). In addition, one inhalation study by (Dahl, 1989) showed that more branched isomers were less well
absorbed than less branched or unbranched isomers. More saturated hydrocarbons were less well absorbed
than unsaturated and more volatile substances were less well absorbed than less volatile (reversely correlated
to chain length), but this may not be a relevant difference for oral exposure situations. The main purpose of
these studies was however to study metabolism, but these inhalation exposure studies do in general not
provide appropriate mass balance data. For that reason, apart from the two oral and one inhalation study
(Dahl, 1989) which give insight in mass balance, the studies by (Bahima et al., 1984; Perbellini et al., 1986;
Perbellini et al., 1982; Fedtke and Bolt, 1987) and (Manini et al., 1999) will be discussed in the section on
biotransformation.
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Male and female rats were given a dose of 2 ml/kg or 1.4 g/kg n-octane by gavage and urine was collected
for up to 48 hours. Urine samples were treated with glucuronidase/sulphatase and the liberated metabolites
were analysed by gas chromatography. Several oxidised metabolites in the urine could be found, but
quantitative data were not given (Olson et al., 1986). A similar study was carried out with n-nonane by Serve
et al. (Serve et al., 1995), but again no quantitative data were provided.
Groups of three or four male F 344 rats were exposed to [4-14C] or [5-14C]-labelled iso-octane (= 2,2,4-
trimethyl pentane (trivial name)) and [1-14C]-octane vapours at approximately 1 and 350 ppm (~ 4.76 or
1700 mg/m3 for both substances) by the nose for two hours. During the experiment exhalant was drawn
through a bubbler train for sampling. Urine and faeces were collected at the same times, except that none
were collected at one and two hours. For iso-octane, all rats exposed to 350 ppm were exposed to C4-labeled
substance, but three of four low-exposure rats were exposed to C5-labeled iso-octane. Values for exhaled
14CO2 were 0.36; 0.31; and 0.52 % of inhaled 14C. For the single rat exposed to C4-labeled iso-octane the
corresponding value was 2 %18. Values for all rats were averaged regardless of position of label. The validity
of conclusions regarding low production of 14CO2 from iso-octane would have been enhanced by exclusive
use of C5-labeled material.
For both n-octane and iso-octane the metabolised fraction was higher at low compared to high inhaled
concentrations. For octane the major route of elimination was as carbon dioxide (15 % of the radioactive
dose within 70 hours). For iso-octane the major route of excretion was urine. Half of the octane-introduced
14C that was retained at the end of the two-hour exposure period was eliminated 5-10 hours post exposure
and the exhalation of radiolabel became undetectable after 30 hours after which 75-85 % of the label was
eliminated. For iso-octane the time to eliminate half of the label was 15 hours and was not completed at the
end of the observation period. Based on a discussion of papers from other research groups, the study authors
suggest that for straight-chain hydrocarbons, breakdown of the carbon skeleton with the release of CO2 is an
important metabolic pathway. The route of excretion for n-octane in this study was markedly affected by the
concentrations of the inhaled vapour. The ratio of total exhaled 14CO2: total 14C in urine was 5:1 after
inhalation at 1 ppm but about 1:1 after inhalation of 350 ppm (Dahl, 1989).
Acyclic Alkenes (Candidate and Structurally Related Supporting Substances from Subgroup II)
When given to male Japanese White rabbits by gavage at a dose of 670 mg/kg bw per day for two days,
approximately 25 % of the total administered amount of myrcene [FL no: 01.008] (19 g to six rabbits) could
be recovered from the urine over a period of three days following administration (Ishida et al., 1981). Only
metabolites of myrcene were identified. The fate of the remaining part of the dose is unclear.
Following intraperitoneal injection of 64 mg [4-14C]-2-methylbuta-1,3-diene /kg to F344 rats and B6C3F1
mice, the majority of radioactivity (≈ 54 and 47 %, respectively) was excreted unchanged in the expired air 
or as urinary metabolites (≈ 32 and 33 %, respectively) over the 24-hours collection period. Less than 2 % of 
the radioactivity was recovered as CO2 for both species, and 0.2 and 7.2 % in rats and mice, respectively, of
the radioactivity was recovered in the faeces over the same time period. Radioactivity remaining in the
carcass and tissues amounted to only 3.1 and 1.7 % in rats and mice, respectively. From the tissues
examined, the highest concentration was found in the kidneys but in both species the renal concentration of
radioactivity was only twice as high as the concentration in blood. Total percentage of the dose recovered
was ≈ 91 % for both rats and mice (Buckley et al., 1999). 
18 In an additional study (not reported in detail), three rats were exposed to C4- or C5-labeled iso-octane at about 350 ppm. More
14CO2 was exhaled during exposure to the C4-labeled material (0.07% of the inhaled amount) than after exposure to the C5-labeled
material (0.03%). This observation also confirms that C5 labelled iso-octane is less well metabolised to CO2 than C4 labelled iso-
octane
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Cyclohexene Derivatives (Candidate and Structurally Related Supporting Substances from Subgroup
III)
Data were only available for one supporting substance in subgroup III, namely d-limonene [FL-no: 01.045].
Following the oral administration of [9-14C]-d-limonene to male Wistar rats by stomach tube at a dose of 800
mg/kg bw, radioactivity was determined in blood, tissues (fat not included), excreta, bile and expired air. The
animals were sacrificed at 48 hours post dosing. Radioactivity reached a peak plasma level at two hours post
dosing, and after maintaining high levels for 10 hours, declined to negligible levels at 48 hours. In most
tissues, peak levels of radioactivity were reached within two hours post dosing indicating rapid distribution.
The liver, kidney and adrenals contained the highest levels of radioactivity (higher than blood or serum);
other tissues (including brain) contained less than 0.2 % of the administered radioactivity. Hardly any
radioactivity could be detected at 48 hours post dosing. Whole body autoradiography confirmed these
findings. At 48 hours post-dosing, about 60 % of the administered radioactivity was recovered from the
urine, 5 % from faeces and 2 % from exhaled air as CO2. Approximately 25 % of the administered
radioactivity was excreted in the bile during 24 hours after administration. Total recovery of radioactivity
was less than 100 % and as there was hardly any radioactivity present in the tissues at 48 hours, this could
point to loss of volatile 14C from the excreta or to the elimination of volatile 14C-compounds other than CO2
(Igimi et al., 1974). When a similar radioactive dose of [9-14C]-d-limonene was given to male rabbits, 72 %
and 7 % of the radioactivity was excreted in the urine and faeces during 72 hours, respectively (Kodama et
al., 1974).
In an additional study with several species (rats, hamsters, guinea pigs, rabbits, dogs and humans) dosed
orally with [9-14C]-d-limonene, urinary excretion of radioactivity in rodents and rabbits comprised 82-96 %
of the dose within 72 hours and faecal excretion 2-9 %. The total excretion rate in dogs was somewhat lower
(77 % via urine and 9 % via faeces within 72 hours), while two human volunteers excreted 55-83 % of the
administered dose in the urine. Faecal excretion in humans was not measured, but may have been
considerable in the person with lower urinary excretion as this person developed a diarrhoea shortly after
administration. In all species, most excretion occurred within the first 24 hours (Kodama et al., 1976).
In vitro, the solubility of d-limonene in blood and olive oil was high, but low in water, which suggests a high
respiratory uptake and accumulation in adipose tissues (Falk et al., 1990a). Indeed, uptake was rapid and
high (68 %) in an experiment in which human volunteers were exposed to d-limonene in air at 225 and 450
mg/m3 for 2 hours while doing light physical exercise. The absorbed d-limonene was metabolised rapidly.
Elimination followed a triphasic pattern, with a short half-life in blood immediately after exposure (2.6
minutes) but a long half-life during the late elimination phase (12.5 hours), which indicates slow elimination
from adipose tissues. Approximately 1 % of the total uptake was eliminated unchanged in expired air, while
approximately 0.003 % was eliminated unchanged in urine (Falk-Filipson et al., 1993).
Aromatic Hydrocarbons (Candidate and Structurally Related Supporting Substances from Subgroup
IV)
The substances previously allocated to the group are no longer supported for use as flavouring substances in
Europe by Industry.
Bicyclic, Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting Substances
from Subgroup V)
No data on absorption on candidate substances in this group were submitted. Some data were retrieved after
database search on longifolene [former FL-no: 01.047] and on several supporting substances including α- 
and β-pinene [FL-no: 01.004 and 01.003], caryophyllene [FL-no: 01.007] and delta-3-carene [FL-no: 
01.029].
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Asakawa et al. (1986) studied the metabolism of (+)-longifolene and caryophyllene in rabbits after gavage
dosing. At two days after administration, metabolites of all of these substances could be detected in the urine,
from which it can be concluded that these substances are absorbed. As no mass balance data were given, the
extent of absorption cannot be assessed (Asakawa et al., 1986).
Male albino rabbits (6/group) were administered single gavage doses of 400 – 700 mg/kg bw of (+)-α-
pinene, (-)-α-pinene, (±)-α-pinene, (-)-β-pinene, or delta-3-carene. Urine of individual animals was collected 
for three days. The animals excreted bicyclic terpene hydrocarbon metabolites as glucuronic acid conjugates
or as further oxidised metabolites, notably carboxylic acids (Schreiner, 2003).
In vitro data on the solubility of α-pinene [FL-no: 01.004], β-pinene [FL-no: 01.003] and delta-3-carene [FL-
no: 01.029] in blood, olive oil and water suggest a high respiratory uptake and accumulation in adipose
tissues. For α-pinene this is supported by a high estimated brain/blood partition coefficient of 18 (Falk et al., 
1990a). Experiments in which human volunteers were exposed to (+)- and (-)-α-pinene or delta-3-carene in 
air at 225 and 450 mg/m3 for two hours while doing light physical exercise confirmed that uptake was rapid
and high for these agents (58-60 % for (+)- and (-)-α-pinene and 70 % for delta-3-carene), and that they were 
metabolized rapidly. Elimination followed a triphasic pattern, with (+)- and (-)-α-pinene exhibiting a rapid 
initial (distribution) phase (4.8 and 5.6 minutes, respectively), a rapid second distribution phase (38 and 40
minutes, respectively), and a slow elimination phase (695 and 555 minutes, respectively). Triphasic
elimination was also observed for delta-3-carene with half-lives of 4.5, 35 and 1800 minutes for the initial,
rapid, and slow phases, respectively. It was estimated that it would require over two or six days to eliminate
α-pinene or delta-3-carene, respectively, from the body. The long half-lives indicate slow elimination from 
adipose tissues. Less than 0.001 % of the total uptake of α-pinene or delta-3-carene was eliminated 
unchanged in the urine, while 7.5-7.8 % and 3 % of the inhaled amount of the α-pinenes and delta-3-carene 
were exhaled (Falk et al., 1990b; Falk et al., 1991).
In another study, humans were exposed for four or six hours to atmospheres containing a mixture of volatile
organic substances, which included α-pinene, at total concentrations of 12 or 24 mg/m3. At a concentration of
24 mg/m3 for the total volatiles, the air concentration of α-pinene was 0.775 mg/m3. The mean pre-exposure
blood concentration of α-pinene of  0.035 µg/l increased to an average concentration of 1.9 µg/l during the 4-
hours exposure (50-240 minutes). Thereafter (330-450 minutes), the mean blood concentration decreased to
0.15 µg/l. Changes proportional to those observed at 24 mg/m3 were recorded at 12 mg/m3 exposure. Similar
results were recorded for the 6-hours exposure. Plasma elimination for α-pinene was best described with a 
three-exponential curve, with half-lives ranging from 0.22-7.8 minutes, 19-58 minutes and >150 minutes for
the initial, mid and terminal phases, respectively (Ashley and Prah, 1997).
In the urine of sawmill workers exposed to an atmosphere containing 31-210 mg/m3 α-pinene [FL-no: 
01.004], 2-17 mg/m3 β-pinene [FL-no: 01.003] and 6-90 mg/m3 delta-3-carene [FL-no: 01.029] for three
days, cis and trans-verbenol were identified as metabolites. They were excreted as conjugates, probably with
glucuronic acid. The authors suggested that these metabolites were formed by hydroxylation of α-pinene 
(Eriksson and Levin, 1990). Analysis of urinary metabolites eliminated by human volunteers within four
hours following a 2-hours exposure to 10 - 450 mg α-pinene /m3 revealed that α-pinene is indeed eliminated 
as cis- and trans-verbenol, in a ratio of 1:10, within 20 hours following exposure (Levin et al., 1992). In a
more extensive metabolic study, urine was collected from sawmill workers at the end of an eight - nine hours
work shift or from chamber-exposed individuals. Following hydrolysis of glucuronic acid conjugates, several
pinene biotransformation products were found (Eriksson and Levin, 1996).
Macrocyclic, Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting
Substances from Subgroup VI)
The substances previously allocated to the group are no longer supported for use as flavouring substances in
Europe by Industry.
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C.3. Conclusions on Absorption, Distribution and Elimination
Based on the available studies it may be concluded that the candidate alkane substances (subgroup I) will be
absorbed after oral exposure. The extent of absorption is not known, but may be high, given their lipophilic
character and their low molecular weight. The ease with which these substances cross the membranes of the
respiratory tract further supports the assumption that these substances will also be absorbed after oral intake.
Data indicate that straight-chain alkanes will predominantly be broken down to carbon dioxide at low dose
levels. At high dose levels, biotransformation becomes saturated and other metabolites will be generated,
which will be excreted via the urine. As illustrated by for iso-octane, metabolism of (highly) branched
alkanes to carbon dioxide is less favourable, and their metabolites will be eliminated more slowly via the
urine.
For the candidate or supporting substances in subgroup II (acyclic alkenes), data were only available for the
supporting substance myrcene [FL-no: 01.008] and for the structurally related substance 2-methylbuta-1,3-
diene (former candidate substance (See “History of the evaluation”)). Given the narrow range of molecular
weights of the candidate substances (all between ~ 68 and 206 D) and their lipophilic nature (Log Kow
values e.g. 2.4 (2-methylbuta-1,3-diene), 6.1 (dodec-1-ene), 4.17 (myrcene) or 4.8 (cis-3,7-dimethyl-1,3,6-
octatriene)), it must be assumed that these candidate flavouring substances will be absorbed from the
gastrointestinal tract, at least to some extent, if not completely. Mass balance data are also incomplete. At
least for myrcene it has been shown its metabolites will be excreted via urine in an amount of 25 % of the
dose within three days after dosing. For 2-methylbuta-1,3-diene a fairly complete mass balance of
elimination has been presented, which shows also elimination via the exhaled air (~ 50 % of the dose), but as
this substance was administered via the intraperitoneal dose route, the elimination pattern may be different
after oral dosing with a lower fraction of the dose exhaled, e.g. because of more efficient first-pass
biotransformation after oral dosing.
For the candidate or supporting substances in subgroup group III (cyclohexene derivatives), data were only
available for d-limonene [FL-no: 01.045], which is a supporting substance. For this substance, data show a
considerable absorption from the gastrointestinal tract. In humans, elimination of the substance followed a
triphasic pattern, but still 55-83 % of an oral dose could be found in the urine within 72 hours post-dosing,
with the major part excreted within 24 hours. Also in other species urinary elimination was most important
accounting for up to 82–96 % of the dose within 72 hours. Hence, it may be argued that monocyclic
cyclohexene derivatives, such as d-limonene, administered orally are absorbed and distributed throughout the
body. Following oral administration to humans, d-limonene was distributed preferentially to fatty tissues, as
indicated by a high oil-blood partition coefficient and a long half-life during the slow elimination phase.
Because of the limited molecular weight of the candidate substances in this group (range ~ 136–204 D) and
their lipophilic character (e.g. log Kow values for β-phellandrene, β-bisabolene and d-limonene are ca. 4.7,
7.1 or 4.6, respectively) it may be assumed that all of the substances in this group will be absorbed to some
degree, although the extent of absorption for individual substances cannot be accurately estimated from these
physico-chemical properties. For the substances in subgroup III with conjugated double bonds no data are
available, but based on the structural similarity with the other substances in subgroup III, it may be
anticipated that at the substances will also be absorbed.
The substances previously allocated to the subgroup IV are no longer supported for use as flavouring
substances in Europe by Industry.
For the substances in subgroup V (bicyclic, non-aromatic hydrocarbons), the available data from oral studies
are few. These studies have only addressed the excretion of some supporting and one related substance
(longifolene) in the form of metabolites via the urine. No mass-balance data were provided. So these studies
only show that these substances will be absorbed to some extent. The same may be anticipated for the (other)
candidate substances in this subgroup. For the supporting substances α- and β-pinene and delta-carene 
information on kinetics is available from humans exposed via inhalation, in occupational settings. These
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studies show that these substances can be absorbed after inhalation exposure and that metabolites will be
excreted into the urine e.g. as glucuronide conjugates. The elimination follows a triphasic pattern with rather
long terminal half-lives. The absorbed amount will be eliminated within several days. Based on the lipophilic
character of these substances it may be anticipated that they will preferentially distribute in the adipose
tissues, which is supported by the slow terminal elimination rates.
The substances previously allocated to the subgroup VI are no longer supported for use as flavouring
substances in Europe by Industry.
C.4. Metabolism
Acyclic Alkanes (Candidate and Structurally Related Supporting Substances from Subgroup I)
Oral
Male and female rats were given a dose of 1400 mg n-octane per kg bw by gavage and urine was collected
for up to 48 hours. Urine samples were treated with glucuronidase/sulphatase and the liberated metabolites
were analysed by gas chromatography. Compounds found in urine were 2-octanol, 3-octanol, 5-oxohexanoic
acid and 6-oxoheptanoic acid. In female rats 2-octanol was found to be the major urinary metabolite and 5-
oxohexanoic acid was the major metabolite in males. The authors state that in contrast to n-hexane and n-
heptane, n-octane was not metabolised to a ketone, diketone or a diol derivative. The structures of the keto
acids that were produced indicate that metabolic oxidation is occurring on both ends of the n-octane
molecule. A former metabolism study of n-heptane did yield gamma-valerolactone, which was presumed to
have been formed on the GC column from 4-hydroxy-1-pentanoic acid, which would involve a 2 carbon loss.
The authors speculate that with n-heptane, n-octane and perhaps higher straight chain hydrocarbon
homologues, a major metabolic pathway involves the formation of acids with loss of carbon (Olson et al.,
1986).
The metabolism of n-nonane has been studied in rats after oral administration of 800 mg/kg bw over a 48
hours excretion period. In the urine the following metabolites were detected: 2-, 3- and 4-nonanol, 4-
nonanone, 2,5-hexanedione, gamma-valerolactone, delta-hexanolactone and delta-heptanolactone and 5-
methyl-2-(3-oxobutyl)furane. The authors also reported the formation of 1-heptanol, but no explanation for
this metabolite is available. Keto-acids, as observed with n-octane could not be detected after administration
on n-nonane (Serve et al., 1995).
Flavouring Group Evaluation 25 Revision 3
EFSA Journal 2015;13(4):4069 88
Other Routes of Exposure
Rats were exposed to n-heptane in a concentration of 8100 mg/m3 in the air for six hours per day five
days/week for 12 weeks. After exposure the animals were kept in a metabolism cage to collect urine samples
during the next 18 hours for the first week of the experiment and subsequently at the end of every five-day
exposure period. Primary metabolites of n-heptane in the urine were 1-, 2-, 3,- and 4-heptanol, of which the
2- and to a lesser extent the 3- isomer were quantitatively the most important. Subsequent oxidations of these
two secondary alcohols provided 2- and 3-heptanone and the diols 2,6- and 2,5-heptanediol. In follow-up
oxidations, final products were 5-hydroxy-2-heptanone, 6-hydroxy-2-heptanone, 2,6-and 2,5-heptanedione
and 6-hydroxy-3-heptanone, which was de-acetylated to yield 4-hydroxy-pentanoic acid. This metabolite
was detected in the urine as gamma-valerolactone. The alcoholic metabolites were rapidly excreted as
sulphate and glucuronide conjugates. Although 2,5-heptanedione is a gamma-diketone, no signs of peripheral
neuropathy were observed. The authors speculated that the plasma levels of this ketone did not become high
enough to trigger this effect, because of the rapid conjugation of the precursor alcohols which was supported
by the minute amounts in which they were present in the urine, although their (conjugated) precursors
reached much higher concentrations (Bahima et al., 1984).
In Sprague-Dawley rats exposed to vapours (7680 mg/m3) of n-heptane for six hours, main urinary
metabolites were 2- and 3-heptanol. Other metabolites detected were 2- and 3- heptanone, 4-heptanol, 2,5-
heptanedione, gamma-valerolactone, 2,6-dimethyl-2,3-dihydropyrane and 2-ethyl-5-methyl-2,3,-
dihydrofurane. In humans, occupationally exposed to n-heptane (5-196 mg/m3) 2- and 3-heptanol were found
in the urine. Other metabolites detected were 2- and 4- heptanone and 2,5-heptanedione. In human urinary
samples no ring-closure products could be detected, but it is noted that the human exposure was less than that
of the rats. In rat tissues (blood, muscle, kidney, nervous tissue, liver), levels of 2-heptanol were between 0.2
and 2 mg/l. Levels of n-heptane in the same tissues were around 20 mg/l (Perbellini et al., 1986).
After oral administration of n-octane (1400 mg/kg bw) to rats in the urine the following metabolites could be
detected within 48 hours after dosing: 2- and 3-octanol and 5-keto-hexanoic and 6-keto-heptanoic acid. In
contrast to heptane, n-octane was not converted into mono- or diketones or into diols (Olson et al., 1986).
Based on this study and the data for n-heptane, the authors argued that for n-heptane and higher straight-
chain alkanes, formation of carboxylic acids and subsequent loss of carbon may be a major metabolic
pathway. However, the quantitative contribution of de-carboxylation was not thoroughly studied (e.g. no
studies with radioactive material) and no mass balances were provided. It has been proposed that n-octane is
also converted into 1-octanol and further into octanoic acid, but no detailed information on these studies was
submitted (Low et al., 1987).
Groups of three or six rats (Sprague-Dawley, 300-600g), groups of two male rabbits (New Zealand, 1600-
2000g) and one male monkey (Maccaca mulatta, 1600-2000g) were subjected to single inhalatory treatments
of 5000 ppm (~ 18 000 mg/m3) n-hexane for 6, 12 and 24 hours. After treatment animals were kept in
metabolic cages for the following 72 hours. Urine from treated and control animals were collected during
treatment and at various intervals thereafter. For rats blood was collected during and after treatment. Urine
samples were subjected to enzymatic and then acid hydrolysis and analysed by gas chromatography. In urine
of rats 2-hexanol, 3-hexanol, 2,5-dimethylfurane, gamma-valerolactone and 2,5-hexanedione along with
methyl n-butylketone were found. The metabolites detected in urine from rabbit and monkey were 2-
hexanol, 3-hexanol, methyl n-butylketone and 2,5-hexanedione. 1-hexanol and 2,5-hexanediol were not
detectable in any of the species. In rats peaks of 2,5-hexanedione and 2,5-dimethylfurane in urine were
preceded by analogous peaks in blood, while blood concentrations of n-hexane, methyl n-butylketone and 2-
hexanol “peaked” immediately after termination of exposure (Perbellini et al., 1982).
Male rats were exposed to n-hexane by inhalation at concentrations ranging from approximately 180 to
approximately 11000 mg/m3 for 8 hours in an all-glass exposure system. Urinary kinetics for the metabolites
1-hexanol, 2-hexanol, 3-hexanol, 2 hexanone, 2,5-hexanedione and 4,5-dihydroxy-2-hexanone were
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assessed. Urine samples were collected up to 48 hours following the start of exposure. Amounts of
metabolites were linearly dependent on the exposure concentrations, up to an exposure of about 1070 mg/m3.
Above this the metabolite excretion indicated saturation kinetics in the metabolism. 2-Hexanol amounted to
about twice the excretion of all other metabolites excreted. In quantity 4,5-dihydroxy-2-hexanone was the
second metabolite, the amount in urine being about 10 times higher than that of excreted 2,5-hexanedione. 2-
Hexanol and 4,5-dihydroxy-2-hexanone accounted for 90 % of the total excretion (Fedtke and Bolt, 1987).
A male volunteer was exposed to a mean n-hexane atmosphere of 217 ppm (~ 800 mg/m3) for 4 hours. The
occurrence of 4,5-dihydroxy-2-hexanone as a metabolite in urine of the man was confirmed. Twenty-six
hours after exposure the excretion of 4,5-dihydroxy-2-hexanone reached a level that was four times higher
than the excretion of 2,5-hexanedione. The authors conclude that formation of 4,5-dihydroxy-2-hexanone
may be viewed as a route of detoxification, and also state that it is clear that 4,5-dihydroxy-2-hexanone is
responsible for an artificial appearance of 2,5-hexanedione after drastic acid treatment of human urine,
presumably via 2,5-dimethylfuran as intermediate (Fedtke and Bolt, 1987).
Groups of three or four male F 344 rats were exposed to [4-14C]-labelled iso-octane (2,2,4-trimethyl pentane)
and [1-14C]-octane vapours at approximately 1 and 350 ppm (~ 4.76 or 1700 mg/m3 for both substances) for
two hours. During the experiment exhalant was drawn through a bubbler train for sampling. Urine and faeces
were collected at the same times, except that none were collected at one or two hours. Exhalation of 14CO2
appeared to be much more important for n-octane than for iso-octane, from which a larger part of the
radioactivity is eliminated via urine. Based on this observation and on a discussion of papers from other
research groups, the study authors suggest that for straight-chain hydrocarbons, breakdown of the carbon
skeleton with the release of CO2 is an important metabolic pathway. The route of excretion for n-octane in
this study was markedly affected by the concentrations of the inhaled vapour. The ratio of 14CO2: 14C in urine
was 5:1 after inhalation at 1 ppm but 1:1 after inhalation of 350 ppm (Dahl, 1989). The radioactivity
eliminated via the urine was not identified.
Hexane was given to rats via subcutaneous injections during three consecutive days. Urinary metabolites
were various hexanols, 5-hydroxy-2-hexanone, 4,5-dihydroxy-2-hexanone, 2,5-hexanedione, 2-hexanone and
the ring closure products gamma-valerolactone and 2,5-dimethylfurane. It was noted that most of the
alcoholic metabolites were excreted as conjugates (in particular glucuronide) (Manini et al., 1999). Such
conjugation has also been reported in the other alkane biotransformation studies discussed in this Appendix.
The study authors (Manini et al., 1999) further demonstrated that the cyclization products (i.e. the lactones
and furans) may be formed under the acidic conditions during deconjugation procedures for sample
treatment.
Conclusions on the metabolism of subgroup I substances
The substances in subgroup I can be expected to be metabolised through omega-oxidation, which will lead to
the formation of alcohols, and after oxidation to carboxylic acids, which may be further oxidised via β-
oxidation to yield carbon dioxide. Extensive mass balance data are not available, but in some of the studies
described above some excretion of carboxylic acids and carbon dioxide has been reported. Formation of
keto-acids has also been reported, and these may be formed from omega-oxidation at one end of the
molecule and omega-1 or -2 oxidation at the other end. More interest has been put in the identification of
metabolites which did not undergo substantial chain shortening. These metabolites will arise from oxidation
of the non-terminal carbon atoms, e.g. via omega-1, -2, -3 or even -4 oxidations. The resulting secondary
alcohols can be conjugated with e.g. glucuronic acid and excreted via the urine, or can be further oxidised to
yield ketones. A subsequent introduction of another secondary hydroxyl group may result in the formation of
diketones. With n-hexane, the resulting 2,5-hexanedione (a gamma-diketone) has been demonstrated to be
responsible for hexane-induced neurotoxicity. Neurotoxicity is a common feature of gamma-diketones, and
for that reason, the candidate substance 3-methylhexane [FL-no: 01.050] cannot be anticipated to be
metabolised into innocuous compounds. In addition, it is known that methyl-branching of the carbon chain
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potentiates the neurotoxicity of the gamma-diketone (Topping et al., 1994; EFSA, 2004b). The two other
hexane derivatives in this group [FL-no: 01.033 and 01.034] cannot be oxidised to gamma-diketone, due to
the presence of methyl groups on the C2 and C5 carbon atoms. Therefore, these substances may be
metabolised to innocuous metabolites. For the longer chain alkanes in this group, it would require oxidation
of the more central carbon atoms in order to be converted into gamma-diketones. Such oxidations are less
favourable than omega, omega-1 or -2 oxidations, and therefore it is concluded that oxidation of these higher
alkanes will not result in toxicologically relevant levels of gamma-diketones, also because of rapid
conjugation of the precursor alcohols. For heptane it was shown that this substance does not result in
neurotoxicity (Bahima et al., 1984), although the gamma-diketone itself (2,5-heptanedione) is known to be
neurotoxic (Topping et al., 1994). The remaining three candidate flavouring substances in this group i.e. [FL-
no: 01.038, 01.054 and 01.057] can be expected to be metabolised to innocuous products.
Acyclic Alkenes (Candidate and Structurally Related Supporting Substances from Subgroup II)
For the substances in this group, information is only available on the biotransformation of myrcene ([FL-no:
01.008]; a supporting substance) and 2-methylbuta-1,3-diene (a structurally related substance). Some
additional information on the related industrial chemical 1,3-butadiene has also been added. Two of the
substances in this group (dodec-1-ene; [FL-no: 01.037] and 1-octene [FL-no: 01.070) bear a terminal double
bond without any other structural features (e.g. hydroxyl groups, methyl substituents). No further data for
these or similar substances are available. The metabolic aspects of terminal double bond substances have
been discussed in FGE.07 and FGE.18 (EFSA, 2004b; EFSA, 2006). The relevant parts of these FGEs will
also be included in the current discussion.
Myrcene [FL-no: 01.008]
In the urine of rabbits, orally administered myrcene via gavage (670 mg/kg bw per day for two days), 25 %
of the total amount administered could be recovered from the urine within three days post-dosing, and >
80 % of the myrcene-derived substances were neutral metabolites; the rest were acidic substances. The main
metabolites identified were myrcene-3,10-glycol, myrcene-1,2-glycol and uroterpenol (as acetate) (40.7, 20.8
and 11.8 %, respectively, of the neutral metabolites). Additionally, the glycols underwent further oxidation to
yield 2-hydroxymyrcene-1-carboxylic acid and 3-hydroxymyrcene-10-carboxylic acid (no quantitative data
were given for these acidic metabolites). The authors suggested that uroterpenol (or limonene-8,9-diol) may
have been formed from limonene, which is derived from cyclization of myrcene in the acidic conditions of
the rabbit stomach (Ishida et al., 1981). A graphic representation of myrcene metabolites has been presented
in Figure C.1.
When rats were administered 800 mg/kg bw per day of myrcene orally via gavage for 20 days, the principal
metabolites isolated from the urine were 10-hydroxylinalool (or myrcene-3,10-glycol) and, to a lesser extent,
7-methyl-3-methylene-oct-6-ene-1,2-diol (or myrcene-1,2-glycol). Other minor metabolites included the
hydroxy- acids of both the 3,10- and 1,2-glycols (10-carboxylinalool (or 3-hydroxymyrcene-10-carboxylic
acid) and 2-hydroxy-7-methyl-3-methylene-oct-6-enoic acid (or 2-hydroxymyrcene-1-carboxylic acid),
respectively) and a cyclic diol, 1-hydroxymethyl-4-isopropenylcyclohexanol (or p-menth-8-ene-1,7-diol),
formed by intramolecular cyclization of an open chain metabolite (Madyastha and Srivatsan, 1987). It was
demonstrated that the biotransformation of myrcene was cytochrome P450 (CYP)-mediated and that it could
be enhanced by pretreatment of animals with phenobarbital (Madyastha and Srivatsan, 1987).
Aside from being a substrate for CYP enzymes, myrcene has also been shown to induce these enzymes at
high dose levels (1000 mg/kg bw per day orally for three days), especially those from the CYP2B
(phenobarbital-inducible) subfamily (De-Oliveira et al., 1997). At lower dose levels (40 mg/kg bw per day
intraperitoneally for three days) such induction was not observed (Austin et al., 1988).
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Figure C.1. Metabolism of myrcene in rats and rabbits
2-Methylbuta-1,3-diene
In a sequence of inhalation exposure studies in which rats and mice were exposed to 2-methylbuta-1,3-diene
in the air in concentration of 13-11 000 mg/m3, the metabolism of isoprene became saturated at a level of ca.
700 mg/m3 in the rat and ca. 840 mg/m3 in the mouse. Maximal rates of metabolism were 130 micromol/kg
bw/hour in the rat and 400 micromol/kg bw/h in the mouse. It was demonstrated that 2-methylbuta-1,3-diene
is also produced endogenously at rates of 1.9 micromol/(hour × kg) in rats and 0.4 micromol/(hour × kg) in
mice. Part of the endogenous 2-methylbuta-1,3-diene is exhaled by animals, but it is metabolised
extensively. The rate of metabolism of endogenously produced and systemically available 2-methylbuta-1,3-
diene is 1.6 micromol/(hour × kg) in rats and 0.3 micromol/(hour × kg) in mice, respectively (Peter et al.,
1987). The authors quoted literature demonstrating that 2-methylbuta-1,3-diene is also endogenously
produced in humans (Gelmont et al., 1981 as cited in (Peter et al., 1987)).
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Liver microsomes from mice, rats, rabbits and hamsters metabolise 2-methylbuta-1,3-diene to the
corresponding monoepoxides, 1,2-epoxy-2-methyl-3-butene (major) and 3,4-epoxy-2-methyl-1-butene
(minor). Both monoepoxides are hydrolysed to their respective diols (for chemical structures, see
Figure C.2). The main metabolite of 2-methylbuta-1,3-diene (i.e. 1,2-epoxy-2-methyl-3-butene) exhibited a
half-life of 75 minutes in aqueous environments; whereas the minor metabolite, 3,4-epoxy-2-methyl-1-
butene (14 – 25 % with respect to the main metabolite) is more stable (half-life not specified). The kinetic
constants for the formation of the major epoxide metabolite (trans-2-methyl-3-butene-1,2-diol) of 2-
methylbuta-1,3-diene were determined in the four test species as apparent Km = 0.06 – 0.2 mM and Vmax =
0.24 – 1.79 nmol trans-2-methyl-3-butene-1,2-diol/mg protein × min. The minor metabolite, 3,4-epoxy-2-
methyl-1-butene, was further epoxidised to the diepoxide, 2-methyl-1,2:3,4-diepoxybutane, by microsomes
of all rodents studied. The authors argued that the latter diepoxide metabolite could be responsible for the
genotoxic and carcinogenic activity of 2-methylbuta-1,3-diene, as the two mono-epoxies were not reported to
be genotoxic (Del Monte et al., 1985; Longo et al., 1985).
The in vitro metabolism of 2-methylbuta-1,3-diene was investigated in rat, mouse and human liver
microsomes and in microsomes derived from cell lines expressing eight different human cytochrome P-450
enzymes. Human CYP2E1 showed the highest rates for formation of the monoepoxides, 1,2-epoxy-2-
methyl-3-butene and 3,4-epoxy-2-methyl-1-butene, and CYP2B6 showed the second highest rate. Only
CYP2E1 catalysed formation of the diepoxide, 2-methyl-1,2:3,4-diepoxybutane. With human liver
microsomes in the presence of an epoxide hydrolase inhibitor, the formation of 1,2-epoxy-2-methyl-3-butene
was four times faster than the formation of the 3,4-epoxy-2-methyl-1-butene, which is comparable to the
results in rats and mice obtained by others (e.g. Del Monte et al., 1985; Longo et al., 1985). The rates of
monoepoxide formation from isoprene and diepoxide formation from either monoepoxide intermediate were
strongly correlated with the microsomal activity of CYP2E1, rather than with the activities of the other CYP
enzymes, and both monoepoxides were equally good substrates for the formation of the diepoxide.
Also, species differences with regard to the role of epoxide hydrolase were investigated by comparing the
epoxidation of 2-methylbuta-1,3-diene by rat, mouse and human liver microsomes. When an epoxide
hydrolase inhibitor was used, similar rates of monoepoxide formation in mouse, rat and human liver
microsome systems were measured. However, without epoxide hydrolase inhibition, the total amount of 1,2-
epoxy-2-methyl-3-butene measured at the end of the incubation period was twice as high for mouse as for rat
liver microsomes and 30 times as high for mouse as for human liver microsomes in which formation of this
epoxide was reduced to 4 % of the rate in presence of the inhibitor. For the 3,4-epoxy 2-methyl-1-butene
metabolite the effect of epoxide hydrolase inhibition was less dramatic. While hardly any effect was
observed in mouse or rat microsomes, in the human microsomes, the rate was reduced to approximately
25 %. The effect of epoxide inhibition on the rate of formation of the diepoxide was not studied. The authors
concluded that differences in epoxide hydrolase activity between species may be of crucial importance for
the toxicity of 2-methylbuta-1,3-diene in various species (Bogaards et al., 1996).
Following intraperitoneal injection of 64 mg [4-14C]-2-methylbuta-1,3-diene per kg to F344 rats, the parent
compound was excreted unchanged in the breath (> 50 % of the dose together with < 4 % unidentified
material) or via the urine in the form of metabolites (≈ 32 %) over the 24-hours collection period. Only 1.7 % 
was expired as CO2 and 0.2 % was eliminated via faeces. 3 % remained in the carcass. In the urine 2-
methylbuta-1,3-diene was excreted primarily as 2-hydroxy-2-methyl-3-butenoic acid (53 % of total urinary
metabolites excreted), 2-methyl-3-buten-1,2-diol (23 %), and the C-1 glucuronide conjugate of 2-methyl-3-
buten-1,2-diol (13 %). A fraction of 7 % of the radioactivity in the urine was (an) unidentified polar material.
The principal urinary acidic metabolite forms via oxidation of the corresponding 1,2-diol. These metabolites
indicate a preferential epoxidation of the methyl-substituted vinyl group of 2-methylbuta-1,3-diene (see
Figure C.2) in the rat (Buckley et al., 1999).
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Figure C.2. Major metabolic pathways for 2-methylbuta-1,3-diene (after Del Monte et al. (1985) and Buckley et al.
(1999)).
Following intraperitoneal injection of 64 mg [4-14C]-2-methylbuta-1,3-diene /kg to B6C3F1 mice, the parent
compound was excreted unchanged in the breath (≈ 44 % of the dose and < 3 % unidentified material) or as 
urinary metabolites (≈ 33 %) over the 24-hours collection period. Only 1.9 % was expired as CO2 and 7 %
was eliminated via faeces. 2 % remained in the carcass. In comparison with rat urine (see above), the urine of
the mice contained several other metabolites, including an unidentified polar fraction which comprised 25 %
of the total urinary radioactivity as compared to 7 % in rat urine. The major identified metabolite in mouse
urine, 2-hydroxy-2-methyl-3-butenoic acid, accounted for ≈ 15 % of the total urinary radioactivity, whereas 
2-methyl-3-buten-1,2-diol and its glucuronide conjugate accounted for ≈ 3.5 and 2.5 %, respectively 
(Buckley et al., 1999). The authors speculated that the unidentified metabolite in the urine of rats and mice
could be related to glutathione conjugates. They concluded that if this were the case, in rats glutathione
conjugation of 2-methylbuta-1,3-diene is less important than in mice.
Special features of terminal double bond oxidation
Double bonds are usually oxidised by P450 to the corresponding epoxides, which are highly reactive
molecules. Due to the large strain associated with the three membered ring structure epoxides easily react
with nucleophilic sites of cellular macromolecules; conversely they are readily detoxified either
spontaneously or by the action of epoxide hydrolase to diols or conjugated with reduced glutathione by
glutathione-S-transferases. 1-Alkenes are metabolised by cytochrome P450, through double bond oxidation
to the corresponding epoxide or alternatively allylic oxidation (Chiappe et al., 1998). The rates of the two
reactions measured with different cytochrome P450 isoforms indicate that epoxide formation is generally
favoured (Chiappe et al., 1998) and this may also apply in particular to the candidate substances dodec-1-ene
[FL-no: 01.037] and 1-octene [FL-no: 01.070].
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Based on this information and the data available for myrcene and 2-methylbuta-1,3-diene, it cannot be
excluded that the candidate substances with these terminal double bonds [FL-no: 01.037, 01.064 and 01.070]
may be metabolised to epoxides.
Conclusions on the metabolism of subgroup II substances
The data available on the metabolism of one supporting and one structurally related substance in subgroup II
show that metabolic options for the substances in this group are epoxidation of double bonds ultimately
resulting in diols, which can be further conjugated. With the supporting substance myrcene also further
metabolism of the diols into carboxylic acids has been reported. Both in rats and rabbits, the principal urinary
metabolite following gavage administration of myrcene is myrcene-3,10-glycol, formed from the hydration
of the epoxide intermediate in both species. Epoxidation of the 3,10-double bond was favoured over
epoxidation of the 1,2-double bond.
The studies indicate that the formation of diols from the myrcene-epoxides is very efficient. It is noted,
however, that the diols and the related carboxylic acids are all the result of epoxidation of double bonds in
which one of the carbon atoms has only hydrogen substituents, but no further carbon chains. In this respect,
the candidate substance cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] is most similar to myrcene. With
myrcene no diepoxide metabolites or further reaction products thereof have been reported, but it is noted that
mass balance data are incomplete, so some metabolites may have been overlooked.
With the structurally related substance 2-methyl-buta-1,3-diene, epoxidation of the 1,2-double bond is
favoured over epoxidation of the 3,4-double bond. While the 1,2-epoxide is readily hydrolysed, the 3,4-
epoxide is far more stable. Both metabolites can be converted to the corresponding diols and at least one
hydroxy-carboxylic acid (2-hydroxy-2-methyl-3-butenoic acid) has been identified. In addition, in particular
the 3,4-epoxide metabolite can be oxidised a second time, resulting in the formation of a diepoxide
metabolite, which is known to be reactive and has been suggested to be responsible for 2-methylbuta-1,3-
diene-induced DNA damage. For candidate substance dodec-1-ene [FL-no: 01.037], diol- and α-hydroxy-
carboxylic acid formation may also be expected. In addition, this substance may also undergo omega and
omega-1 or -2 oxidation at the other (saturated) end of the carbon chain (similar to the candidate substances
in subgroup I).
Apart from myrcene and 2-methylbuta-1,3-diene, terminal double bonds appear in candidate substances [FL-
no: 01.037, 01.064 and 01.070]. In contrast to corresponding substances in FGE.07 and FGE.18 there is no
other functional group in the molecule (e.g. hydroxyl- or keto-group) that could provide a more direct option
for detoxication e.g. via conjugation with glucuronide or sulphate. In the two FGEs mentioned above the
presence of such groups was an argument to consider that the metabolism of the particular candidate
substances would go via innocuous products. It would not be possible to conclude similarly for the candidate
substances in FGE.25. The other candidate substances in this subgroup (II) might also be oxidised in the
various methyl groups but no data are available to substantiate this. Because of these considerations, it
cannot be concluded that the candidate substances in this subgroup [FL-no: 01.032, 01.035, 01.037, 01.064,
01.070 and 01.078] will be metabolised to innocuous products.
Cyclohexene derivatives (Candidate and structurally related supporting substances from subgroup
III)
For the candidate substances in this group, data for one supporting substance (d-limonene; [FL-no: 01.045])
were submitted.
More than 10 metabolites were found in the urine of rats given an oral gavage dose of 800 mg/kg bw d-
limonene (or p-mentha-1,8-diene). Four of the metabolites were identified as perillic acid, p-menth-1-ene-
8,9-diol (= limonene-8,9-diol), perillic acid-8,9-diol and 8-hydroxy-p-menth-1-en-9-yl-glucuronic acid. The
bile of these rats contained three metabolites, the most important of which was 8-hydroxy-p-menth-1-en-9-
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yl-β-D-glucuronic acid (Igimi et al., 1974). Six metabolites were identified in the urine of rabbits given the 
same oral dose. In addition to the four metabolites identified in rat urine, the rabbit urine contained p-
mentha-1,8-dien-10-ol (= limonene-10-ol) and p-mentha-1,8-dien-10-yl-glucuronic acid (= p-mentha-1,8-
dien-10-ol-glucuronide). Although not determined quantitatively, perillic acid, perillic acid-8,9-diol and both
glucuronic acid conjugates were the major metabolites in rabbit urine, and no unchanged d-limonene was
detected (Kodama et al., 1974). The same authors identified five additional metabolites in the urine of rats
and dogs treated orally with d-limonene. These were characterised as 2-hydroxy-p-menth-8-en-7-oic acid,
perillylglycine, perillyl-glucuronide, p-mentha-1,8-dien-6-ol (or limonene-6-ol) and p-menth-1-ene-6,8,9-
triol. They also found some species differences in the nature of the major metabolites in urine. Perillic acid-
8,9-diol was the main metabolite in rats and rabbits, perillyl-glucuronide in hamsters, limonene-8,9-diol in
dogs and limonene-8,9-diol-glucuronide in guinea pigs and humans. It should be noted that the fate of only
40-65 % of the d-limonene dose administered orally to these animals and humans was accounted for
(Kodama et al., 1976). The metabolites of d-limonene are shown in Figure C.3.
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Figure C.3. Metabolism of d-limonene
Perillic acid, dihydroperillic acid and limonene-1,2-diol were the major metabolites identified in the plasma
of humans given an oral dose of d-limonene. Minor metabolites were the methyl esters of perillic acid and
dihydroperillic acid, and d-limonene itself (Crowell et al., 1994). Apart from the parent compound (Poon et
al., 1996) and (Vigushin et al., 1998) also identified perillic acid, dihydroperillic acid and limonene-1,2-diol
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as major metabolites in human plasma. However, they also found two other metabolites, i.e. p-mentha-1,8-
diene-10-carboxylic acid and limonene-8,9-diol, whereas they did not detect the methyl esters of perillic acid
and dihydroperillic acid. Peak plasma levels for all metabolites were achieved four to six hours after
administration, with the exception of limonene-8,9-diol which reached its peak level one hour after
administration (Poon et al., 1986). Metabolites in human urine comprised the glucuronic acid conjugates of
perillic acid, dihydroperillic acid, p-mentha-1,8-diene-10-carboxylic acid, limonene-8,9-diol and limonene-
10-ol (Poon et al., 1986).
Experiments with rat liver microsomes have shown that epoxidation of the C8 double bond (in the vinyl
substituent) of d-limonene is favoured over epoxidation of the C1-double bond (the one in the ring), due to
steric hindrance by the 1-methyl group, which was demonstrated by comparison of the metabolism of d-
limonene with that of 4-vinylcyclohex-1-ene. Upon incubation with rat liver microsomes, the majority of d-
limonene was converted to the 8,9-epoxide and the 8,9-diol, and to a much lesser extent to the 1,2-epoxide
and the 1,2-diol (ratio of 8,9- vs.1,2-epoxidation = 4:1). In contrast, with 4-vinylcyclohex-1-ene the
epoxidation rate of the ring double bond was about four times as fast as the epoxidation rate of the vinyl
double bond. Because the 1,2-epoxide of d-limonene is a very poor substrate for microsomal epoxide
hydrolase, the 1,2-diol could not be found in microsomal incubates, whereas the 8,9-diol could be found
(Watabe et al., 1981). Both epoxides of d-limonene were tested for mutagenicity in several Salmonella
strains and showed to be inactive. The mono-epoxides of 4-vinylcyclohex-1-ene were inactive in Salmonella
strain TA100, but were not tested in the other strains. However, the diepoxide of 4-vinylcyclohex-1ene was
mutagenic in this bacterial strain, but this diepoxide was not detected in the microsomal metabolism studies
with 4-vinylcyclohex-1-ene as starting material (Watabe et al., 1981).
Other in vitro experiments have shown that male rats can convert d- and l-limonene into the corresponding
trans-perillyl alcohol (by hydroxylation of the methyl group at C7) and carveol (or limonene-6-ol; by ring
C6-hydroxylation). These reactions are catalysed by CYP2C11 and, when pretreated with phenobarbital,
CYP2B1. In female rats, the activity for conversion to either alcohol is much lower. Apparently, the female-
specific CYP2C12 has no activity with respect to d- and l-limonene hydroxylation. In males, the
hydroxylation activities were not detectable with foetal liver microsomes, but they increased after birth,
closely related to the developmental increase in CYP2C11. This study also investigated whether the d- and l-
limonene enantiomers are differently metabolised by liver microsomes. Both in liver microsomes from
untreated and treated with phenobarbital, approximately the same amounts of carveol and perillyl alcohol
were formed from the two limonene enantiomars. Ratios over the two routes of metabolism were
carveol/perillyl alcohol: 0.87/1.23 for d-limonene and 0.61/1.03 for l-limonene. Also the rate of formation of
carveol and perillyl alcohol from d- and l-limonene is similar using either liver microsomes or recombinant
P450 enzymes (Miyazawa et al., 2002).
In male rats orally administered 3 mmol/kg (408 mg/kg) of [14C]-d-limonene radioactivity was detected in
the renal cytosol. Forty percent of the total cytosolic radioactivity was reversibly associated with the protein
fraction and further analysis showed that > 97 % of this activity was associated with one single protein,
which was identified as α2u-globulin. 1,2-Limonene epoxide, 1,2-limonene-diol and d-limonene comprised
82, 5 or 13 %, respectively, of the radioactivity associated with this protein (Lehman-McKeeman et al.,
1989).
d-Limonene has been shown to induce P450 enzymes of the CYP2B and CYP2C subfamilies and epoxide
hydrolase in rats (Austin et al., 1988; Maltzman et al., 1991).
Conclusions on the metabolism of subgroup III substances
In the subgroup III there are only metabolism data available for one supporting substance, d-limonene, which
in several animal species and humans has been demonstrated to be oxidised in both side chains and at the
cyclohexene ring, resulting in alcohols and/or carboxylic acids. Ring and side chain hydroxylation has also
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been described for its structural isomer l-limonene (a constituent of candidate substance [FL no: 01.001] and
a candidate substance on its own [FL-no: 01.046]) in rat liver microsomes. The metabolites of these
limonenes are, at least partly, conjugated and eliminated with the urine. It is anticipated that three out of the
six candidate substances [FL-no: 01.027, 01.028 and 01.039] in subgroup III are metabolised in a similar
way to innocuous products. It cannot be anticipated based on the data available that β-phellandrene [FL-no: 
01.055] with a double bond directly on the ring and in conjugation with double bond in the cyclohexene ring
can be metabolised to innocuous products.
Aromatic Hydrocarbons (Candidate and Structurally Related Supporting Substances from Subgroup
IV)
The substances previously allocated to the group are no longer supported for use as flavouring substances in
Europe by Industry.
Bicyclic Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting Substances
from Subgroup V)
Analysis of urinary metabolites eliminated by human volunteers within four hours following a 2-hour
inhalation exposure to 10 – 450 mg (+)-α-pinene/m3 [FL-no: 01.004] in a pharmacokinetic study (Falk et al.,
1990b) revealed cis- and trans-verbenol in a ratio of 1:10, with 3.8 and 1.7 % being eliminated at 10 and 450
mg/m3, respectively. Most of the verbenols were eliminated within 20 hours. In a more extensive metabolic
study, urine was collected from sawmill workers at the end of an 8-9 hours work shift or from chamber-
exposed individuals. Following hydrolysis of glucuronic acid conjugates, cis- and trans-verbenol were
identified in the urine along with two diols, cis- and trans-4-hydroxymyrtenol, formed by methyl group
hydroxylation of cis- and trans-verbenol. trans-4-Hydroxymyrtenal was also detected (see Figure C.4)
(Eriksson and Levin, 1990).
Analysis of the urinary metabolites of a patient attempting suicide with 400 – 500 ml pine oil containing
57 % α-pinene showed the presence of myrtenol, verbenol, and borneol. Renal excretion reached a peak level 
five days after ingestion (Koppel et al., 1981).
Male albino rabbits (six/group) administered single gavage doses of 400 – 700 mg/kg bw of (+)-α-pinene, (-
)-α-pinene, (+/-)-α-pinene, (-)-β-pinene, or delta-3-carene, excreted bicyclic terpene hydrocarbon metabolites 
as (glucuronic acid) conjugates or as further oxidised metabolites, notably carboxylic acids. Animals were
housed individually and urine was collected daily for three days.
The principal neutral metabolite formed by oxidation at the C4 position in the alicyclic ring of each of the
three α stereochemical forms of pinene was trans-verbenol (see Figure C.4). As a minor pathway, allylic
oxidation of the exocyclic methyl group to yield myrtenol was observed for all three α-pinene stereoisomers, 
with also myrtenic acid as minor metabolite (Ishida et al., 1981).
The presence of an exocyclic alkene function in (-)-β-pinene provided additional metabolic options, and four 
neutral and one acidic metabolites were identified. Allylic oxidation of the methyl group at the C2 position
yields (+)-trans-pinocarveol, while epoxidation of the exocyclic alkene followed by hydration or
rearrangement yields (-)-trans-10-pinanol and (-)-1-p-menthene-7,8-diol, respectively. Ring cleavage yields
(-)-α-terpineol. These metabolites comprised 11, 39, 30 or 5 % of the total urinary neutral metabolite 
fraction, respectively. The acidic metabolite identified was identical to the one identified for the α-pinenes 
(i.e. myrtenic acid), which was suggested to be formed via double bond epoxidation and subsequent
rearrangement to give myrtenol and further oxidation to the carboxylic acid (Ishida et al., 1981).
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Figure C.4. Metabolism of α-pinene and β-pinene in animals 
Trans-verbenol and myrtenic acid have also been found in faeces or urine of brushtail possum fed α-pinene. 
When the same species was fed β-pinene, only myrtenic acid was found in the excreta (Southwell et al., 
1980).
It has been stated in a limited review paper that in rabbits, α- and β-pinenes can be excreted as glucuronide 
conjugates of undetermined nature, which can release cymene upon heating in diluted acids (Williams, 1959
as cited in (Opdyke, 1978)).
Delta-3-Carene [FL-no: 01.029] undergoes stereoselective hydroxylation at the gem-methyl group (yielding
3-caren-9-ol) followed by carboxylation, allylic oxidation of the C10 methyl group followed by carboxylation
or, as the main route, allylic ring opening and hydroxylation at a secondary carbon atom, yielding (-)-m-
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mentha-4,6-dien-8-ol (72 % of the total urinary neutral metabolite fraction) and m-cymen-8-ol (Ishida et al.,
1981).
In addition to the terpenoids pinene and carene, the group of Ishida has also studied the metabolism of the
saturated analogues pinane and carane19 (Ishida et al., 1981). Only a relatively small part of the dose (in total
18 g given to six rabbits) was identified, among which were 3- and 4-pinalol, α-terpineol, trans-sobrerol, 
trans-carveol, and verbenol (some of the structures have been shown in Figure C.4). In short, these products
result from hydroxylations of secondary carbon atoms in the 6-membered ring, or cleavage of the 4-
membered ring in combination with hydroxylation in the remaining 6-membered ring. In addition,
desaturation of the 6-membered ring was also observed and hence, some of the metabolites may be
considered as cyclohexene derivatives. No hydroxylation of the primary carbon atom (i.e. the methyl ring
substituent) in pinane was observed. With carane, however, the hydroxylation of one of the gem-methyl
groups and hydroxylation of the C10 exocyclic carbon atom was observed, ultimately resulting in the
formation of carane-9,10-dicarboxylic acid.
In rabbits, β-caryophyllene [FL-no: 01.007] undergoes epoxidation of the endocylic 5,6-double bond to yield 
a stable epoxide metabolite and hydroxylation at the gem-dimethyl group. The resulting metabolite 14-
hydroxycaryophyllene-5,6-epoxide and its C14-acetylated conjugate could be detected in the urine. A second
epoxidation of the 5,6-epoxide’s exocyclic 2,12-double bond, ultimately resulting in the 14-
hydroxycaryophyllene-5,6-epoxide-2,12-diol, was also reported (Asakawa et al., 1981; Asakawa et al.,
1986).
Data were also found on the metabolism of camphene20. Ishida et al. (1979) administered dl-camphene [FL-
no: 01.009] to five starved male rabbits at a dose level of 800 mg/kg bw via stomach tube. In total 8 g of the
substance was given. Urinary metabolites, collected over three days post-dosing were examined. The
following metabolites were identified in urine samples after treatment with β-glucuronidase/sulphatase: 
camphene-2,10-glycol (after epoxidation of the double bond), 6-exo-hydroxycamphene, 7-
hydroxycamphene, 10-hydroxytricyclene and 3-hydroxytricyclene. Quantitative information was provided
only for the diol which was found in a total amount of 260 mg which corresponds to ca. 3 % of the dose
(Ishida et al., 1979).
In a human volunteer and in a young pig, camphene was eliminated from the body by exhalation and via bile
as unchanged substance or as glucuronide conjugate via the urine (Opdyke, 1975).
(+)-Longifolene [former FL-no: 01.047] metabolism was studied following the oral administration of about 2
g/animal as a suspension in 0.02 % Tween80 aqueous solution to six male rabbits. Urine samples were
collected daily for three days and treated with β-glucuronidase / sulphatase. Due to imprecise description of 
dose and amounts recovered, it is not possible to indicate the extent of metabolism and excretion as
percentage of the dose. Deconjugated metabolites were extracted in a neutral and an acidic fraction. In the
neutral fraction (10 % of the dose), many peaks were observed but only one was further characterised to be
(2S, 7S)-(+)-14-hydroxyisolongifolaldehyde (35 % of the neutral metabolite fraction). It was concluded that
19
Pinane:
34
Carane: 2
13
64
5
7
10
9
8
20 camphene: 3,3-dimethyl-2-methylenenenorbornane
CH2
CH3
CH3
Flavouring Group Evaluation 25 Revision 3
EFSA Journal 2015;13(4):4069 100
(+)-longifolene is metabolised at two sites in two subsequent steps: 1) oxidation of the exo-methylene group
to form its epoxide with subsequent isomerisation to form a stable aldehyde, and 2) hydroxylation of the
gem-dimethyl group to form a primary alcohol (Ishida et al., 1982; Asakawa et al., 1986; Ford et al., 1992).
An in vitro study with rat liver microsomes demonstrated the involvement of cytochrome P450 enzymes in
the metabolism of α-pinene. Metabolites present were β-pinene and d-limonene together with smaller
amounts of trans-verbenol, myrtenol, verbenone, and pinene oxide (White and Agrosin, 1980).
α-Pinene and cadinene, have been shown to induce cytochrome P450 enzymes, especially those from the 
CYP2B subfamily, and to a lesser extent also CYP3A2 (cadinene) and CYP4A2 (α-pinene) (Austin et al.,
1988; Hiroi et al., 1995). Based on similarity with β-pinene it may be speculated that the candidate substance 
4(10)-thujene [FL-no: 01.059] may be hydroxylated to thujyl alcohol, which is known to be conjugated with
glucuronic acid and eliminated via urine (Hämäläinen, 1912; EFSA, 2009a). However, based on the same
similarity, epoxidation of the exocyclic double bond may also be expected, and it is not clear what other
reactions might occur. No indications of the relevance of the various routes are available.
Conclusions on the metabolism of the subgroup V substance
Metabolism data for subgroup V are available for some supporting substances (pinenes, camphene,
caryophyllene, delta-3-carene, pinane and carane) and longifolene [former FL-no: 01.047]. In general the
metabolic options for these substances include oxidation of methyl ring substituent groups to give the
corresponding alcohol and further oxidation products. For the substances studied, double bond epoxidation
has also been demonstrated. In addition, ring cleavage has also been observed, e.g. for β-pinene resulting in 
the formation of monocyclic terpenoid derivatives like α-terpineol. Hydroxylated metabolites (i.e. alcohols) 
or further metabolic products may be eliminated as conjugates e.g. with glucuronic acid. However, given the
diversity of this group, the lack of data on any of the candidate substances, it cannot be concluded that the
candidate substance in this subgroup [FL-no: 01.059] can be metabolised to innocuous products.
Macrocyclic, Non-Aromatic Hydrocarbons (Candidate and Structurally Related Supporting
Substances from Subgroup VI)
The substances previously allocated to the group are no longer supported for use as flavouring substances in
Europe by Industry.
C.5. Summary on Absorption, Distribution, Metabolism and Excretion
Given the diverse nature of the chemical structures of the candidate flavouring substances in this FGE, it is
impossible to draw conclusions, which are applicable to all substances. The amount on information on
kinetics of either candidate or supporting substances is very limited. For these reasons, the available
information is presented here in a subgroup-wise manner.
Absorption, Distribution and Elimination
Subgroup I
From the available studies it may be concluded that the candidate alkane substances in subgroup 1 will be
absorbed after oral exposure. The extent of absorption is not known, but may be high, given their lipophilic
character and their low molecular weight. The ease with which these substances cross the membranes of the
respiratory tract further supports the assumption that these substances will also be absorbed after oral intake.
Data indicate that straight-chain alkanes will predominantly be broken down to carbon dioxide at low dose
levels. At high dose levels, biotransformation becomes saturated and other metabolites will be generated
which will be excreted via the urine.
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Subgroup II
For the candidate and supporting substances in subgroup II, the acyclic alkenes, data were only available for
myrcene [FL-no: 01.008] and 2-methylbuta-1,3-diene (a structurally related substance). Given the narrow
range of molecular weights of the candidate substances (between ~ 68 and 206 D) and their lipophilic nature
(estimated or measured Log Kow values e.g. 2.4 (2-methylbuta-1,3-diene), 6.1 (dodec-1-ene), 4.17
(myrcene) or 4.8 (cis-3,7-dimethyl-1,3,6-octatriene)), it is assumed that these candidate flavouring
substances may be absorbed from the gastrointestinal tract. Mass balance data for myrcene are incomplete.
For 2-methylbuta-1,3-diene a mass balance of elimination has been presented, which also shows elimination
via the exhaled air (~ 50 % of the dose), but as this substance was administered via the intraperitoneal route,
the elimination pattern may be different after oral dosing with a lower fraction of the dose exhaled, e.g.
because of more efficient first-pass biotransformation after oral dosing.
Subgroup III
For the candidate and supporting substances in subgroup III (cyclohexene derivatives), data were only
available for d-limonene [FL-no: 01.045]. For this substance, data show a considerable absorption from the
gastrointestinal tract. In humans, elimination of the substance followed a triphasic pattern, but still 55-83 %
of an oral dose could be found in the urine within 72 hours post dosing, with the major part excreted within
24 hours. Also in other species urinary elimination was most important accounting for up to 82-96 % of the
dose within 72 hours. Hence, it may be anticipated that monocyclic cyclohexene derivatives, such as d-
limonene, administered orally, are absorbed and distributed throughout the body. Following oral
administration to humans, d-limonene was distributed preferentially to fatty tissues, as indicated by a high
oil-blood partition coefficient and a long half-life during the slow elimination phase. Because of the limited
molecular weight of the candidate substances in this group (range ~ 136-204 D) and their lipophilic character
(e.g. estimated or measured log Kow values for β-phellandrene, β-bisabolene and d-limonene are
approximately 4.7, 7.1 or 4.6, respectively) it may be assumed that all of the substances in this group may be
absorbed, although the extent of absorption for individual substances cannot be accurately estimated from
these physico-chemical properties.
Subgroup IV
The substances previously allocated to the group are no longer supported for use as flavouring substances in
Europe by Industry.
Subgroup V
For the substances in subgroup V (bicyclic, non-aromatic hydrocarbons), the available data from oral studies
are incomplete. These studies have only addressed the excretion of some supporting and longifolene [former
FL-no: 01.047] in the form of metabolites via the urine. No mass-balance data were provided. So, these
studies only show that these substances will be absorbed to some extent. The same may be anticipated for the
other candidate substances in this subgroup. For the supporting substances α- and β-pinene and delta-carene 
information on kinetics is available from humans exposed via inhalation, in occupational settings. These
studies show that these substances can be absorbed after inhalation exposure and that metabolites will be
excreted into the urine e.g. as glucuronide conjugates. The elimination follows a triphasic pattern with rather
long terminal half-lives and the absorbed amount will be eliminated within several days. Based on the
lipophilic character of these substances it may be anticipated that they will preferentially distribute in the
adipose tissues, which is supported by the slow terminal elimination rates.
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Subgroup VI
The substances previously allocated to the group are no longer supported for use as flavouring substances in
Europe by Industry.
Metabolism
Subgroup I
The substances in subgroup I can be expected to be metabolised through omega-oxidation which will lead to
the formation of alcohols, and after subsequent further oxidation to carboxylic acids, which may be further
oxidised via β-oxidation to yield carbon dioxide. Extensive mass balance data are not available, but in some 
of the available studies excretion of carboxylic acids and carbon dioxide has been reported. Formation of
keto-acids has also been reported, and these may be thought to be formed from omega-oxidation at one end
of the molecule and omega-1 or -2 oxidation at the other end. More interest has been put in the identification
of metabolites, which did not undergo substantial chain shortening. These metabolites will arise from
oxidation of the non-terminal carbon atoms, e.g. via omega-1, -2, -3 or even -4 oxidation. The resulting
secondary alcohols can be conjugated with e.g. glucuronic acid and excreted via the urine, or can be further
oxidised to yield ketones. A subsequent introduction of another secondary hydroxyl group may result in the
formation of diketones. With n-hexane, the resulting 2,5-hexanedione (a gamma-diketone) has been
demonstrated to be responsible for hexane-induced neurotoxicity. Neurotoxicity is a common feature of
gamma-diketones, and for that reason, candidate substance 3-methylhexane [FL-no: 01.050] cannot be
anticipated to be metabolised into innocuous compounds. In addition, it is known that methyl-branching of
the carbon chain potentiates the neurotoxicity of the gamma-diketone (Topping et al., 1994; EFSA, 2004b).
The two other hexane derivatives in this group [FL-no: 01.033 and 01.034] cannot be oxidised to give a
gamma-diketone, due to the presence of methyl groups on the C2 and C5 carbon atoms. Therefore, these
substances may be considered as being metabolised to innocuous metabolites. For the longer chain alkanes in
this group it would require oxidation of the more central carbon atoms in order to be converted into gamma-
diketones. Such oxidations are less favourable than omega, omega-1 or -2 oxidations and therefore it is
concluded that oxidation of these higher alkanes will not result in toxicologically relevant levels of gamma-
diketones, also because of rapid conjugation of the precursor alcohols. For heptane it was shown that this
substance does not result in neurotoxicity (Bahima et al., 1984), although the gamma-diketone itself (2,5-
heptanedione) is known to be neurotoxic (Topping et al., 1994). The remaining three candidate flavouring
substances in this group (i.e. [FL-no: 01.038, 01.054 and 01.057]) can be expected to be metabolised to
innocuous products.
Subgroup II
The data available on the metabolism of one supporting and one structurally related substance in subgroup II
show that metabolic options for the chemicals in this group are epoxidation of double bonds, ultimately
resulting in diols, which can be further conjugated. With the supporting substance myrcene, further
metabolism of the diols into carboxylic acids has also been reported. Both in rats and rabbits, the principal
urinary metabolite following gavage administration of myrcene is myrcene-3,10-glycol, formed from the
hydration of the epoxide intermediate in both species. Epoxidation of the 3,10-double bond was favoured
over epoxidation of the 1,2-double bond.
The studies indicate that the formation of diols from the myrcene-epoxides is very efficient. It is noted,
however, that the diols and the related carboxylic acids are all the result of epoxidation of double bonds in
which one of the carbon atoms has only hydrogen substituents, but no further carbon chains. In this respect,
the candidate substance cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] is most similar to myrcene. With
myrcene no diepoxide metabolites or further reaction products thereof have been reported, but it is noted that
mass balance data are highly incomplete, so some metabolites may have been overlooked.
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With the structurally related substance, 2-methyl-buta-1,3-diene, epoxidation of the 1,2-double bond is
favoured over epoxidation of the 3,4-double bond. While the 1,2-epoxide is readily hydrolysed, the 3,4-
epoxide is far more stable. Both metabolites can be converted to the corresponding diols and at least one
hydroxy-carboxylic acid (2-hydroxy-2-methyl-3-butenoic acid) has been identified. In addition, in particular
the 3,4-epoxide metabolite can be oxidised for a second time, resulting in the formation of a diepoxide
metabolite, which is known to be reactive and has been suggested to be responsible for 2-methylbuta-1,3-
diene-induced DNA damage.
Apart from myrcene and 2-methylbuta-1,3-diene, terminal double bonds appear in candidate substances [FL-
no: 01.064 and 01.070]. In contrast to corresponding substances in FGE.07 and FGE.18 there are no other
functional groups in the molecule (e.g. hydroxyl- or keto-group) that could provide a more direct option for
detoxication e.g. via conjugation with glucuronide or sulphate. In the two FGEs mentioned above, the
presence of such groups was an argument to conclude that the metabolism of the particular candidate
substances would give rise to innocuous products. It would not be possible to conclude similarly for the
candidate substances in FGE.25. The other candidate substances in this subgroup (II) might also be oxidised
in the various methyl groups but no data are available to substantiate this. Because of these considerations, it
cannot be concluded that the candidate substances in this subgroup [FL-no: 01.035, 01.064 and 01.070] will
be metabolised to innocuous products.
Subgroup III
Hardly any data are available on the metabolism of the candidate substances in subgroup III. Only for l-
limonene a very limited amount of data was available on biotransformation in incubations with rat liver
microsomes. In comparison with the structures of the candidate substances in subgroup III, the structure of
the one supporting chemical d-limonene is comparatively simple. Major differences between d-limonene and
the candidate substances are the length of the ring substituents and the number of double bonds.
Allylic oxidation is by far the major pathway for metabolism of limonene in humans. Minor pathways in
limonene metabolism reported for the rat include epoxidation of either the 1,2- or the 8,9-double bond and
subsequent hydrolysis to the diol. Given the many metabolic options for this substance, a myriad of
metabolites has been found, including conjugates, and for a change mass balance data are available, which
show that in various animal species the substance is completely eliminated within three days, predominantly
via the urine. No genotoxicity of limonene epoxides could be detected, and it may well be concluded that d-
limonene is metabolised to innocuous substances. However, although it is very likely that the candidate
substances may undergo the same metabolic conversions (allylic oxidations and double bond epoxidation)
the conclusion for d-limonene cannot be extrapolated to all of the candidate substances because of the
structural dissimilarities and the absence of any further data on molecules with closer resemblance to the
candidate substances. The data available for l-limonene do not indicate that major differences are to be
anticipated between the metabolism of d-limonene and l-limonene. For bisabola-1,8,12-triene [FL-no:
01.027], β-bisabolene [FL-no: 01.028] and delta-elemene [FL-no: 01.039] it may be concluded that these are 
metabolised to innocuous products.
It is noted that d-limonene (metabolites) causes α2µ-microglobulin accumulation in male kidneys, an event 
known to be associated with male rat specific nephropathy21, and irrelevant for human toxicological risk
assessment.
Subgroup IV
The substances previously allocated to the group are no longer supported for use as flavouring substances in
Europe by Industry.
21 For introduction into this area see e.g. the referred paper by Lehman-McKeeman et al. (1989)
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Subgroup V
Metabolism data for subgroup V are available for the supporting substances pinenes, camphene,
caryophyllene, delta-3-carene, pinane and carane. In general the metabolic options for these substances
include oxidation of methyl ring substituent groups to give the corresponding alcohol and further oxidation
products. For the substances studied, double bond epoxidation has also been demonstrated. In addition, ring
cleavage has also been observed, e.g. for β-pinene resulting in the formation of monocyclic terpenoid 
derivatives like α-terpineol. Hydroxylated metabolites or further metabolised products may be eliminated as 
conjugates e.g. with glucuronic acid. However, given the lack of data on the candidate substances it cannot
be concluded that the candidate substance in this subgroup [FL-no: 01.059] can be metabolised to innocuous
products.
Based on similarity with β-pinene it may be speculated that the candidate substance 4(10)-thujene [FL-no: 
01.059] may be hydroxylated to thujyl alcohol, which is known to be conjugated with glucuronic acid and
eliminated via urine (Hämäläinen, 1912; EFSA, 2009a). However, based on the same similarity, epoxidation
of the exocyclic double bond may also be expected, and it is not clear what other reactions might occur. No
indications of the relevance of these various routes is available. Hence, despite the knowledge of the fate of
thujyl alcohol, also for thujene it cannot be concluded that it will be metabolised to innocuous products.
Subgroup VI
The substances previously allocated to the group are no longer supported for use as flavouring substances in
Europe by Industry.
C.6. Overall Conclusion on Absorption, Distribution, Metabolism and Elimination.
Generally, the available data indicate that the aliphatic and aromatic hydrocarbons participate in similar
pathways of metabolic detoxication. Being lipophilic and of low molecular weight, these hydrocarbons may
be assumed to be absorbed by the gastrointestinal tract. Subsequently, they are oxidised to more polar
oxygenated metabolites e.g. by CYP-450 enzymes. The phase I metabolites are then conjugated and excreted
mainly in the urine. The candidate substances and supporting substances are oxidised either by side chain
oxidation or epoxidation of the exocyclic or endocyclic double bond. Oxidation initially yields hydroxylated
metabolites that may be excreted in conjugated form or undergo further oxidation, yielding more polar
metabolites that are also excreted. If a double bond is present, epoxide metabolites may form that are further
metabolised either by hydrolysis to yield diols or by conjugation with glutathione to yield mercapturic acid
derivatives. The saturated alkanes in this group may be metabolised via omega and omega-1, -2, -3 or -4
oxidation. Whereas omega oxidation would ultimately lead to the formation of carboxylic acids, the other
oxidations would give rise to secondary alcohols and ketones. The carboxylic acids may be expected to
participate in the endogenous fatty acid metabolism. However, for most of the subgroups the information
was incomplete and the similarity between supporting and candidate substances was limited. In addition,
proper mass balance data were not available. Some mass balance data available indicated slow elimination.
For several subgroups no data were available at all. In Table C.2 the final conclusions for each of the
candidate substances has been presented, together with a brief explanatory statement, about the conclusion
reached. It is noted that the subgroup III supporting substance d-limonene causes α2µ-microglobulin 
accumulation in male kidneys, an event known to be associated with male rat specific nephropathy, and
irrelevant for human toxicological risk assessment.
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Table C.2 Can innocuous metabolites be expected to be formed based on available data?
FL-no: Substance name Innocuous metabolites?
Subgroup I: ACYCLIC ALKANES
01.033 2,2-Dimethylhexane Yes
01.034 2,4-Dimethylhexane Yes
01.038 Dodecane Yes
01.054 Pentadecane Yes
01.057 Tetradecane Yes
Subgroup II: ACYCLIC ALKENES
01.035 2,6-Dimethylocta-2,4,6-triene No (lack of supporting data)
Deleted
from the
Register
2-Methylbuta-1,3-diene No (known biotransformation to reactive metabolite
responsible for toxicity and genotoxicity)
01.064 cis-3,7-Dimethyl-1,3,6-octatriene No (presence of terminal double bond which may give rise to
reactive metabolites without counteracting metabolic
options)
01.070 1-Octene No (presence of terminal double bond which may give rise to
reactive metabolites without counteracting metabolic
options)
Subgroup III: CYCLOHEXENE HYDROCARBONS
01.027 Bisabola-1,8,12-triene Yes
01.028 β-Bisabolene Yes
01.039 delta-Elemene Yes
01.001 Limonene Yes
01.046 l-Limonene Yes
Subgroup IV: AROMATIC HYDROCARBONS
The substances previously allocated to the group are no longer supported for use as flavouring substances in Europe by Industry.
Subgroup V: BICYCLIC, NON-AROMATIC HYDROCARBONS
01.059 4(10)-Thujene No (but supported by the supporting substance β-
caryophyllene [FL-no: 01.007])
Subgroup VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS
The substances previously allocated to the group are no longer supported for use as flavouring substances in Europe by Industry.
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Appendix D. Substances no Longer Supported for Use as Flavouring Substances in Europe by
Industry
Since the publication of FGE.25Rev2 (EFSA CEF Panel, 2011), the following 23 substances [former FL-no:
01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050,
01.051, 01.052, 01.053, 01.055, 01.056, 01.058, 01.060, 01.066, 01.067 and 01.078] of 37 candidate
substances evaluated in FGE.25Rev2 are no longer supported for use as flavouring substances in Europe by
Industry and will therefore not be considered any further (DG SANCO, 2012).
The 23 substances were evaluated via the B-side of the Procedure scheme and as they all had estimated
European daily per capita intakes below the threshold of concern for their respective structural class they all
proceeded to step B4 of the Procedure. Here the Panel concluded that additional data were required for these
substances as no NOAELs were available for any of these substances or for any structurally related
substances. The 23 substances are listed here below together with their specifications.
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Table D1: Specification Summary of the Substances no Longer Supported by Industry
Former
FL-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility(a)
Solubility in
ethanol(b)
Boiling point,
°C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index(d)
Spec.gravity(e)
Specification
comments
01.021 delta-Cadinene
10982
29350-73-0
Liquid
C15H24
204.36
Freely soluble
286
MS
95 %
1.497-1.503
0.917-0.923 No longer
supported by
Industry (DG
SANCO, 2012).
01.022 α-Cedrene H
H 10985
469-61-4
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
119 (13 hPa)
MS
95 %
1.500-1.506
0.932-0.938 No longer
supported by
Industry (DG
SANCO, 2012).
01.023 1(5),11-Guaiadiene
11003
3691-12-1
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
78 (3 hPa)
MS
95 %
1.493-1.499
0.897-0.903 No longer
supported by
Industry (DG
SANCO, 2012).
01.030 β-Cubebene 
10989
13744-15-5
Solid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
284
60
MS
95 %
n.a.
n.a. No longer
supported by
Industry (DG
SANCO, 2012).
01.031 1,2-Dihydro-1,1,6-
trimethylnaphthalen
e 30364-38-6
Liquid
C13H16
172.27
Practically
insoluble or
insoluble
Freely soluble
115 (24 hPa)
MS
95 %
1.542-1.548
0.942-0.948 No longer
supported by
Industry (DG
SANCO, 2012).
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Table D1: Specification Summary of the Substances no Longer Supported by Industry
Former
FL-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility(a)
Solubility in
ethanol(b)
Boiling point,
°C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index(d)
Spec.gravity(e)
Specification
comments
01.032 2,3-
Dihydrofarnesene
7681-88-1
Liquid
C15H26
206.37
Practically
insoluble or
insoluble
Freely soluble
130 (15 hPa)
NMR
95 %
1.468-1.474
0.817-0.823 No longer
supported by
Industry (DG
SANCO, 2012).
01.036 Diphenylmethane
11847
101-81-5
Solid
C13H12
168.24
Practically
insoluble or
insoluble
Freely soluble
262
27
MS
95 %
n.a.
n.a. No longer
supported by
Industry (DG
SANCO, 2012).
01.037 Dodec-1-ene
10992
112-41-4
Liquid
C12H24
168.23
Practically
insoluble or
insoluble
Freely soluble
213
MS
95 %
1.425-1.431
0.755-0.761 No longer
supported by
Industry (DG
SANCO, 2012).
01.042 Germacra-
1(10),4(14),5-triene
23986-74-5
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
308
MS
95 %
1.507-1.513
0.896-0.892 No longer
supported by
Industry (DG
SANCO, 2012).
01.043 3,7,10-Humulatriene
11004
6753-98-6
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
123 (13 hPa)
MS
95 %
1.499-1.505
0.889-0.895 No longer
supported by
Industry (DG
SANCO, 2012).
01.044 Isolongifolene
1135-66-6
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
120 (16 hPa)
MS
95 %
1.495-1.501
0.926-0.932 No longer
supported by
Industry (DG
SANCO, 2012).
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Table D1: Specification Summary of the Substances no Longer Supported by Industry
Former
FL-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility(a)
Solubility in
ethanol(b)
Boiling point,
°C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index(d)
Spec.gravity(e)
Specification
comments
01.047 Longifolene
H
H
H 475-20-7
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
115 (13 hPa)
MS
95 %
1.498-1.504
0.929-0.935 No longer
supported by
Industry (DG
SANCO, 2012).
01.050 3-Methylhexane
589-34-4
Liquid
C7H16
100.20
Practically
insoluble or
insoluble
Freely soluble
92
MS
95 %
1.385-1.391
0.684-0.690 No longer
supported by
Industry (DG
SANCO, 2012).
01.051 2-
Methylnaphthalene 11010
91-57-6
Solid
C11H10
142.20
Practically
insoluble or
insoluble
Freely soluble
241
35
MS
95 %
n.a.
n.a. No longer
supported by
Industry (DG
SANCO, 2012).
01.052 α-Muurolene 
11011
10208-80-7
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
118 (17 hPa)
MS
95 %
1.502-1.508
0.911-0.917 No longer
supported by
Industry (DG
SANCO, 2012).
01.053 Naphthalene
11014
91-20-3
Solid
C10H8
128.17
Practically
insoluble or
insoluble
Freely soluble
218
80
MS
95 %
n.a.
n.a. No longer
supported by
Industry (DG
SANCO, 2012).
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Table D1: Specification Summary of the Substances no Longer Supported by Industry
Former
FL-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility(a)
Solubility in
ethanol(b)
Boiling point,
°C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index(d)
Spec.gravity(e)
Specification
comments
01.055 β-Phellandrene 
11017
555-10-2
Liquid
C10H16
136.24
Practically
insoluble or
insoluble
Freely soluble
174
MS
95 %
1.476-1.482
0.839-0.845 No longer
supported by
Industry (DG
SANCO, 2012).
01.056 α-Santalene 
512-61-8
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
112 (9 hPa)
MS
95 %
1.480-1.486
0.895-0.901 No longer
supported by
Industry (DG
SANCO, 2012).
01.058 1,2,3,4-Tetrahydro-
1,1,6-
trimethylnaphthalen
e
475-03-6
Liquid
C13H18
174.29
Practically
insoluble or
insoluble
Freely soluble
245
MS
95 %
1.519-1.525
0.932-0.938 No longer
supported by
Industry (DG
SANCO, 2012).
01.060 1,1,7-
Trimethyltricyclo[2.
2.1.0.(2.6)]heptane 508-32-7
Solid
C10H16
136.24
Practically
insoluble or
insoluble
Freely soluble
152
66
MS
95 %
n.a.
n.a. No longer
supported by
Industry (DG
SANCO, 2012).
01.066 2-Cedrene H
H
Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
82 (11 hPa)
MS
95 %
1.495-1.501
0.928-0.934 No longer
supported by
Industry (DG
SANCO, 2012).
01.067 8(14)-Cedrene HH Liquid
C15H24
204.35
Practically
insoluble or
insoluble
Freely soluble
118 (13 hPa)
MS
95 %
1.498-1.504
0.930-0.936 No longer
supported by
Industry (DG
SANCO, 2012).
01.078 2,4-Nonadiene 4292
56700-78-8
Liquid
C9H16
124.23
Insoluble
Slightly soluble
155
MS
1.446
0.755 No longer
supported by
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Table D1: Specification Summary of the Substances no Longer Supported by Industry
Former
FL-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility(a)
Solubility in
ethanol(b)
Boiling point,
°C(c)
Melting point, °C
ID test
Assay minimum
Refrac. Index(d)
Spec.gravity(e)
Specification
comments
79 % Industry (DG
SANCO, 2012).
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95 % ethanol, if not otherwise stated.
(c): At 1013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
n.a. Not applicable
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The candidate substances in FGE.25Rev2 were allocated to subgroups. The subgrouping of the 23
substances no longer supported by Industry is shown here (Table D2). Subgroups still remaining in
FGE.25Rev3 are: I, II, III and V. The Subgroups IVa, IVb, IVc and VI no longer contain any
substances.
Table D2: Subgroups of Substances no longer Supported by Industry.
Former
FL-no
Name Structural formula Structural class
I: ACYCLIC ALKANES
01.050 3-Methylhexane I
II: ACYCLIC ALKENES
01.032 2,3-Dihydrofarnesene I
01.037 Dodec-1-ene I
01.078 2,4-Nonadiene I
III: CYCLOHEXENE HYDROCARBONS
01.055 β-Phellandrene I
IV: AROMATIC HYDROCARBONS
IVa: BENZENE HYDROCARBONS
01.031 1,2-Dihydro-1,1,6-trimethylnaphthalene I
01.058 1,2,3,4-Tetrahydro-1,1,6-
trimethylnaphthalene
II
IVb: NAPHTHALENE HYDROCARBONS
01.051 2-Methylnaphthalene III
01.053 Naphthalene III
(01.014) (1-Methylnaphthalene) III
IVc: DIPHENYLMETHANE
01.036 Diphenylmethane III
V: BI- and TRICYCLIC, NON-AROMATIC HYDROCARBONS
01.021 Delta-Cadinene III
01.022 α-Cedrene
H
H I
01.023 1(5),11-Guaiadiene I
01.030 β-Cubebene I
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Table D2: Subgroups of Substances no longer Supported by Industry.
Former
FL-no
Name Structural formula Structural class
01.044 Isolongifolene I
01.047 Longifolene
H
H
H
I
01.052 α-Muurolene I
01.056 α-Santalene I
01.060 1,1,7-
Trimethyltricyclo[2.2.1.0.(2.6)]heptane
I
01.066 2-Cedrene I
01.067 8(14)-Cedrene I
VI: MACROCYCLIC, NON-AROMATIC HYDROCARBONS
01.042 Germacra-1(10),4(14),5-triene I
01.043 3,7,10-Humulatriene I
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ABBREVIATIONS
ADI Acceptable Daily Intake
BW Body weight
CAS Chemical Abstract Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHO Chinese hamster ovary (cells)
CoE Council of Europe
CPN Chronic progressive nephropathy
DNA Deoxyribonucleic acid
DTU-NFI Danish Technical University – National Food Institute
EC European Commission
EFFA European Flavour and Fragrance Association
EPA United States Environmental Protection Agency
EU European Union
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GLP Good laboratory practise
ID Identity
IOFI International Organization of the Flavor Industry
Ip Intraperitoneal
IR Infrared spectroscopy
ISS Istituto Superiore di Sanita
JECFA Joint FAO/WHO Expert Committee on Food Additives
LOAEL Lowest Observed Adverse Effect Level
MSDI Maximised Survey-derived Daily Intake
mTAMDI Modified Theoretical Added Maximum Daily Intake
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NCE Normochromatic erythrocyte
NOAEL No observed adverse effect level
NTP National Toxicology Program
OECD Organisation for Economic Co-operation and Development
PCE Polychromatic erythrocyte
SCE Sister chromatic exchange
SCF Scientific Committee on Food
UDS Unscheduled DNA Synthesis
US EPA United States Environmental Protection Agency
WHO World Health Organization
